fbpx
Wikipedia

Schizophrenia

March 20, 2023

For other uses, see Schizophrenia (disambiguation).

Schizophrenia is a mental disorder[13] characterized by continuous or relapsing episodes of psychosis.[5] Major symptoms include hallucinations (typically hearing voices), delusions, and disorganized thinking.[7] Other symptoms include social withdrawal, decreased emotional expression, and apathy.[5] Symptoms typically develop gradually, begin during young adulthood, and in many cases never become resolved.[3][7] There is no objective diagnostic test; diagnosis is based on observed behavior, a psychiatric history that includes the person's reported experiences, and reports of others familiar with the person.[7] To be diagnosed with schizophrenia, symptoms and functional impairment need to be present for six months (DSM-5) or one month (ICD-11).[7][14] Many people with schizophrenia have other mental disorders, especially substance use disorders, depressive disorders, anxiety disorders, and obsessive–compulsive disorder.[7]

Schizophrenia
Cloth embroidered by a person diagnosed with schizophrenia
Pronunciation
SpecialtyPsychiatry
SymptomsHallucinations (usually hearing voices), delusions, confused thinking[2][3]
ComplicationsSuicide, heart disease, lifestyle diseases[4]
Usual onsetAges 16 to 30[3]
DurationChronic[3]
CausesEnvironmental and genetic factors[5]
Risk factorsFamily history, cannabis use in adolescence, problems during pregnancy, childhood adversity, birth in late winter or early spring, older father, being born or raised in a city[5][6]
Diagnostic methodBased on observed behavior, reported experiences, and reports of others familiar with the person[7]
Differential diagnosisSubstance use disorder, Huntington's disease, mood disorders (bipolar disorder), autism,[8] borderline personality disorder[9]
ManagementCounseling, life skills training[2][5]
MedicationAntipsychotics[5]
Prognosis20–28 years shorter life expectancy[10][11]
Deaths~17,000 (2015)[12]

About 0.3% to 0.7% of people are diagnosed with schizophrenia during their lifetime.[15] In 2017, there were an estimated 1.1 million new cases and in 2022 a total of 24 million cases globally.[2][16] Males are more often affected and on average have an earlier onset.[2] The causes of schizophrenia include genetic and environmental factors.[5] Genetic factors include a variety of common and rare genetic variants.[17] Possible environmental factors include being raised in a city, childhood adversity, cannabis use during adolescence, infections, the ages of a person's mother or father, and poor nutrition during pregnancy.[5][18]

About half of those diagnosed with schizophrenia will have a significant improvement over the long term with no further relapses, and a small proportion of these will recover completely.[7][19] The other half will have a lifelong impairment.[20] In severe cases, people may be admitted to hospitals.[19] Social problems such as long-term unemployment, poverty, homelessness, exploitation, and victimization are commonly correlated with schizophrenia.[21][22] Compared to the general population, people with schizophrenia have a higher suicide rate (about 5% overall) and more physical health problems,[23][24] leading to an average decrease in life expectancy by 20[10] to 28 years.[11] In 2015, an estimated 17,000 deaths were linked to schizophrenia.[12]

The mainstay of treatment is antipsychotic medication, along with counseling, job training, and social rehabilitation.[5] Up to a third of people do not respond to initial antipsychotics, in which case clozapine may be used.[25] In a network comparative meta-analysis of 15 antipsychotic drugs, clozapine was significantly more effective than all other drugs, although clozapine's heavily multimodal action may cause more side effects.[26] In situations where doctors judge that there is a risk of harm to self or others, they may impose short involuntary hospitalization.[27] Long-term hospitalization is used on a small number of people with severe schizophrenia.[28] In some countries where supportive services are limited or unavailable, long-term hospital stays are more common.[29]

Signs and symptoms

 
My Eyes at the Moment of the Apparitions by German artist August Natterer, who had schizophrenia

Schizophrenia is a mental disorder characterized by significant alterations in perception, thoughts, mood, and behavior.[30] Symptoms are described in terms of positive, negative, and cognitive symptoms.[3][31] The positive symptoms of schizophrenia are the same for any psychosis and are sometimes referred to as psychotic symptoms. These may be present in any of the different psychoses, and are often transient making early diagnosis of schizophrenia problematic. Psychosis noted for the first time in a person who is later diagnosed with schizophrenia is referred to as a first-episode psychosis (FEP).[32][33]

Positive symptoms

Positive symptoms are those symptoms that are not normally experienced, but are present in people during a psychotic episode in schizophrenia. They include delusions, hallucinations, and disorganized thoughts and speech, typically regarded as manifestations of psychosis.[32] Hallucinations occur at some point in the lifetimes of 80% of those with schizophrenia[34] and most commonly involve the sense of hearing (most often hearing voices) but can sometimes involve any of the other senses of taste, sight, smell, and touch.[35] The frequency of hallucinations involving multiple senses is double the rate of those involving only one sense.[34] They are also typically related to the content of the delusional theme.[36] Delusions are bizarre or persecutory in nature. Distortions of self-experience such as feeling as if one's thoughts or feelings are not really one's own, to believing that thoughts are being inserted into one's mind, sometimes termed passivity phenomena, are also common.[37] Thought disorders can include thought blocking, and disorganized speech.[3] Positive symptoms generally respond well to medication,[5] and become reduced over the course of the illness, perhaps related to the age-related decline in dopamine activity.[7]

Negative symptoms

Negative symptoms are deficits of normal emotional responses, or of other thought processes. The five recognized domains of negative symptoms are: blunted affect – showing flat expressions or little emotion; alogia – a poverty of speech; anhedonia – an inability to feel pleasure; asociality – the lack of desire to form relationships, and avolition – a lack of motivation and apathy.[38][39] Avolition and anhedonia are seen as motivational deficits resulting from impaired reward processing.[40][41] Reward is the main driver of motivation and this is mostly mediated by dopamine.[41] It has been suggested that negative symptoms are multidimensional and they have been categorised into two subdomains of apathy or lack of motivation, and diminished expression.[38][42] Apathy includes avolition, anhedonia, and social withdrawal; diminished expression includes blunt affect and alogia.[43] Sometimes diminished expression is treated as both verbal and non-verbal.[44]

Apathy accounts for around 50 percent of the most often found negative symptoms and affects functional outcome and subsequent quality of life. Apathy is related to disrupted cognitive processing affecting memory and planning including goal-directed behaviour.[45] The two subdomains have suggested a need for separate treatment approaches.[46] A lack of distress – relating to a reduced experience of depression and anxiety is another noted negative symptom.[47] A distinction is often made between those negative symptoms that are inherent to schizophrenia, termed primary; and those that result from positive symptoms, from the side effects of antipsychotics, substance use disorder, and social deprivation – termed secondary negative symptoms.[48] Negative symptoms are less responsive to medication and the most difficult to treat.[46] However, if properly assessed, secondary negative symptoms are amenable to treatment.[42]

Scales for specifically assessing the presence of negative symptoms, and for measuring their severity, and their changes have been introduced since the earlier scales such as the PANNS that deals with all types of symptoms.[46] These scales are the Clinical Assessment Interview for Negative Symptoms (CAINS), and the Brief Negative Symptom Scale (BNSS) also known as second-generation scales.[46][47][49] In 2020, ten years after its introduction, a cross-cultural study of the use of BNSS found valid and reliable psychometric evidence for the five-domain structure cross-culturally.[47] The BNSS is designed to assess both the presence and severity and change of negative symptoms of the five recognized domains, and the additional item of reduced normal distress.[47] BNSS can register changes in negative symptoms concerning psychosocial and pharmacological intervention trials. BNSS has also been used to study a proposed non-D2 treatment called SEP-363856. Findings supported the favouring of five domains over the two-dimensional proposition.[47]

Cognitive symptoms

See also: Visual processing abnormalities in schizophrenia
 
Map of deficits in neural tissue throughout the human brain in a patient with schizophrenia. Lighter colored areas have more deficiencies.

An estimated 70% of those with schizophrenia have cognitive deficits, and these are most pronounced in early onset and late-onset illness.[50][51] These are often evident long before the onset of illness in the prodromal stage, and may be present in early adolescence, or childhood.[52][53] They are a core feature but not considered to be core symptoms, as are positive and negative symptoms.[54][55] However, their presence and degree of dysfunction is taken as a better indicator of functionality than the presentation of core symptoms.[52] Cognitive deficits become worse at first episode psychosis but then return to baseline, and remain fairly stable over the course of the illness.[56][57]

The deficits in cognition are seen to drive the negative psychosocial outcome in schizophrenia, and are claimed to equate to a possible reduction in IQ from the norm of 100 to 70–85.[58][59] Cognitive deficits may be of neurocognition (nonsocial) or of social cognition.[50] Neurocognition is the ability to receive and remember information, and includes verbal fluency, memory, reasoning, problem solving, speed of processing, and auditory and visual perception.[57] Verbal memory and attention are seen to be the most affected.[59][60] Verbal memory impairment is associated with a decreased level of semantic processing (relating meaning to words).[61] Another memory impairment is that of episodic memory.[62] An impairment in visual perception that is consistently found in schizophrenia is that of visual backward masking.[57] Visual processing impairments include an inability to perceive complex visual illusions.[63] Social cognition is concerned with the mental operations needed to interpret, and understand the self and others in the social world.[57][50] This is also an associated impairment, and facial emotion perception is often found to be difficult.[64][65] Facial perception is critical for ordinary social interaction.[66] Cognitive impairments do not usually respond to antipsychotics, and there are a number of interventions that are used to try to improve them; cognitive remediation therapy is of particular help.[55]

Neurological soft signs of clumsiness and loss of fine motor movement are often found in schizophrenia, which may resolve with effective treatment of FEP.[14][67]

Onset

Further information: Basic symptoms of schizophrenia
See also: Childhood schizophrenia and Adolescence § Changes in the brain

Onset typically occurs between the late teens and early 30s, with the peak incidence occurring in males in the early to mid-twenties, and in females in the late twenties.[3][7][14] Onset before the age of 17 is known as early-onset,[68] and before the age of 13, as can sometimes occur, is known as childhood schizophrenia or very early-onset.[7][69] Onset can occur between the ages of 40 and 60, known as late-onset schizophrenia.[50] Onset over the age of 60, which may be difficult to differentiate as schizophrenia, is known as very-late-onset schizophrenia-like psychosis.[50] Late onset has shown that a higher rate of females are affected; they have less severe symptoms and need lower doses of antipsychotics.[50] The tendency for earlier onset in males is later seen to be balanced by a post-menopausal increase in the development in females. Estrogen produced pre-menopause has a dampening effect on dopamine receptors but its protection can be overridden by a genetic overload.[70] There has been a dramatic increase in the numbers of older adults with schizophrenia.[71]

Onset may happen suddenly or may occur after the slow and gradual development of a number of signs and symptoms, a period known as the prodromal stage.[7] Up to 75% of those with schizophrenia go through a prodromal stage.[72] The negative and cognitive symptoms in the prodrome stage can precede FEP (first episode psychosis) by many months and up to five years.[56][73] The period from FEP and treatment is known as the duration of untreated psychosis (DUP) which is seen to be a factor in functional outcome. The prodromal stage is the high-risk stage for the development of psychosis.[57] Since the progression to first episode psychosis is not inevitable, an alternative term is often preferred of at risk mental state.[57] Cognitive dysfunction at an early age impacts a young person's usual cognitive development.[74] Recognition and early intervention at the prodromal stage would minimize the associated disruption to educational and social development and has been the focus of many studies.[56][73]

Risk factors

Main article: Risk factors of schizophrenia

Schizophrenia is described as a neurodevelopmental disorder with no precise boundary, or single cause, and is thought to develop from gene–environment interactions with involved vulnerability factors.[5][75][76] The interactions of these risk factors are complex, as numerous and diverse insults from conception to adulthood can be involved.[76] A genetic predisposition on its own, without interacting environmental factors, will not give rise to the development of schizophrenia.[76][77] The genetic component means that prenatal brain development is disturbed, and environmental influence affects the postnatal development of the brain.[78] Evidence suggests that genetically susceptible children are more likely to be vulnerable to the effects of environmental risk factors.[78]

Genetic

Estimates of the heritability of schizophrenia are between 70% and 80%, which implies that 70% to 80% of the individual differences in risk of schizophrenia are associated with genetics.[17][79] These estimates vary because of the difficulty in separating genetic and environmental influences, and their accuracy has been queried.[80][81] The greatest risk factor for developing schizophrenia is having a first-degree relative with the disease (risk is 6.5%); more than 40% of identical twins of those with schizophrenia are also affected.[82] If one parent is affected the risk is about 13% and if both are affected the risk is nearly 50%.[79] However, the DSM-5 indicates that most people with schizophrenia have no family history of psychosis.[7] Results of candidate gene studies of schizophrenia have generally failed to find consistent associations,[83] and the genetic loci identified by genome-wide association studies explain only a small fraction of the variation in the disease.[84]

Many genes are known to be involved in schizophrenia, each with small effects and unknown transmission and expression.[17][85][86] The summation of these effect sizes into a polygenic risk score can explain at least 7% of the variability in liability for schizophrenia.[87] Around 5% of cases of schizophrenia are understood to be at least partially attributable to rare copy number variations (CNVs); these structural variations are associated with known genomic disorders involving deletions at 22q11.2 (DiGeorge syndrome) and 17q12 (17q12 microdeletion syndrome), duplications at 16p11.2 (most frequently found) and deletions at 15q11.2 (Burnside–Butler syndrome).[88] Some of these CNVs increase the risk of developing schizophrenia by as much as 20-fold, and are frequently comorbid with autism and intellectual disabilities.[88]

The genes CRHR1 and CRHBP are associated with the severity of suicidal behavior. These genes code for stress response proteins needed in the control of the HPA axis, and their interaction can affect this axis. Response to stress can cause lasting changes in the function of the HPA axis possibly disrupting the negative feedback mechanism, homeostasis, and the regulation of emotion leading to altered behaviors.[77]

The question of how schizophrenia could be primarily genetically influenced, given that people with schizophrenia have lower fertility rates, is a paradox. It is expected that genetic variants that increase the risk of schizophrenia would be selected against, due to their negative effects on reproductive fitness. A number of potential explanations have been proposed, including that alleles associated with schizophrenia risk confers a fitness advantage in unaffected individuals.[89][90] While some evidence has not supported this idea,[81] others propose that a large number of alleles each contributing a small amount can persist.[91]

A meta-analysis found that oxidative DNA damage was significantly increased in schizophrenia.[92]

Environmental

Further information: Prenatal nutrition, Prenatal stress, and Neuroplastic effects of pollution

Environmental factors, each associated with a slight risk of developing schizophrenia in later life include oxygen deprivation, infection, prenatal maternal stress, and malnutrition in the mother during prenatal development.[93] A risk is associated with maternal obesity, in increasing oxidative stress, and dysregulating the dopamine and serotonin pathways.[94] Both maternal stress and infection have been demonstrated to alter fetal neurodevelopment through an increase of pro-inflammatory cytokines.[95] There is a slighter risk associated with being born in the winter or spring possibly due to vitamin D deficiency[96] or a prenatal viral infection.[82] Other infections during pregnancy or around the time of birth that have been linked to an increased risk include infections by Toxoplasma gondii and Chlamydia.[97] The increased risk is about five to eight percent.[98] Viral infections of the brain during childhood are also linked to a risk of schizophrenia during adulthood.[99]

Adverse childhood experiences (ACEs), severe forms of which are classed as childhood trauma, range from being bullied or abused, to the death of a parent.[100] Many adverse childhood experiences can cause toxic stress and increase the risk of psychosis.[100][101][102] Chronic trauma, including ACEs, can promote lasting inflammatory dysregulation throughout the nervous system.[103][104] It is suggested that early stress may contribute to the development of schizophrenia through these alterations in the immune system.[103] Schizophrenia was the last diagnosis to benefit from the link made between ACEs and adult mental health outcomes.[105]

Living in an urban environment during childhood or as an adult has consistently been found to increase the risk of schizophrenia by a factor of two,[23][106] even after taking into account drug use, ethnic group, and size of social group.[107] A possible link between the urban environment and pollution has been suggested to be the cause of the elevated risk of schizophrenia.[108] Other risk factors include social isolation, immigration related to social adversity and racial discrimination, family dysfunction, unemployment, and poor housing conditions.[82][109] Having a father older than 40 years, or parents younger than 20 years are also associated with schizophrenia.[5][110]

Substance use

Further information: Risk factors of schizophrenia § Substance use, and Substance-induced psychosis

About half of those with schizophrenia use recreational drugs, including cannabis, tobacco, and alcohol excessively.[111][112] Use of stimulants such as amphetamine and cocaine can lead to a temporary stimulant psychosis, which presents very similarly to schizophrenia. Rarely, alcohol use can also result in a similar alcohol-related psychosis.[82][113] Drugs may also be used as coping mechanisms by people who have schizophrenia, to deal with depression, anxiety, boredom, and loneliness.[111][114] The use of cannabis and tobacco are not associated with the development of cognitive deficits, and sometimes a reverse relationship is found where their use improves these symptoms.[55] However, substance use disorders are associated with an increased risk of suicide, and a poor response to treatment.[115][116]

Cannabis use may be a contributory factor in the development of schizophrenia, potentially increasing the risk of the disease in those who are already at risk.[117][118][119] The increased risk may require the presence of certain genes within an individual.[18] Its use is associated with doubling the rate.[120]

Mechanism

Main article: Mechanisms of schizophrenia
See also: Aberrant salience

The mechanisms of schizophrenia are unknown, and a number of models have been put forward to explain the link between altered brain function and schizophrenia.[23]The prevailing model of schizophrenia is that of a neurodevelopmental disorder, and the underlying changes that occur before symptoms become evident are seen as arising from the interaction between genes and the environment.[121] Extensive studies support this model.[72] Maternal infections, malnutrition and complications during pregnancy and childbirth are known risk factors for the development of schizophrenia, which usually emerges between the ages of 18–25, a period that overlaps with certain stages of neurodevelopment.[122] Gene-environment interactions lead to deficits in the neural circuitry that affect sensory and cognitive functions.[72]

The common dopamine and glutamate models proposed are not mutually exclusive; each is seen to have a role in the neurobiology of schizophrenia.[123] The most common model put forward was the dopamine hypothesis of schizophrenia, which attributes psychosis to the mind's faulty interpretation of the misfiring of dopaminergic neurons.[124] This has been directly related to the symptoms of delusions and hallucinations.[125][126][127] Abnormal dopamine signaling has been implicated in schizophrenia based on the usefulness of medications that affect the dopamine receptor and the observation that dopamine levels are increased during acute psychosis.[128][129] A decrease in D1 receptors in the dorsolateral prefrontal cortex may also be responsible for deficits in working memory.[130][131]

The glutamate hypothesis of schizophrenia links alterations between glutamatergic neurotransmission and the neural oscillations that affect connections between the thalamus and the cortex.[132] Studies have shown that a reduced expression of a glutamate receptor – NMDA receptor, and glutamate blocking drugs such as phencyclidine and ketamine can mimic the symptoms and cognitive problems associated with schizophrenia.[132][133][134] Post-mortem studies consistently find that a subset of these neurons fail to express GAD67 (GAD1),[135] in addition to abnormalities in brain morphometry. The subsets of interneurons that are abnormal in schizophrenia are responsible for the synchronizing of neural ensembles needed during working memory tasks. These give the neural oscillations produced as gamma waves that have a frequency of between 30 and 80 hertz. Both working memory tasks and gamma waves are impaired in schizophrenia, which may reflect abnormal interneuron functionality.[135][136][137][138] An important process that may be disrupted in neurodevelopment is astrogenesis – the formation of astrocytes. Astrocytes are crucial in contributing to the formation and maintenance of neural circuits and it is believed that disruption in this role can result in a number of neurodevelopmental disorders including schizophrenia.[139] Evidence suggests that reduced numbers of astrocytes in deeper cortical layers are assocociated with a diminished expression of EAAT2, a glutamate transporter in astrocytes; supporting the glutamate hypothesis.[139]

Deficits in executive functions, such as planning, inhibition, and working memory, are pervasive in schizophrenia. Although these functions are separable, their dysfunction in schizophrenia may reflect an underlying deficit in the ability to represent goal related information in working memory, and to utilize this to direct cognition and behavior.[140][141] These impairments have been linked to a number of neuroimaging and neuropathological abnormalities. For example, functional neuroimaging studies report evidence of reduced neural processing efficiency, whereby the dorsolateral prefrontal cortex is activated to a greater degree to achieve a certain level of performance relative to controls on working memory tasks. These abnormalities may be linked to the consistent post-mortem finding of reduced neuropil, evidenced by increased pyramidal cell density and reduced dendritic spine density. These cellular and functional abnormalities may also be reflected in structural neuroimaging studies that find reduced grey matter volume in association with deficits in working memory tasks.[142]

Positive symptoms have been linked to cortical thinning in the superior temporal gyrus.[143] The severity of negative symptoms has been linked to reduced thickness in the left medial orbitofrontal cortex.[144] Anhedonia, traditionally defined as a reduced capacity to experience pleasure, is frequently reported in schizophrenia. However, a large body of evidence suggests that hedonic responses are intact in schizophrenia,[145] and that what is reported to be anhedonia is a reflection of dysfunction in other processes related to reward.[146] Overall, a failure of reward prediction is thought to lead to impairment in the generation of cognition and behavior required to obtain rewards, despite normal hedonic responses.[147]

Another theory links abnormal brain lateralization to the development of being left-handed which is significantly more common in those with schizophrenia.[148] This abnormal development of hemispheric asymmetry is noted in schizophrenia.[149] Studies have concluded that the link is a true and verifiable effect that may reflect a genetic link between lateralization and schizophrenia.[148][150]

Bayesian models of brain functioning have been utilized to link abnormalities in cellular functioning to symptoms.[151][152] Both hallucinations and delusions have been suggested to reflect improper encoding of prior expectations, thereby causing expectation to excessively influence sensory perception and the formation of beliefs. In approved models of circuits that mediate predictive coding, reduced NMDA receptor activation, could in theory result in the positive symptoms of delusions and hallucinations.[153][154][155]

Diagnosis

Main article: Diagnosis of schizophrenia

Criteria

Schizophrenia is diagnosed based on criteria in either the Diagnostic and Statistical Manual of Mental Disorders (DSM) published by the American Psychiatric Association or the International Statistical Classification of Diseases and Related Health Problems (ICD) published by the World Health Organization (WHO). These criteria use the self-reported experiences of the person and reported abnormalities in behavior, followed by a psychiatric assessment. The mental status examination is an important part of the assessment.[156] An established tool for assessing the severity of positive and negative symptoms is the Positive and Negative Syndrome Scale (PANSS).[157] This has been seen to have shortcomings relating to negative symptoms, and other scales – the Clinical Assessment Interview for Negative Symptoms (CAINS), and the Brief Negative Symptoms Scale (BNSS) have been introduced.[46] The DSM-5, published in 2013, gives a Scale to Assess the Severity of Symptom Dimensions outlining eight dimensions of symptoms.[54]

DSM-5 states that to be diagnosed with schizophrenia, two diagnostic criteria have to be met over the period of one month, with a significant impact on social or occupational functioning for at least six months. One of the symptoms needs to be either delusions, hallucinations, or disorganized speech. A second symptom could be one of the negative symptoms, or severely disorganized or catatonic behaviour.[7] A different diagnosis of schizophreniform disorder can be made before the six months needed for the diagnosis of schizophrenia.[7]

In Australia, the guideline for diagnosis is for six months or more with symptoms severe enough to affect ordinary functioning.[158] In the UK diagnosis is based on having the symptoms for most of the time for one month, with symptoms that significantly affect the ability to work, study, or carry on ordinary daily living, and with other similar conditions ruled out.[159]

The ICD criteria are typically used in European countries; the DSM criteria are used predominantly in the United States and Canada, and are prevailing in research studies. In practice, agreement between the two systems is high.[160] The current proposal for the ICD-11 criteria for schizophrenia recommends adding self-disorder as a symptom.[37]

A major unresolved difference between the two diagnostic systems is that of the requirement in DSM of an impaired functional outcome. WHO for ICD argues that not all people with schizophrenia have functional deficits and so these are not specific for the diagnosis.[54]

Comorbidities

Many people with schizophrenia may have one or more other mental disorders, such as panic disorder, obsessive–compulsive disorder, or substance use disorder. These are separate disorders that require treatment.[7] When comorbid with schizophrenia, substance use disorder and antisocial personality disorder both increase the risk for violence.[161] Comorbid substance use disorder also increases the risk of suicide.[115]

Sleep disorders often co-occur with schizophrenia, and may be an early sign of relapse.[162] Sleep disorders are linked with positive symptoms such as disorganized thinking and can adversely affect cortical plasticity and cognition.[162] The consolidation of memories is disrupted in sleep disorders.[163] They are associated with severity of illness, a poor prognosis, and poor quality of life.[164][165] Sleep onset and maintenance insomnia is a common symptom, regardless of whether treatment has been received or not.[164] Genetic variations have been found associated with these conditions involving the circadian rhythm, dopamine and histamine metabolism, and signal transduction.[166]

Differential diagnosis

See also: Dual diagnosis and Comparison of bipolar disorder and schizophrenia

To make a diagnosis of schizophrenia other possible causes of psychosis need to be excluded.[167]: 858  Psychotic symptoms lasting less than a month may be diagnosed as brief psychotic disorder, or as schizophreniform disorder. Psychosis is noted in Other specified schizophrenia spectrum and other psychotic disorders as a DSM-5 category. Schizoaffective disorder is diagnosed if symptoms of mood disorder are substantially present alongside psychotic symptoms. Psychosis that results from a general medical condition or substance is termed secondary psychosis.[7]

Psychotic symptoms may be present in several other conditions, including bipolar disorder,[8] borderline personality disorder,[9] substance intoxication, substance-induced psychosis, and a number of drug withdrawal syndromes. Non-bizarre delusions are also present in delusional disorder, and social withdrawal in social anxiety disorder, avoidant personality disorder and schizotypal personality disorder. Schizotypal personality disorder has symptoms that are similar but less severe than those of schizophrenia.[7] Schizophrenia occurs along with obsessive–compulsive disorder (OCD) considerably more often than could be explained by chance, although it can be difficult to distinguish obsessions that occur in OCD from the delusions of schizophrenia.[168] There can be considerable overlap with the symptoms of post-traumatic stress disorder.[169]

A more general medical and neurological examination may be needed to rule out medical illnesses which may rarely produce psychotic schizophrenia-like symptoms, such as metabolic disturbance, systemic infection, syphilis, HIV-associated neurocognitive disorder, epilepsy, limbic encephalitis, and brain lesions. Stroke, multiple sclerosis, hyperthyroidism, hypothyroidism, and dementias such as Alzheimer's disease, Huntington's disease, frontotemporal dementia, and the Lewy body dementias may also be associated with schizophrenia-like psychotic symptoms.[170] It may be necessary to rule out a delirium, which can be distinguished by visual hallucinations, acute onset and fluctuating level of consciousness, and indicates an underlying medical illness. Investigations are not generally repeated for relapse unless there is a specific medical indication or possible adverse effects from antipsychotic medication.[171] In children hallucinations must be separated from typical childhood fantasies.[7] It is difficult to distinguish childhood schizophrenia from autism.[69]

Prevention

Prevention of schizophrenia is difficult as there are no reliable markers for the later development of the disorder.[172] It is unclear as of 2011 whether treating patients in the prodrome phase of schizophrenia provides benefits.[needs update][173]: 43  There is a discrepancy between the growth in the implementation of early intervention programmes for psychosis and the underlying empirical evidence.[173]: 44 

There is some evidence as of 2009 that early intervention in those with first-episode psychosis may improve short-term outcomes, but there is little benefit from these measures after five years.[needs update][23] Cognitive behavioral therapy may reduce the risk of psychosis in those at high risk after a year[174] and is recommended in this group, by the National Institute for Health and Care Excellence (NICE).[30] Another preventive measure is to avoid drugs that have been associated with development of the disorder, including cannabis, cocaine, and amphetamines.[82]

Antipsychotics are prescribed following a first-episode psychosis, and following remission, a preventive maintenance use is continued to avoid relapse. However, it is recognized that some people do recover following a single episode and that long-term use of antipsychotics will not be needed but there is no way of identifying this group.[175]

Management

Main article: Management of schizophrenia

The primary treatment of schizophrenia is the use of antipsychotic medications, often in combination with psychosocial interventions and social supports.[23][176] Community support services including drop-in centers, visits by members of a community mental health team, supported employment,[177] and support groups are common. The time between the onset of psychotic symptoms to being given treatment – the duration of untreated psychosis (DUP) – is associated with a poorer outcome in both the short term and the long term.[178]

Voluntary or involuntary admission to hospital may be imposed by doctors and courts who deem a person to be having a severe episode. In the UK, large mental hospitals termed asylums began to be closed down in the 1950s with the advent of antipsychotics, and with an awareness of the negative impact of long-term hospital stays on recovery.[21] This process was known as deinstitutionalization, and community and supportive services were developed in order to support this change. Many other countries followed suit with the US starting in the 60s.[179] There still remain a smaller group of people who do not improve enough to be discharged.[21][28] In some countries that lack the necessary supportive and social services, long-term hospital stays are more usual.[29]

Medication

 
Risperidone (trade name Risperdal) is a common atypical antipsychotic medication.

The first-line treatment for schizophrenia is an antipsychotic. The first-generation antipsychotics, now called typical antipsychotics, are dopamine antagonists that block D2 receptors, and affect the neurotransmission of dopamine. Those brought out later, the second-generation antipsychotics known as atypical antipsychotics, can also have an effect on another neurotransmitter, serotonin. Antipsychotics can reduce the symptoms of anxiety within hours of their use but for other symptoms they may take several days or weeks to reach their full effect.[32][180] They have little effect on negative and cognitive symptoms, which may be helped by additional psychotherapies and medications.[181] There is no single antipsychotic suitable for first-line treatment for everyone, as responses and tolerances vary between people.[182] Stopping medication may be considered after a single psychotic episode where there has been a full recovery with no symptoms for twelve months. Repeated relapses worsen the long-term outlook and the risk of relapse following a second episode is high, and long-term treatment is usually recommended.[183][184]

About half of those with schizophrenia will respond favourably to antipsychotics, and have a good return of functioning.[185] However, positive symptoms persist in up to a third of people. Following two trials of different antipsychotics over six weeks, that also prove ineffective, they will be classed as having treatment resistant schizophrenia (TRS), and clozapine will be offered.[186][25] Clozapine is of benefit to around half of this group although it has the potentially serious side effect of agranulocytosis (lowered white blood cell count) in less than 4% of people.[23][82][187]

About 30 to 50 percent of people with schizophrenia do not accept that they have an illness or comply with their recommended treatment.[188] For those who are unwilling or unable to take medication regularly, long-acting injections of antipsychotics may be used,[189] which reduce the risk of relapse to a greater degree than oral medications.[190] When used in combination with psychosocial interventions, they may improve long-term adherence to treatment.[191]

Adverse effects

Further information: Antipsychotic § Adverse effects

Extrapyramidal symptoms, including akathisia, are associated with all commercially available antipsychotic to varying degrees.[192]: 566  There is little evidence that second generation antipsychotics have reduced levels of extrapyramidical symptoms compared to typical antipsychotics.[192]: 566  Tardive dyskinesia can occur due to long-term use of antipsychotics, developing after months or years of use.[193] The antipsychotic clozapine is also associated with thromboembolism (including pulmonary embolism), myocarditis, and cardiomyopathy.

Psychosocial interventions

Further information: Management of schizophrenia § Psychosocial

A number of psychosocial interventions that include several types of psychotherapy may be useful in the treatment of schizophrenia such as: family therapy,[194] group therapy, cognitive remediation therapy (CRT),[195] cognitive behavioral therapy (CBT), and metacognitive training.[196][197] Skills training, help with substance use, and weight management – often needed as a side effect of an antipsychotic – are also offered.[198] In the US, interventions for first episode psychosis have been brought together in an overall approach known as coordinated speciality care (CSC) and also includes support for education.[32] In the UK care across all phases is a similar approach that covers many of the treatment guidelines recommended.[30] The aim is to reduce the number of relapses and stays in the hospital.[194]

Other support services for education, employment, and housing are usually offered. For people with severe schizophrenia, who are discharged from a stay in the hospital, these services are often brought together in an integrated approach to offer support in the community away from the hospital setting. In addition to medicine management, housing, and finances, assistance is given for more routine matters such as help with shopping and using public transport. This approach is known as assertive community treatment (ACT) and has been shown to achieve positive results in symptoms, social functioning and quality of life.[199][200] Another more intense approach is known as intensive care management (ICM). ICM is a stage further than ACT and emphasises support of high intensity in smaller caseloads, (less than twenty). This approach is to provide long-term care in the community. Studies show that ICM improves many of the relevant outcomes including social functioning.[201]

Some studies have shown little evidence for the effectiveness of CBT in either reducing symptoms or preventing relapse.[202][203] However, other studies have found that CBT does improve overall psychotic symptoms (when in use with medication) and it has been recommended in Canada, but has been seen to have no effect on social function, relapse, or quality of life.[204] In the UK it is recommended as an add-on therapy in the treatment of schizophrenia.[180][203] Arts therapies are seen to improve negative symptoms in some people, and are recommended by NICE in the UK.[180] This approach is criticised as having not been well-researched,[205][206] and arts therapies are not recommended in Australian guidelines for example.[207] Peer support, in which people with personal experience of schizophrenia, provide help to each other, is of unclear benefit.[208]

Other

Exercise including aerobic exercise has been shown to improve positive and negative symptoms, cognition, working memory, and improve quality of life.[209][210] Exercise has also been shown to increase the volume of the hippocampus in those with schizophrenia. A decrease in hippocampal volume is one of the factors linked to the development of the disease.[209] However, there still remains the problem of increasing motivation for, and maintaining participation in physical activity.[211] Supervised sessions are recommended.[210] In the UK healthy eating advice is offered alongside exercise programs.[212]

An inadequate diet is often found in schizophrenia, and associated vitamin deficiencies including those of folate, and vitamin D are linked to the risk factors for the development of schizophrenia and for early death including heart disease.[213][214] Those with schizophrenia possibly have the worst diet of all the mental disorders. Lower levels of folate and vitamin D have been noted as significantly lower in first episode psychosis.[213] The use of supplemental folate is recommended.[215] A zinc deficiency has also been noted.[216] Vitamin B12 is also often deficient and this is linked to worse symptoms. Supplementation with B vitamins has been shown to significantly improve symptoms, and to put in reverse some of the cognitive deficits.[213] It is also suggested that the noted dysfunction in gut microbiota might benefit from the use of probiotics.[216]

Prognosis

Main article: Prognosis of schizophrenia
See also: Physical health in schizophrenia
 
Disability-adjusted life years lost due to schizophrenia per 100,000 inhabitants in 2004

Schizophrenia has great human and economic costs.[5] It decreases life expectancy by between 20[10] and 28 years.[11] This is primarily because of its association with heart disease,[217] diabetes,[11] obesity, poor diet, a sedentary lifestyle, and smoking, with an increased rate of suicide playing a lesser role.[10][218] Side effects of antipsychotics may also increase the risk.[10]

Almost 40% of those with schizophrenia die from complications of cardiovascular disease which is seen to be increasingly associated.[214] An underlying factor of sudden cardiac death may be Brugada syndrome (BrS) – BrS mutations that overlap with those linked with schizophrenia are the calcium channel mutations.[214] BrS may also be drug-induced from certain antipsychotics and antidepressants.[214] Primary polydipsia, or excessive fluid intake, is relatively common in people with chronic schizophrenia.[219][220] This may lead to hyponatremia which can be life-threatening. Antipsychotics can lead to a dry mouth, but there are several other factors that may contribute to the disorder; it may reduce life expectancy by 13 per cent.[220] Barriers to improving the mortality rate in schizophrenia are poverty, overlooking the symptoms of other illnesses, stress, stigma, and medication side effects.[221]

Schizophrenia is a major cause of disability. In 2016, it was classed as the 12th most disabling condition.[222] Approximately 75% of people with schizophrenia have ongoing disability with relapses.[223] Some people do recover completely and others function well in society.[224] Most people with schizophrenia live independently with community support.[23] About 85% are unemployed.[5] In people with a first episode of psychosis in schizophrenia a good long-term outcome occurs in 31%, an intermediate outcome in 42% and a poor outcome in 31%.[225] Males are affected more often than females, and have a worse outcome.[226] Studies showing that outcomes for schizophrenia appear better in the developing than the developed world[227] have been questioned.[228] Social problems, such as long-term unemployment, poverty, homelessness, exploitation, stigmatization and victimization are common consequences, and lead to social exclusion.[21][22]

There is a higher than average suicide rate associated with schizophrenia estimated at 5% to 6%, most often occurring in the period following onset or first hospital admission.[14][24] Several times more (20 to 40%) attempt suicide at least once.[7][96] There are a variety of risk factors, including male sex, depression, a high IQ,[229] heavy smoking,[230] and substance use.[115] Repeated relapse is linked to an increased risk of suicidal behavior.[175] The use of clozapine can reduce the risk of suicide, and of aggression.[231]

A strong association between schizophrenia and tobacco smoking has been shown in worldwide studies.[232][233] Smoking is especially high in those diagnosed with schizophrenia, with estimates ranging from 80 to 90% being regular smokers, as compared to 20% of the general population.[233] Those who smoke tend to smoke heavily, and additionally smoke cigarettes with high nicotine content.[36] Some propose that this is in an effort to improve symptoms.[234] Among people with schizophrenia use of cannabis is also common.[115]

Schizophrenia leads to an increased risk of dementia.[235]

Violence

Most people with schizophrenia are not aggressive, and are more likely to be victims of violence rather than perpetrators.[7] People with schizophrenia are commonly exploited and victimized by violent crime as part of a broader dynamic of social exclusion.[21][22] People diagnosed with schizophrenia are also subject to forced drug injections, seclusion, and restraint at high rates.[27][28]

The risk of violence by people with schizophrenia is small. There are minor subgroups where the risk is high.[161] This risk is usually associated with a comorbid disorder such as a substance use disorder – in particular alcohol, or with antisocial personality disorder.[161] Substance use disorder is strongly linked, and other risk factors are linked to deficits in cognition and social cognition including facial perception and insight that are in part included in theory of mind impairments.[236][237] Poor cognitive functioning, decision-making, and facial perception may contribute to making a wrong judgement of a situation that could result in an inappropriate response such as violence.[238] These associated risk factors are also present in antisocial personality disorder which when present as a comorbid disorder greatly increases the risk of violence.[239][240]

Epidemiology

Main article: Epidemiology of schizophrenia
 
Deaths per million persons due to schizophrenia in 2012
  0–0
  1–1
  2–2
  3–3
  4–6
  7–20

In 2017,[needs update] the Global Burden of Disease Study estimated there were 1.1 million new cases;[16] in 2022 the World Health Organization (WHO) reported a total of 24 million cases globally.[2] Schizophrenia affects around 0.3–0.7% of people at some point in their life.[15][11] In areas of conflict this figure can rise to between 4.0 and 6.5%.[241] It occurs 1.4 times more frequently in males than females and typically appears earlier in men.[82]

Worldwide, schizophrenia is the most common psychotic disorder.[51] The frequency of schizophrenia varies across the world,[7] within countries,[242] and at the local and neighborhood level;[243] this variation in prevalence between studies over time, across geographical locations, and by gender is as high as fivefold.[5]

Schizophrenia causes approximately one percent of worldwide disability adjusted life years[needs update][82] and resulted in 17,000 deaths in 2015.[12]

In 2000,[needs update] WHO found the percentage of people affected and the number of new cases that develop each year is roughly similar around the world, with age-standardized prevalence per 100,000 ranging from 343 in Africa to 544 in Japan and Oceania for men, and from 378 in Africa to 527 in Southeastern Europe for women.[244]

History

Main article: History of schizophrenia

Conceptual development

Main article: History of schizophrenia § Conceptual development
Further information: Dementia praecox
 
The term "schizophrenia" was coined by Eugen Bleuler.

Accounts of a schizophrenia-like syndrome are rare in records before the 19th century; the earliest case reports were in 1797 and 1809.[245] Dementia praecox, meaning premature dementia, was used by German psychiatrist Heinrich Schüle in 1886, and then in 1891 by Arnold Pick in a case report of hebephrenia. In 1893 Emil Kraepelin used the term in making a distinction, known as the Kraepelinian dichotomy, between the two psychoses – dementia praecox, and manic depression (now called bipolar disorder).[10] When it became evident that the disorder was not a degenerative dementia, it was renamed schizophrenia by Eugen Bleuler in 1908.[246]

The word schizophrenia translates as 'splitting of the mind' and is Modern Latin from the Greek words schizein (σχίζειν, 'to split') and phrēn, (φρήν, 'mind')[247] Its use was intended to describe the separation of function between personality, thinking, memory, and perception.[246]

In the early 20th century, the psychiatrist Kurt Schneider categorized the psychotic symptoms of schizophrenia into two groups – hallucinations and delusions. The hallucinations were listed as specific to auditory and the delusions included thought disorders. These were seen as important symptoms, termed first-rank. The most common first-rank symptom was found to belong to thought disorders.[page needed][248][page needed][249] In 2013 the first-rank symptoms were excluded from the DSM-5 criteria;[250] while they may not be useful in diagnosing schizophrenia, they can assist in differential diagnosis.[251]

Subtypes of schizophrenia – classified as paranoid, disorganized, catatonic, undifferentiated, and residual – were difficult to distinguish and are no longer recognized as separate conditions by DSM-5 (2013) or ICD-11.[252][253][254]

Breadth of diagnosis

Before the 1960s, nonviolent petty criminals and women were sometimes diagnosed with schizophrenia, categorizing the latter as ill for not performing their duties within patriarchy as wives and mothers.[255] In the mid-to-late 1960s, black men were categorized as "hostile and aggressive" and diagnosed as schizophrenic at much higher rates, their civil rights and Black Power activism labeled as delusions.[255][256]

In the early 1970s in the US, the diagnostic model for schizophrenia was broad and clinically based using DSM II. Schizophrenia was diagnosed far more in the US than in Europe which used the ICD-9 criteria. The US model was criticised for failing to demarcate clearly those people with a mental illness. In 1980 DSM III was published and showed a shift in focus from the clinically based biopsychosocial model to a reason-based medical model.[257] DSM IV brought an increased focus on an evidence-based medical model.[258]

Historical treatment

Main article: History of schizophrenia § Development of treatments in the 20th century
 
A molecule of chlorpromazine, the first antipsychotic developed in the 1950s

In the 1930s a number of shock procedures which induced seizures (convulsions) or comas were used to treat schizophrenia.[259] Insulin shock involved injecting large doses of insulin to induce comas, which in turn produced hypoglycemia and convulsions.[259][260] The use of electricity to induce seizures was in use as electroconvulsive therapy (ECT) by 1938.[261]

Psychosurgery, including the lobotomy and frontal lobotomy – carried out from the 1930s until the 1970s in the United States, and until the 1980s in France – are recognized as a human rights abuse.[262][263] In the mid-1950s the first typical antipsychotic, chlorpromazine, was introduced,[264] followed in the 1970s by the first atypical antipsychotic, clozapine.[265]

Political abuse

Further information: Political abuse of psychiatry

From the 1960s until 1989, psychiatrists in the USSR and Eastern Bloc diagnosed thousands of people with sluggish schizophrenia,[266][267] without signs of psychosis, based on "the assumption that symptoms would later appear".[268] Now discredited, the diagnosis provided a convenient way to confine political dissidents.[269]

Society and culture

See also: Social construction of schizophrenia, List of people with schizophrenia, and Religion and schizophrenia

In the United States, the annual cost of schizophrenia – including direct costs (outpatient, inpatient, drugs, and long-term care) and non-healthcare costs (law enforcement, reduced workplace productivity, and unemployment) – was estimated at $62.7 billion for the year 2002.[270][a] In the UK the cost in 2016 was put at £11.8 billion per year with a third of that figure directly attributable to the cost of hospital, social care and treatment.[5]

Stigma

 
John Nash, an American mathematician and joint recipient of the 1994 Nobel Memorial Prize in Economic Sciences, had schizophrenia. His life was the subject of the 1998 book, A Beautiful Mind by Sylvia Nasar.

In 2002, the term for schizophrenia in Japan was changed from seishin-bunretsu-byō (精神分裂病, lit. 'mind-split disease') to tōgō-shitchō-shō (統合失調症, lit. 'integration–dysregulation syndrome') to reduce stigma.[273] The new name, also interpreted as "integration disorder", was inspired by the biopsychosocial model.[274] A similar change was made in South Korea in 2012 to attunement disorder.[275]

Cultural depictions

The book A Beautiful Mind chronicled the life of John Forbes Nash who had been diagnosed with schizophrenia and won the Nobel Memorial Prize in Economic Sciences. The book was made into a film with the same name; an earlier documentary film was A Brilliant Madness.

In 1964 a case study of three males diagnosed with schizophrenia who each had the delusional belief that they were Jesus Christ was published as The Three Christs of Ypsilanti; a film with the title Three Christs was released in 2020.[276][277]

Media coverage reinforces public perception of an association between schizophrenia and violence;[278] in film, people with schizophrenia are highly likely to be portrayed as a danger to others.[279] In the UK guidelines for reporting conditions and award campaigns have shown a reduction in negative reporting since 2013.[280]

Research directions

See also: Animal models of schizophrenia

A 2015 Cochrane review found unclear evidence of benefit from brain stimulation techniques to treat the positive symptoms of schizophrenia, in particular auditory verbal hallucinations (AVHs).[281] Most studies focus on transcranial direct-current stimulation (tDCM), and repetitive transcranial magnetic stimulation (rTMS).[282] Techniques based on focused ultrasound for deep brain stimulation could provide insight for the treatment of AVHs.[282]

The study of potential biomarkers that would help in diagnosis and treatment of schizophrenia is an active area of research as of 2020. Possible biomarkers include markers of inflammation,[95] neuroimaging,[283] brain-derived neurotrophic factor (BDNF),[284] and speech analysis. Some markers such as C-reactive protein are useful in detecting levels of inflammation implicated in some psychiatric disorders but they are not disorder-specific. Other inflammatory cytokines are found to be elevated in first episode psychosis and acute relapse that are normalized after treatment with antipsychotics, and these may be considered as state markers.[285] Deficits in sleep spindles in schizophrenia may serve as a marker of an impaired thalamocortical circuit, and a mechanism for memory impairment.[163] MicroRNAs are highly influential in early neuronal development, and their disruption is implicated in several CNS disorders; circulating microRNAs (cimiRNAs) are found in body fluids such as blood and cerebrospinal fluid, and changes in their levels are seen to relate to changes in microRNA levels in specific regions of brain tissue. These studies suggest that cimiRNAs have the potential to be early and accurate biomarkers in a number of disorders including schizophrenia.[286][287]

Explanatory notes

  1. ^ A 2007 review stated that the 2002 estimate was still the best available,[271] and a 2018 review cited the same $62.7 billion.[272]

References

  1. ^ Jones D (2003) [1917]. Roach P, Hartmann J, Setter J (eds.). English Pronouncing Dictionary. Cambridge University Press. ISBN 978-3-12-539683-8.
  2. ^ a b c d e "Schizophrenia Fact sheet". World Health Organization. 10 January 2022. Retrieved 23 August 2022.
  3. ^ a b c d e f g "Schizophrenia". Health topics. US National Institute of Mental Health. April 2022. Retrieved 22 August 2022.
  4. ^ "Medicinal treatment of psychosis/schizophrenia". Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU). 21 November 2012. from the original on 29 June 2017. Retrieved 26 June 2017.
  5. ^ a b c d e f g h i j k l m n o p Owen MJ, Sawa A, Mortensen PB (July 2016). "Schizophrenia". The Lancet. 388 (10039): 86–97. doi:10.1016/S0140-6736(15)01121-6. PMC 4940219. PMID 26777917.
  6. ^ Gruebner O, Rapp MA, Adli M, et al. (February 2017). "Cities and mental health". Deutsches Ärzteblatt International. 114 (8): 121–127. doi:10.3238/arztebl.2017.0121. PMC 5374256. PMID 28302261.
  7. ^ a b c d e f g h i j k l m n o p q r s t u Diagnostic and Statistical Manual of Mental Disorders: DSM-5 (5th ed.). Arlington, VA: American Psychiatric Association. 2013. pp. 99–105. ISBN 978-0-89042-555-8.
  8. ^ a b Ferri FF (2010). "Chapter S". Ferri's differential diagnosis: a practical guide to the differential diagnosis of symptoms, signs, and clinical disorders (2nd ed.). Philadelphia: Elsevier/Mosby. ISBN 978-0-323-07699-9.
  9. ^ a b Paris J (December 2018). "Differential Diagnosis of Borderline Personality Disorder". The Psychiatric Clinics of North America. 41 (4): 575–582. doi:10.1016/j.psc.2018.07.001. PMID 30447725. S2CID 53951650.
  10. ^ a b c d e f Laursen TM, Nordentoft M, Mortensen PB (2014). "Excess early mortality in schizophrenia". Annual Review of Clinical Psychology. 10: 425–448. doi:10.1146/annurev-clinpsy-032813-153657. PMID 24313570.
  11. ^ a b c d e "Schizophrenia". Statistics. US National Institute of Mental Health (NIMH). 22 April 2022. Retrieved 23 August 2022.
  12. ^ a b c Wang H, Naghavi M, Allen C, et al. (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
  13. ^ "ICD-11: 6A20 Schizophrenia". World Health Organization. Retrieved 23 August 2022.
  14. ^ a b c d Ferri FF (2019). Ferri's clinical advisor 2019: 5 books in 1. pp. 1225–1226. ISBN 9780323530422.
  15. ^ a b Javitt DC (June 2014). "Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overview". The American Journal of Managed Care. 20 (8 Suppl): S160-165. PMID 25180705.
  16. ^ a b James SL, Abate D (November 2018). "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017". The Lancet. 392 (10159): 1789–1858. doi:10.1016/S0140-6736(18)32279-7. PMC 6227754. PMID 30496104.
  17. ^ a b c van de Leemput J, Hess JL, Glatt SJ, Tsuang MT (2016). "Genetics of Schizophrenia: Historical Insights and Prevailing Evidence". Advances in Genetics. 96: 99–141. doi:10.1016/bs.adgen.2016.08.001. PMID 27968732.
  18. ^ a b Parakh P, Basu D (August 2013). "Cannabis and psychosis: have we found the missing links?". Asian Journal of Psychiatry (Review). 6 (4): 281–287. doi:10.1016/j.ajp.2013.03.012. PMID 23810133. Cannabis acts as a component cause of psychosis, that is, it increases the risk of psychosis in people with certain genetic or environmental vulnerabilities, though by itself, it is neither a sufficient nor a necessary cause of psychosis.
  19. ^ a b Vita A, Barlati S (May 2018). "Recovery from schizophrenia: is it possible?". Current Opinion in Psychiatry. 31 (3): 246–255. doi:10.1097/YCO.0000000000000407. PMID 29474266. S2CID 35299996.
  20. ^ Lawrence RE, First MB, Lieberman JA (2015). "Chapter 48: Schizophrenia and Other Psychoses". In Tasman A, Kay J, Lieberman JA, First MB, Riba MB (eds.). Psychiatry (fourth ed.). John Wiley & Sons, Ltd. pp. 798, 816, 819. doi:10.1002/9781118753378.ch48. ISBN 978-1-118-84547-9.
  21. ^ a b c d e Killaspy H (September 2014). "Contemporary mental health rehabilitation". East Asian Archives of Psychiatry. 24 (3): 89–94. PMID 25316799.
  22. ^ a b c Charlson FJ, Ferrari AJ, Santomauro DF, et al. (17 October 2018). "Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016". Schizophrenia Bulletin. 44 (6): 1195–1203. doi:10.1093/schbul/sby058. PMC 6192504. PMID 29762765.
  23. ^ a b c d e f g van Os J, Kapur S (August 2009). (PDF). Lancet. 374 (9690): 635–645. doi:10.1016/S0140-6736(09)60995-8. PMID 19700006. S2CID 208792724. Archived from the original (PDF) on 23 June 2013. Retrieved 23 December 2011.
  24. ^ a b Hor K, Taylor M (November 2010). "Suicide and schizophrenia: a systematic review of rates and risk factors". Journal of Psychopharmacology. 24 (4 Suppl): 81–90. doi:10.1177/1359786810385490. PMC 2951591. PMID 20923923.
  25. ^ a b Siskind D, Siskind V, Kisely S (November 2017). "Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis". Canadian Journal of Psychiatry. 62 (11): 772–777. doi:10.1177/0706743717718167. PMC 5697625. PMID 28655284.
  26. ^ Leucht S, Cipriani A, Spineli L, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". The Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
  27. ^ a b Becker T, Kilian R (2006). "Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care?". Acta Psychiatrica Scandinavica. Supplementum. 113 (429): 9–16. doi:10.1111/j.1600-0447.2005.00711.x. PMID 16445476. S2CID 34615961.
  28. ^ a b c Capdevielle D, Boulenger JP, Villebrun D, Ritchie K (September 2009). "Durées d'hospitalisation des patients souffrant de schizophrénie: implication des systèmes de soin et conséquences médicoéconomiques" [Schizophrenic patients' length of stay: mental health care implication and medicoeconomic consequences]. L'Encéphale (in French). 35 (4): 394–399. doi:10.1016/j.encep.2008.11.005. PMID 19748377.
  29. ^ a b Narayan KK, Kumar DS (January 2012). "Disability in a Group of Long-stay Patients with Schizophrenia: Experience from a Mental Hospital". Indian Journal of Psychological Medicine. 34 (1): 70–75. doi:10.4103/0253-7176.96164. PMC 3361848. PMID 22661812.
  30. ^ a b c (PDF). National Institute for Health and Care Excellence (NICE). March 2014. pp. 4–34. Archived from the original (PDF) on 20 April 2014. Retrieved 19 April 2014.
  31. ^ Stępnicki P, Kondej M, Kaczor AA (20 August 2018). "Current Concepts and Treatments of Schizophrenia". Molecules. 23 (8): 2087. doi:10.3390/molecules23082087. PMC 6222385. PMID 30127324.
  32. ^ a b c d "RAISE Questions and Answers". US National Institute of Mental Health. Retrieved 29 December 2019.
  33. ^ Marshall M (September 2005). "Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review". Archives of General Psychiatry. 62 (9): 975–983. doi:10.1001/archpsyc.62.9.975. PMID 16143729.
  34. ^ a b Montagnese M, Leptourgos P, Fernyhough C, et al. (January 2021). "A Review of Multimodal Hallucinations: Categorization, Assessment, Theoretical Perspectives, and Clinical Recommendations". Schizophr Bull. 47 (1): 237–248. doi:10.1093/schbul/sbaa101. PMC 7825001. PMID 32772114.
  35. ^ Császár N, Kapócs G, Bókkon I (27 May 2019). "A possible key role of vision in the development of schizophrenia". Reviews in the Neurosciences. 30 (4): 359–379. doi:10.1515/revneuro-2018-0022. PMID 30244235. S2CID 52813070.
  36. ^ a b American Psychiatric Association. Task Force on DSM-IV. (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Pub. pp. 299–304. ISBN 978-0-89042-025-6.
  37. ^ a b Heinz A, Voss M, Lawrie SM, et al. (September 2016). "Shall we really say goodbye to first rank symptoms?". European Psychiatry. 37: 8–13. doi:10.1016/j.eurpsy.2016.04.010. PMID 27429167. S2CID 13761854.
  38. ^ a b Adida M, Azorin JM, Belzeaux R, Fakra E (December 2015). "[Negative Symptoms: Clinical and Psychometric Aspects]". L'Encephale. 41 (6 Suppl 1): 6S15–17. doi:10.1016/S0013-7006(16)30004-5. PMID 26776385.
  39. ^ Mach C, Dollfus S (April 2016). "[Scale for Assessing Negative Symptoms in Schizophrenia: A Systematic Review]". L'Encephale. 42 (2): 165–171. doi:10.1016/j.encep.2015.12.020. PMID 26923997.
  40. ^ Waltz JA, Gold JM (2016). "Motivational Deficits in Schizophrenia and the Representation of Expected Value". Current Topics in Behavioral Neurosciences. 27: 375–410. doi:10.1007/7854_2015_385. ISBN 978-3-319-26933-7. PMC 4792780. PMID 26370946.
  41. ^ a b Husain M, Roiser JP (August 2018). "Neuroscience of apathy and anhedonia: a transdiagnostic approach". Nature Reviews. Neuroscience. 19 (8): 470–484. doi:10.1038/s41583-018-0029-9. PMID 29946157. S2CID 49428707.
  42. ^ a b Galderisi S, Mucci A, Buchanan RW, Arango C (August 2018). "Negative symptoms of schizophrenia: new developments and unanswered research questions". The Lancet. Psychiatry. 5 (8): 664–677. doi:10.1016/S2215-0366(18)30050-6. PMID 29602739. S2CID 4483198.
  43. ^ Klaus F, Dorsaz O, Kaiser S (19 September 2018). "[Negative symptoms in schizophrenia – overview and practical implications]". Revue médicale suisse. 14 (619): 1660–1664. doi:10.53738/REVMED.2018.14.619.1660. PMID 30230774. S2CID 246764656.
  44. ^ Batinic B (June 2019). "Cognitive Models of Positive and Negative Symptoms of Schizophrenia and Implications for Treatment". Psychiatria Danubina. 31 (Suppl 2): 181–184. PMID 31158119.
  45. ^ Bortolon C, Macgregor A, Capdevielle D, Raffard S (September 2018). "Apathy in schizophrenia: A review of neuropsychological and neuroanatomical studies". Neuropsychologia. 118 (Pt B): 22–33. doi:10.1016/j.neuropsychologia.2017.09.033. PMID 28966139. S2CID 13411386.
  46. ^ a b c d e Marder SR, Kirkpatrick B (May 2014). "Defining and measuring negative symptoms of schizophrenia in clinical trials". European Neuropsychopharmacology. 24 (5): 737–743. doi:10.1016/j.euroneuro.2013.10.016. PMID 24275698. S2CID 5172022.
  47. ^ a b c d e Tatsumi K, Kirkpatrick B, Strauss GP, Opler M (April 2020). "The brief negative symptom scale in translation: A review of psychometric properties and beyond". European Neuropsychopharmacology. 33: 36–44. doi:10.1016/j.euroneuro.2020.01.018. PMID 32081498. S2CID 211141678.
  48. ^ Klaus F, Kaiser S, Kirschner M (June 2018). "[Negative Symptoms in Schizophrenia – an Overview]". Therapeutische Umschau. 75 (1): 51–56. doi:10.1024/0040-5930/a000966. PMID 29909762. S2CID 196502392.
  49. ^ Wójciak P, Rybakowski J (30 April 2018). "Clinical picture, pathogenesis and psychometric assessment of negative symptoms of schizophrenia". Psychiatria Polska. 52 (2): 185–197. doi:10.12740/PP/70610. PMID 29975360.
  50. ^ a b c d e f Murante T, Cohen CI (January 2017). "Cognitive Functioning in Older Adults With Schizophrenia". Focus (American Psychiatric Publishing). 15 (1): 26–34. doi:10.1176/appi.focus.20160032. PMC 6519630. PMID 31975837.
  51. ^ a b Kar SK, Jain M (July 2016). "Current understandings about cognition and the neurobiological correlates in schizophrenia". Journal of Neurosciences in Rural Practice. 7 (3): 412–418. doi:10.4103/0976-3147.176185. PMC 4898111. PMID 27365960.
  52. ^ a b Bozikas VP, Andreou C (February 2011). "Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature". The Australian and New Zealand Journal of Psychiatry. 45 (2): 93–108. doi:10.3109/00048674.2010.541418. PMID 21320033. S2CID 26135485.
  53. ^ Shah JN, Qureshi SU, Jawaid A, Schulz PE (June 2012). "Is there evidence for late cognitive decline in chronic schizophrenia?". The Psychiatric Quarterly. 83 (2): 127–144. doi:10.1007/s11126-011-9189-8. PMID 21863346. S2CID 10970088.
  54. ^ a b c Biedermann F, Fleischhacker WW (August 2016). "Psychotic disorders in DSM-5 and ICD-11". CNS Spectrums. 21 (4): 349–354. doi:10.1017/S1092852916000316. PMID 27418328. S2CID 24728447.
  55. ^ a b c Vidailhet P (September 2013). "[First-episode psychosis, cognitive difficulties and remediation]". L'Encéphale (in French). 39 Suppl 2: S83-92. doi:10.1016/S0013-7006(13)70101-5. PMID 24084427.
  56. ^ a b c Hashimoto K (5 July 2019). "Recent Advances in the Early Intervention in Schizophrenia: Future Direction from Preclinical Findings". Current Psychiatry Reports. 21 (8): 75. doi:10.1007/s11920-019-1063-7. PMID 31278495. S2CID 195814019.
  57. ^ a b c d e f Green MF, Horan WP, Lee J (June 2019). "Nonsocial and social cognition in schizophrenia: current evidence and future directions". World Psychiatry. 18 (2): 146–161. doi:10.1002/wps.20624. PMC 6502429. PMID 31059632.
  58. ^ Javitt DC, Sweet RA (September 2015). "Auditory dysfunction in schizophrenia: integrating clinical and basic features". Nature Reviews. Neuroscience. 16 (9): 535–550. doi:10.1038/nrn4002. PMC 4692466. PMID 26289573.
  59. ^ a b Megreya AM (2016). "Face perception in schizophrenia: a specific deficit". Cognitive Neuropsychiatry. 21 (1): 60–72. doi:10.1080/13546805.2015.1133407. PMID 26816133. S2CID 26125559.
  60. ^ Eack SM (July 2012). "Cognitive remediation: a new generation of psychosocial interventions for people with schizophrenia". Social Work. 57 (3): 235–246. doi:10.1093/sw/sws008. PMC 3683242. PMID 23252315.
  61. ^ Pomarol-Clotet E, Oh M, Laws KR, McKenna PJ (February 2008). "Semantic priming in schizophrenia: systematic review and meta-analysis". The British Journal of Psychiatry. 192 (2): 92–97. doi:10.1192/bjp.bp.106.032102. hdl:2299/2735. PMID 18245021.
  62. ^ Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD (April 2010). "Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies". Neuropsychopharmacology. 35 (5): 1053–1062. doi:10.1038/npp.2009.211. PMC 3055399. PMID 20090669.
  63. ^ King DJ, Hodgekins J, Chouinard PA, Chouinard VA, Sperandio I (June 2017). "A review of abnormalities in the perception of visual illusions in schizophrenia". Psychonomic Bulletin and Review. 24 (3): 734–751. doi:10.3758/s13423-016-1168-5. PMC 5486866. PMID 27730532.
  64. ^ Kohler CG, Walker JB, Martin EA, Healey KM, Moberg PJ (September 2010). "Facial emotion perception in schizophrenia: a meta-analytic review". Schizophrenia Bulletin. 36 (5): 1009–1019. doi:10.1093/schbul/sbn192. PMC 2930336. PMID 19329561.
  65. ^ Le Gall E, Iakimova G (December 2018). "[Social cognition in schizophrenia and autism spectrum disorder: Points of convergence and functional differences]". L'Encéphale. 44 (6): 523–537. doi:10.1016/j.encep.2018.03.004. PMID 30122298. S2CID 150099236.
  66. ^ Grill-Spector K, Weiner KS, Kay K, Gomez J (September 2017). "The Functional Neuroanatomy of Human Face Perception". Annual Review of Vision Science. 3: 167–196. doi:10.1146/annurev-vision-102016-061214. PMC 6345578. PMID 28715955.
  67. ^ Fountoulakis KN, Panagiotidis P, Kimiskidis V, Nimatoudis I, Gonda X (February 2019). "Neurological soft signs in familial and sporadic schizophrenia". Psychiatry Research. 272: 222–229. doi:10.1016/j.psychres.2018.12.105. PMID 30590276. S2CID 56476015.
  68. ^ Bourgou Gaha S, Halayem Dhouib S, Amado I, Bouden A (June 2015). "[Neurological soft signs in early onset schizophrenia]". L'Encephale. 41 (3): 209–214. doi:10.1016/j.encep.2014.01.005. PMID 24854724.
  69. ^ a b Da Fonseca D, Fourneret P (December 2018). "[Very early onset schizophrenia]". L'Encephale. 44 (6S): S8–S11. doi:10.1016/S0013-7006(19)30071-5. PMID 30935493. S2CID 150798223.
  70. ^ Häfner H (2019). "From Onset and Prodromal Stage to a Life-Long Course of Schizophrenia and Its Symptom Dimensions: How Sex, Age, and Other Risk Factors Influence Incidence and Course of Illness". Psychiatry Journal. 2019: 9804836. doi:10.1155/2019/9804836. PMC 6500669. PMID 31139639.
  71. ^ Cohen CI, Freeman K, Ghoneim D, et al. (March 2018). "Advances in the Conceptualization and Study of Schizophrenia in Later Life". The Psychiatric Clinics of North America. 41 (1): 39–53. doi:10.1016/j.psc.2017.10.004. PMID 29412847.
  72. ^ a b c George M, Maheshwari S, Chandran S, Manohar JS, Sathyanarayana Rao TS (October 2017). "Understanding the schizophrenia prodrome". Indian Journal of Psychiatry. 59 (4): 505–509. doi:10.4103/psychiatry.IndianJPsychiatry_464_17 (inactive 31 December 2022). PMC 5806335. PMID 29497198.{{cite journal}}: CS1 maint: DOI inactive as of December 2022 (link)
  73. ^ a b Conroy S, Francis M, Hulvershorn LA (March 2018). "Identifying and treating the prodromal phases of bipolar disorder and schizophrenia". Current Treatment Options in Psychiatry. 5 (1): 113–128. doi:10.1007/s40501-018-0138-0. PMC 6196741. PMID 30364516.
  74. ^ Lecardeur L, Meunier-Cussac S, Dollfus S (May 2013). "[Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment]". L'Encephale. 39 Suppl 1: S64-71. doi:10.1016/j.encep.2012.10.011. PMID 23528322.
  75. ^ Mullin AP, Gokhale A, Moreno-De-Luca A, Sanyal S, Waddington JL, Faundez V (December 2013). "Neurodevelopmental disorders: mechanisms and boundary definitions from genomes, interactomes and proteomes". Transl Psychiatry. 3 (12): e329. doi:10.1038/tp.2013.108. PMC 4030327. PMID 24301647.
  76. ^ a b c Davis J, Eyre H, Jacka FN, et al. (June 2016). "A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis". Neurosci Biobehav Rev. 65: 185–194. doi:10.1016/j.neubiorev.2016.03.017. PMC 4876729. PMID 27073049.
  77. ^ a b Perkovic MN, Erjavec GN, Strac DS, et al. (March 2017). "Theranostic biomarkers for schizophrenia". International Journal of Molecular Sciences. 18 (4): 733. doi:10.3390/ijms18040733. PMC 5412319. PMID 28358316.
  78. ^ a b Suvisaari J (2010). "[Risk factors of schizophrenia]". Duodecim (in Finnish). 126 (8): 869–876. PMID 20597333.
  79. ^ a b Combs DR, Mueser KT, Gutierrez MM (2011). "Chapter 8: Schizophrenia: Etiological considerations". In Hersen M, Beidel DC (eds.). Adult psychopathology and diagnosis (6th ed.). John Wiley & Sons. ISBN 978-1-118-13884-7.
  80. ^ O'Donovan MC, Williams NM, Owen MJ (October 2003). "Recent advances in the genetics of schizophrenia". Human Molecular Genetics. 12 Spec No 2: R125–133. doi:10.1093/hmg/ddg302. PMID 12952866.
  81. ^ a b Torrey EF, Yolken RH (August 2019). "Schizophrenia as a pseudogenetic disease: A call for more gene-environmental studies". Psychiatry Research. 278: 146–150. doi:10.1016/j.psychres.2019.06.006. PMID 31200193. S2CID 173991937.
  82. ^ a b c d e f g h Picchioni MM, Murray RM (July 2007). "Schizophrenia". BMJ. 335 (7610): 91–95. doi:10.1136/bmj.39227.616447.BE. PMC 1914490. PMID 17626963.
  83. ^ Farrell MS, Werge T, Sklar P, et al. (May 2015). "Evaluating historical candidate genes for schizophrenia". Molecular Psychiatry. 20 (5): 555–562. doi:10.1038/mp.2015.16. PMC 4414705. PMID 25754081.
  84. ^ Schulz SC, Green MF, Nelson KJ (2016). Schizophrenia and Psychotic Spectrum Disorders. Oxford University Press. pp. 124–125. ISBN 9780199378067.
  85. ^ Schork AJ, Wang Y, Thompson WK, Dale AM, Andreassen OA (February 2016). "New statistical approaches exploit the polygenic architecture of schizophrenia—implications for the underlying neurobiology". Current Opinion in Neurobiology. 36: 89–98. doi:10.1016/j.conb.2015.10.008. PMC 5380793. PMID 26555806.
  86. ^ Coelewij L, Curtis D (2018). "Mini-review: Update on the genetics of schizophrenia". Annals of Human Genetics. 82 (5): 239–243. doi:10.1111/ahg.12259. ISSN 0003-4800. PMID 29923609. S2CID 49311660.
  87. ^ Kendler KS (March 2016). "The Schizophrenia Polygenic Risk Score: To What Does It Predispose in Adolescence?". JAMA Psychiatry. 73 (3): 193–194. doi:10.1001/jamapsychiatry.2015.2964. PMID 26817666.
  88. ^ a b Lowther C, Costain G, Baribeau DA, Bassett AS (September 2017). "Genomic Disorders in Psychiatry—What Does the Clinician Need to Know?". Current Psychiatry Reports. 19 (11): 82. doi:10.1007/s11920-017-0831-5. PMID 28929285. S2CID 4776174.
  89. ^ Bundy H, Stahl D, MacCabe JH (February 2011). "A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives: Fertility in schizophrenia". Acta Psychiatrica Scandinavica. 123 (2): 98–106. doi:10.1111/j.1600-0447.2010.01623.x. PMID 20958271. S2CID 45179016.
  90. ^ van Dongen J, Boomsma DI (March 2013). "The evolutionary paradox and the missing heritability of schizophrenia". American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 162 (2): 122–136. doi:10.1002/ajmg.b.32135. PMID 23355297. S2CID 9648115.
  91. ^ Owen MJ, Sawa A, Mortensen PB (2 July 2016). "Schizophrenia". Lancet. 388 (10039): 86–97. doi:10.1016/S0140-6736(15)01121-6. PMC 4940219. PMID 26777917.
  92. ^ Goh XX, Tang PY, Tee SF (July 2021). "8-Hydroxy-2'-Deoxyguanosine and Reactive Oxygen Species as Biomarkers of Oxidative Stress in Mental Illnesses: A Meta-Analysis". Psychiatry Investig (Meta-analysis). 18 (7): 603–618. doi:10.30773/pi.2020.0417. PMC 8328836. PMID 34340273.
  93. ^ Stilo SA, Murray RM (14 September 2019). "Non-Genetic Factors in Schizophrenia". Current Psychiatry Reports. 21 (10): 100. doi:10.1007/s11920-019-1091-3. PMC 6745031. PMID 31522306.
  94. ^ Cirulli F, Musillo C, Berry A (5 February 2020). "Maternal Obesity as a Risk Factor for Brain Development and Mental Health in the Offspring". Neuroscience. 447: 122–135. doi:10.1016/j.neuroscience.2020.01.023. hdl:11573/1387747. PMID 32032668. S2CID 211029692.
  95. ^ a b Upthegrove R, Khandaker GM (2020). "Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia" (PDF). Current Topics in Behavioral Neurosciences. 44: 49–66. doi:10.1007/7854_2018_88. ISBN 978-3-030-39140-9. PMID 31115797. S2CID 162169817.
  96. ^ a b Chiang M, Natarajan R, Fan X (February 2016). "Vitamin D in schizophrenia: a clinical review". Evidence-Based Mental Health. 19 (1): 6–9. doi:10.1136/eb-2015-102117. PMID 26767392. S2CID 206926835.
  97. ^ Arias I, Sorlozano A, Villegas E, et al. (April 2012). "Infectious agents associated with schizophrenia: a meta-analysis". Schizophrenia Research. 136 (1–3): 128–136. doi:10.1016/j.schres.2011.10.026. PMID 22104141. S2CID 2687441.
  98. ^ Yolken R (June 2004). "Viruses and schizophrenia: a focus on herpes simplex virus". Herpes. 11 Suppl 2 (Suppl 2): 83A–88A. PMID 15319094.
  99. ^ Khandaker GM (August 2012). "Childhood infection and adult schizophrenia: a meta-analysis of population-based studies". Schizophr. Res. 139 (1–3): 161–168. doi:10.1016/j.schres.2012.05.023. PMC 3485564. PMID 22704639.
  100. ^ a b Pearce J, Murray C, Larkin W (July 2019). "Childhood adversity and trauma:experiences of professionals trained to routinely enquire about childhood adversity". Heliyon. 5 (7): e01900. doi:10.1016/j.heliyon.2019.e01900. PMC 6658729. PMID 31372522.
  101. ^ Dvir Y, Denietolis B, Frazier JA (October 2013). "Childhood trauma and psychosis". Child and Adolescent Psychiatric Clinics of North America. 22 (4): 629–641. doi:10.1016/j.chc.2013.04.006. PMID 24012077. S2CID 40053289.
  102. ^ Misiak B, Krefft M, Bielawski T, Moustafa AA, Sąsiadek MM, Frydecka D (April 2017). "Toward a unified theory of childhood trauma and psychosis: A comprehensive review of epidemiological, clinical, neuropsychological and biological findings". Neuroscience and Biobehavioral Reviews. 75: 393–406. doi:10.1016/j.neubiorev.2017.02.015. PMID 28216171. S2CID 21614845.
  103. ^ a b Nettis MA, Pariante CM, Mondelli V (2020). "Early-Life Adversity, Systemic Inflammation and Comorbid Physical and Psychiatric Illnesses of Adult Life". Current Topics in Behavioral Neurosciences. 44: 207–225. doi:10.1007/7854_2019_89. ISBN 978-3-030-39140-9. PMID 30895531. S2CID 84842249.
  104. ^ Kasznia, Justyna; Pytel, Aleksandra; Stańczykiewicz, Bartłomiej; Samochowiec, Jerzy; Waszczuk, Katarzyna; Kulik, Małgorzata; Cyran, Agnieszka; Misiak, Błażej (2021). "The Impact of Adverse Childhood Experiences on Coping Strategies in Schizophrenia Spectrum Disorders: A Case-Control Study". Psychology Research and Behavior Management. 14: 1315–1323. doi:10.2147/PRBM.S324152. ISSN 1179-1578. PMC 8403075. PMID 34466040.
  105. ^ Guloksuz S, van Os J (January 2018). "The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum". Psychological Medicine. 48 (2): 229–244. doi:10.1017/S0033291717001775. PMID 28689498.
  106. ^ Costa E, Silva JA, Steffen RE (November 2019). "Urban environment and psychiatric disorders: a review of the neuroscience and biology". Metabolism: Clinical and Experimental. 100S: 153940. doi:10.1016/j.metabol.2019.07.004. PMID 31610855. S2CID 204704312.
  107. ^ van Os J (April 2004). "Does the urban environment cause psychosis?". The British Journal of Psychiatry. 184 (4): 287–8. doi:10.1192/bjp.184.4.287. PMID 15056569.
  108. ^ Attademo L, Bernardini F, Garinella R, Compton MT (March 2017). "Environmental pollution and risk of psychotic disorders: A review of the science to date". Schizophrenia Research. 181: 55–59. doi:10.1016/j.schres.2016.10.003. PMID 27720315. S2CID 25505446.
  109. ^ Selten JP, Cantor-Graae E, Kahn RS (March 2007). "Migration and schizophrenia". Current Opinion in Psychiatry. 20 (2): 111–115. doi:10.1097/YCO.0b013e328017f68e. PMID 17278906. S2CID 21391349.
  110. ^ Sharma R, Agarwal A, Rohra VK, et al. (April 2015). "Effects of increased paternal age on sperm quality, reproductive outcome and associated epigenetic risks to offspring". Reprod. Biol. Endocrinol. 13: 35. doi:10.1186/s12958-015-0028-x. PMC 4455614. PMID 25928123.
  111. ^ a b Gregg L, Barrowclough C, Haddock G (May 2007). "Reasons for increased substance use in psychosis". Clinical Psychology Review. 27 (4): 494–510. doi:10.1016/j.cpr.2006.09.004. PMID 17240501.
  112. ^ Sagud M, Mihaljević-Peles A, Mück-Seler D, et al. (September 2009). "Smoking and schizophrenia". Psychiatria Danubina. 21 (3): 371–375. PMID 19794359.
  113. ^ Larson M (30 March 2006). "Alcohol-Related Psychosis". EMedicine. from the original on 9 November 2008. Retrieved 27 September 2006.
  114. ^ Leweke FM, Koethe D (June 2008). "Cannabis and psychiatric disorders: it is not only addiction". Addiction Biology. 13 (2): 264–75. doi:10.1111/j.1369-1600.2008.00106.x. PMID 18482435. S2CID 205400285.
  115. ^ a b c d Khokhar JY, Henricks AM, Sullivan ED, Green AI (2018). "Unique Effects of Clozapine: A Pharmacological Perspective". Apprentices to Genius: A tribute to Solomon H. Snyder. Advances in Pharmacology. Vol. 82. pp. 137–162. doi:10.1016/bs.apha.2017.09.009. ISBN 978-0128140871. PMC 7197512. PMID 29413518.
  116. ^ Bighelli, Irene; Rodolico, Alessandro; García-Mieres, Helena; Pitschel-Walz, Gabi; Hansen, Wulf-Peter; Schneider-Thoma, Johannes; Siafis, Spyridon; Wu, Hui; Wang, Dongfang; Salanti, Georgia; Furukawa, Toshi A; Barbui, Corrado; Leucht, Stefan (2021). "Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis". The Lancet Psychiatry. 8 (11): 969–980. doi:10.1016/S2215-0366(21)00243-1. PMID 34653393. S2CID 239003358.
  117. ^ Patel S, Khan S, M S, Hamid P (July 2020). "The Association Between Cannabis Use and Schizophrenia: Causative or Curative? A Systematic Review". Cureus. 12 (7): e9309. doi:10.7759/cureus.9309. PMC 7442038. PMID 32839678.
  118. ^ Hasan A, von Keller R, Friemel CM, Hall W, Schneider M, Koethe D, Leweke FM, Strube W, Hoch E (June 2020). "Cannabis use and psychosis: a review of reviews". Eur Arch Psychiatry Clin Neurosci. 270 (4): 403–412. doi:10.1007/s00406-019-01068-z. PMID 31563981. S2CID 203567900.
  119. ^ "Causes — Schizophrenia". UK National Health Service. 11 November 2019. Retrieved 8 December 2021.
  120. ^ Ortiz-Medina MB, Perea M, Torales J, et al. (November 2018). "Cannabis consumption and psychosis or schizophrenia development". The International Journal of Social Psychiatry. 64 (7): 690–704. doi:10.1177/0020764018801690. PMID 30442059. S2CID 53563635.
  121. ^ Hayes D, Kyriakopoulos M (August 2018). "Dilemmas in the treatment of early-onset first-episode psychosis". Therapeutic Advances in Psychopharmacology. 8 (8): 231–239. doi:10.1177/2045125318765725. PMC 6058451. PMID 30065814.
  122. ^ Cannon TD (December 2015). "How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis". Trends Cogn Sci. 19 (12): 744–756. doi:10.1016/j.tics.2015.09.009. PMC 4673025. PMID 26493362.
  123. ^ Correll CU, Schooler NR (2020). "Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment". Neuropsychiatric Disease and Treatment. 16: 519–534. doi:10.2147/NDT.S225643. PMC 7041437. PMID 32110026.
  124. ^ Howes OD (1 January 2017). "The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia". Biological Psychiatry. 81 (1): 9–20. doi:10.1016/j.biopsych.2016.07.014. PMC 5675052. PMID 27720198.
  125. ^ Broyd A, Balzan RP, Woodward TS, Allen P (June 2017). "Dopamine, cognitive biases and assessment of certainty: A neurocognitive model of delusions". Clinical Psychology Review. 54: 96–106. doi:10.1016/j.cpr.2017.04.006. PMID 28448827.
  126. ^ Howes OD, Murray RM (May 2014). "Schizophrenia: an integrated sociodevelopmental-cognitive model". Lancet. 383 (9929): 1677–1687. doi:10.1016/S0140-6736(13)62036-X. PMC 4127444. PMID 24315522.
  127. ^ Grace AA (August 2016). "Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression". Nature Reviews. Neuroscience. 17 (8): 524–532. doi:10.1038/nrn.2016.57. PMC 5166560. PMID 27256556.
  128. ^ Fusar-Poli P, Meyer-Lindenberg A (January 2013). "Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies". Schizophrenia Bulletin. 39 (1): 33–42. doi:10.1093/schbul/sbr180. PMC 3523905. PMID 22282454.
  129. ^ Howes OD, Kambeitz J, Kim E, et al. (August 2012). "The nature of dopamine dysfunction in schizophrenia and what this means for treatment". Archives of General Psychiatry. 69 (8): 776–786. doi:10.1001/archgenpsychiatry.2012.169. PMC 3730746. PMID 22474070.
  130. ^ Arnsten AF, Girgis RR, Gray DL, Mailman RB (January 2017). "Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia". Biological Psychiatry. 81 (1): 67–77. doi:10.1016/j.biopsych.2015.12.028. PMC 4949134. PMID 26946382.
  131. ^ Maia TV, Frank MJ (January 2017). "An Integrative Perspective on the Role of Dopamine in Schizophrenia". Biological Psychiatry. 81 (1): 52–66. doi:10.1016/j.biopsych.2016.05.021. PMC 5486232. PMID 27452791.
  132. ^ a b Pratt J, Dawson N, Morris BJ, et al. (February 2017). "Thalamo-cortical communication, glutamatergic neurotransmission and neural oscillations: A unique window into the origins of ScZ?" (PDF). Schizophrenia Research. 180: 4–12. doi:10.1016/j.schres.2016.05.013. PMID 27317361. S2CID 205075178.
  133. ^ Catts VS, Lai YL, Weickert CS, Weickert TW, Catts SV (April 2016). "A quantitative review of the post-mortem evidence for decreased cortical N-methyl-D-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits?". Biological Psychology. 116: 57–67. doi:10.1016/j.biopsycho.2015.10.013. PMID 26549579.
  134. ^ Michie PT, Malmierca MS, Harms L, Todd J (April 2016). "The neurobiology of MMN and implications for schizophrenia". Biological Psychology. 116: 90–97. doi:10.1016/j.biopsycho.2016.01.011. PMID 26826620. S2CID 41179430.
  135. ^ a b Marín O (January 2012). "Interneuron dysfunction in psychiatric disorders". Nature Reviews. Neuroscience. 13 (2): 107–120. doi:10.1038/nrn3155. PMID 22251963. S2CID 205507186.
  136. ^ Lewis DA, Hashimoto T, Volk DW (April 2005). "Cortical inhibitory neurons and schizophrenia". Nature Reviews. Neuroscience. 6 (4): 312–324. doi:10.1038/nrn1648. PMID 15803162. S2CID 3335493.
  137. ^ Senkowski D, Gallinat J (June 2015). "Dysfunctional prefrontal gamma-band oscillations reflect working memory and other cognitive deficits in schizophrenia". Biological Psychiatry. 77 (12): 1010–1019. doi:10.1016/j.biopsych.2015.02.034. PMID 25847179. S2CID 206104940. Several studies that investigated perceptual processes found impaired GBR in ScZ patients over sensory areas, such as the auditory and visual cortex. Moreover, studies examining steady-state auditory-evoked potentials showed deficits in the gen- eration of oscillations in the gamma band.
  138. ^ Reilly TJ, Nottage JF, Studerus E, et al. (July 2018). "Gamma band oscillations in the early phase of psychosis: A systematic review". Neuroscience and Biobehavioral Reviews. 90: 381–399. doi:10.1016/j.neubiorev.2018.04.006. PMID 29656029. S2CID 4891072. Decreased gamma power in response to a task was a relatively consistent finding, with 5 out of 6 studies reported reduced evoked or induced power.
  139. ^ a b Sloan SA, Barres BA (August 2014). "Mechanisms of astrocyte development and their contributions to neurodevelopmental disorders". Curr Opin Neurobiol. 27: 75–81. doi:10.1016/j.conb.2014.03.005. PMC 4433289. PMID 24694749.
  140. ^ Lesh TA, Niendam TA, Minzenberg MJ, Carter CS (January 2011). "Cognitive control deficits in schizophrenia: mechanisms and meaning". Neuropsychopharmacology. 36 (1): 316–338. doi:10.1038/npp.2010.156. PMC 3052853. PMID 20844478.
  141. ^ Barch DM, Ceaser A (January 2012). "Cognition in schizophrenia: core psychological and neural mechanisms". Trends in Cognitive Sciences. 16 (1): 27–34. doi:10.1016/j.tics.2011.11.015. PMC 3860986. PMID 22169777.
  142. ^ Eisenberg DP, Berman KF (January 2010). "Executive function, neural circuitry, and genetic mechanisms in schizophrenia". Neuropsychopharmacology. 35 (1): 258–277. doi:10.1038/npp.2009.111. PMC 2794926. PMID 19693005.
  143. ^ Walton E, Hibar DP, van Erp TG, et al. (May 2017). "Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium". Acta Psychiatrica Scandinavica. 135 (5): 439–447. doi:10.1111/acps.12718. PMC 5399182. PMID 28369804.
  144. ^ Walton E, Hibar DP, van Erp TG, et al. (Karolinska Schizophrenia Project Consortium (KaSP)) (January 2018). "Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium". Psychological Medicine. 48 (1): 82–94. doi:10.1017/S0033291717001283. PMC 5826665. PMID 28545597.
  145. ^ Cohen AS, Minor KS (January 2010). "Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies". Schizophrenia Bulletin. 36 (1): 143–150. doi:10.1093/schbul/sbn061. PMC 2800132. PMID 18562345.
  146. ^ Strauss GP, Gold JM (April 2012). "A new perspective on anhedonia in schizophrenia". The American Journal of Psychiatry. 169 (4): 364–373. doi:10.1176/appi.ajp.2011.11030447. PMC 3732829. PMID 22407079.
  147. ^ Young J, Anticevic A, Barch D (2018). "Cognitive and Motivational Neuroscience of Psychotic Disorders". In Charney D, Buxbaum J, Sklar P, Nestler E (eds.). Charney & Nestler's Neurobiology of Mental Illness (5th ed.). New York: Oxford University Press. pp. 215, 217. ISBN 9780190681425. Several recent reviews (e.g., Cohen and Minor, 2010) have found that individuals with schizophrenia show relatively intact self-reported emotional responses to affect-eliciting stimuli as well as other indicators of intact response(215)...Taken together, the literature increasingly suggests that there may be a deficit in putatively DA-mediated reward learning and/ or reward prediction functions in schizophrenia. Such findings suggest that impairment in striatal reward prediction mechanisms may influence "wanting" in schizophrenia in a way that reduces the ability of individuals with schizophrenia to use anticipated rewards to drive motivated behavior.(217)
  148. ^ a b Wiberg A, Ng M, Al Omran Y, et al. (1 October 2019). "Handedness, language areas and neuropsychiatric diseases: insights from brain imaging and genetics". Brain: A Journal of Neurology. 142 (10): 2938–2947. doi:10.1093/brain/awz257. PMC 6763735. PMID 31504236.
  149. ^ Tzourio-Mazoyer N, Kennedy H, Van Essen DC, Christen Y (2016). "Intra- and Inter-hemispheric Connectivity Supporting Hemispheric Specialization". Micro-, Meso- and Macro-Connectomics of the Brain. Research and Perspectives in Neurosciences. pp. 129–146. doi:10.1007/978-3-319-27777-6_9. ISBN 978-3-319-27776-9. PMID 28590670. S2CID 147813648.
  150. ^ Ocklenburg S, Güntürkün O, Hugdahl K, Hirnstein M (December 2015). "Laterality and mental disorders in the postgenomic age—A closer look at schizophrenia and language lateralization". Neuroscience and Biobehavioral Reviews. 59: 100–110. doi:10.1016/j.neubiorev.2015.08.019. PMID 26598216. S2CID 15983622.
  151. ^ Friston KJ, Stephan KE, Montague R, Dolan RJ (July 2014). "Computational psychiatry: the brain as a phantastic organ". The Lancet. Psychiatry. 1 (2): 148–158. doi:10.1016/S2215-0366(14)70275-5. PMID 26360579.
  152. ^ Griffin JD, Fletcher PC (May 2017). "Predictive Processing, Source Monitoring, and Psychosis". Annual Review of Clinical Psychology. 13: 265–289. doi:10.1146/annurev-clinpsy-032816-045145. PMC 5424073. PMID 28375719.
  153. ^ Fletcher PC, Frith CD (January 2009). "Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia" (PDF). Nature Reviews. Neuroscience. 10 (1): 48–58. doi:10.1038/nrn2536. PMID 19050712. S2CID 6219485.
  154. ^ Corlett PR, Taylor JR, Wang XJ, Fletcher PC, Krystal JH (November 2010). "Toward a neurobiology of delusions". Progress in Neurobiology. 92 (3): 345–369. doi:10.1016/j.pneurobio.2010.06.007. PMC 3676875. PMID 20558235.
  155. ^ Bastos AM, Usrey WM, Adams RA, et al. (21 November 2012). "Canonical microcircuits for predictive coding". Neuron. 76 (4): 695–711. doi:10.1016/j.neuron.2012.10.038. PMC 3777738. PMID 23177956.
  156. ^ Soltan M, Girguis J (8 May 2017). "How to approach the mental state examination". BMJ. 357: j1821. doi:10.1136/sbmj.j1821. PMID 31055448. S2CID 145820368. Retrieved 9 January 2020.
  157. ^ Lindenmayer JP (1 December 2017). "Are Shorter Versions of the Positive and Negative Syndrome Scale (PANSS) Doable? A Critical Review". Innovations in Clinical Neuroscience. 14 (11–12): 73–76. PMC 5788254. PMID 29410940.
  158. ^ "Diagnosis of schizophrenia". Australian Department of Health. 10 January 2019. Retrieved 28 January 2020.
  159. ^ "Schizophrenia – Diagnosis". UK National Health Service. 23 October 2017. Retrieved 28 January 2020.
  160. ^ Jakobsen KD, Frederiksen JN, Hansen T, et al. (2005). "Reliability of clinical ICD-10 schizophrenia diagnoses". Nordic Journal of Psychiatry. 59 (3): 209–212. doi:10.1080/08039480510027698. PMID 16195122. S2CID 24590483.
  161. ^ a b c Richard-Devantoy S, Olie JP, Gourevitch R (December 2009). "[Risk of homicide and major mental disorders: a critical review]". L'Encephale. 35 (6): 521–530. doi:10.1016/j.encep.2008.10.009. PMID 20004282.
  162. ^ a b Staedt J, Hauser M, Gudlowski Y, Stoppe G (February 2010). "Sleep disorders in schizophrenia". Fortschritte der Neurologie-Psychiatrie. 78 (2): 70–80. doi:10.1055/s-0028-1109967. PMID 20066610.
  163. ^ a b Pocivavsek A, Rowland LM (13 January 2018). "Basic Neuroscience Illuminates Causal Relationship Between Sleep and Memory: Translating to Schizophrenia". Schizophrenia Bulletin. 44 (1): 7–14. doi:10.1093/schbul/sbx151. PMC 5768044. PMID 29136236.
  164. ^ a b Monti JM, BaHammam AS, Pandi-Perumal SR, et al. (3 June 2013). "Sleep and circadian rhythm dysregulation in schizophrenia". Progress in Neuro-psychopharmacology & Biological Psychiatry. 43: 209–216. doi:10.1016/j.pnpbp.2012.12.021. PMID 23318689. S2CID 19626589.
  165. ^ Faulkner SM, Bee PE, Meyer N, Dijk DJ, Drake RJ (August 2019). "Light therapies to improve sleep in intrinsic circadian rhythm sleep disorders and neuro-psychiatric illness: A systematic review and meta-analysis". Sleep Medicine Reviews. 46: 108–123. doi:10.1016/j.smrv.2019.04.012. PMID 31108433.
  166. ^ Assimakopoulos K, Karaivazoglou K, Skokou M, et al. (24 March 2018). "Genetic Variations Associated with Sleep Disorders in Patients with Schizophrenia: A Systematic Review". Medicines. 5 (2): 27. doi:10.3390/medicines5020027. PMC 6023503. PMID 29587340.
  167. ^ Schrimpf LA, Aggarwal A, Lauriello J (June 2018). "Psychosis". Continuum (Minneap Minn). 24 (3): 845–860. doi:10.1212/CON.0000000000000602. PMID 29851881. S2CID 243933980.
  168. ^ Bottas A (15 April 2009). "Comorbidity: Schizophrenia With Obsessive-Compulsive Disorder". Psychiatric Times. 26 (4). from the original on 3 April 2013.
  169. ^ OConghaile A, DeLisi LE (May 2015). "Distinguishing schizophrenia from posttraumatic stress disorder with psychosis". Curr Opin Psychiatry. 28 (3): 249–255. doi:10.1097/YCO.0000000000000158. PMID 25785709. S2CID 12523516.
  170. ^ Murray ED, Buttner N, Price BH (2012). "Depression and Psychosis in Neurological Practice". In Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds.). Bradley's neurology in clinical practice. Vol. 1 (6th ed.). Philadelphia, PA: Elsevier/Saunders. pp. 92–111. ISBN 978-1-4377-0434-1.
  171. ^ Leucht, Stefan; Bauer, Sofia; Siafis, Spyridon; Hamza, Tasnim; Wu, Hui; Schneider-Thoma, Johannes; Salanti, Georgia; Davis, John M. (1 November 2021). "Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis". JAMA Psychiatry. 78 (11): 1238–1248. doi:10.1001/jamapsychiatry.2021.2130. ISSN 2168-622X. PMC 8374744. PMID 34406325.
  172. ^ Cannon TD, Cornblatt B, McGorry P (May 2007). "The empirical status of the ultra high-risk (prodromal) research paradigm". Schizophrenia Bulletin. 33 (3): 661–664. doi:10.1093/schbul/sbm031. PMC 2526144. PMID 17470445.
  173. ^ a b Marshall M, Rathbone J (June 2011). "Early intervention for psychosis". The Cochrane Database of Systematic Reviews (6): CD004718. doi:10.1002/14651858.CD004718.pub3. PMC 4163966. PMID 21678345.
  174. ^ Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T (January 2013). "Early interventions to prevent psychosis: systematic review and meta-analysis". BMJ. 346: f185. doi:10.1136/bmj.f185. PMC 3548617. PMID 23335473.
  175. ^ a b Taylor M, Jauhar S (September 2019). "Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia". Therapeutic Advances in Psychopharmacology. 9: 204512531987003. doi:10.1177/2045125319870033. PMC 6732843. PMID 31523418.
  176. ^ Weiden PJ (July 2016). "Beyond Psychopharmacology: Emerging Psychosocial Interventions for Core Symptoms of Schizophrenia". Focus (American Psychiatric Publishing). 14 (3): 315–327. doi:10.1176/appi.focus.20160014. PMC 6526802. PMID 31975812.
  177. ^ McGurk SR, Mueser KT, Feldman K, Wolfe R, Pascaris A (March 2007). "Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial". The American Journal of Psychiatry. 164 (3): 437–441. doi:10.1176/appi.ajp.164.3.437. PMID 17329468.
  178. ^ Souaiby L, Gaillard R, Krebs MO (August 2016). "[Duration of untreated psychosis: A state-of-the-art review and critical analysis]". Encephale. 42 (4): 361–366. doi:10.1016/j.encep.2015.09.007. PMID 27161262.
  179. ^ Fuller Torrey E (June 2015). "Deinstitutionalization and the rise of violence". CNS Spectrums. 20 (3): 207–214. doi:10.1017/S1092852914000753. PMID 25683467.
  180. ^ a b c "Schizophrenia – Treatment". UK National Health Service. 23 October 2017. Retrieved 8 January 2020.
  181. ^ Ortiz-Orendain J, Covarrubias-Castillo SA, Vazquez-Alvarez AO, Castiello-de Obeso S, Arias Quiñones GE, Seegers M, Colunga-Lozano LE (December 2019). "Modafinil for people with schizophrenia or related disorders". The Cochrane Database of Systematic Reviews. 12 (12): CD008661. doi:10.1002/14651858.CD008661.pub2. PMC 6906203. PMID 31828767.
  182. ^ Lally J, MacCabe JH (June 2015). "Antipsychotic medication in schizophrenia: a review". British Medical Bulletin. 114 (1): 169–179. doi:10.1093/bmb/ldv017. PMID 25957394.
  183. ^ Keks N, Schwartz D, Hope J (October 2019). "Stopping and switching antipsychotic drugs". Australian Prescriber. 42 (5): 152–157. doi:10.18773/austprescr.2019.052. PMC 6787301. PMID 31631928.
  184. ^ Harrow M, Jobe TH (September 2013). "Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?". Schizophrenia Bulletin. 39 (5): 962–5. doi:10.1093/schbul/sbt034. PMC 3756791. PMID 23512950.
  185. ^ Elkis H, Buckley PF (June 2016). "Treatment-Resistant Schizophrenia". The Psychiatric Clinics of North America. 39 (2): 239–65. doi:10.1016/j.psc.2016.01.006. PMID 27216902.
  186. ^ Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH (13 January 2017). "Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review". BMC Psychiatry. 17 (1): 12. doi:10.1186/s12888-016-1177-y. PMC 5237235. PMID 28086761.
  187. ^ Essali A, Al-Haj Haasan N, Li C, Rathbone J (January 2009). "Clozapine versus typical neuroleptic medication for schizophrenia". The Cochrane Database of Systematic Reviews. 2009 (1): CD000059. doi:10.1002/14651858.CD000059.pub2. PMC 7065592. PMID 19160174.
  188. ^ Baier M (August 2010). "Insight in schizophrenia: a review". Current Psychiatry Reports. 12 (4): 356–361. doi:10.1007/s11920-010-0125-7. PMID 20526897. S2CID 29323212.
  189. ^ Peters L, Krogmann A, von Hardenberg L, et al. (19 November 2019). "Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016 – March 2019". Current Psychiatry Reports. 21 (12): 124. doi:10.1007/s11920-019-1114-0. PMID 31745659. S2CID 208144438.
  190. ^ Leucht S, Tardy M, Komossa K, et al. (June 2012). "Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis". Lancet. 379 (9831): 2063–2071. doi:10.1016/S0140-6736(12)60239-6. PMID 22560607. S2CID 2018124.
  191. ^ McEvoy JP (2006). "Risks versus benefits of different types of long-acting injectable antipsychotics". The Journal of Clinical Psychiatry. 67 Suppl 5: 15–18. PMID 16822092.
  192. ^ a b Chow CL, Kadouh NK, Bostwick JR, VandenBerg AM (June 2020). "Akathisia and Newer Second-Generation Antipsychotic Drugs: A Review of Current Evidence". Pharmacotherapy. 40 (6): 565–574. doi:10.1002/phar.2404. hdl:2027.42/155998. PMID 32342999. S2CID 216596357.
  193. ^ Carbon M, Kane JM, Leucht S, Correll CU (October 2018). "Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis". World Psychiatry. 17 (3): 330–340. doi:10.1002/wps.20579. PMC 6127753. PMID 30192088.
  194. ^ a b Pharoah F, Mari J, Rathbone J, Wong W (December 2010). Pharoah F (ed.). "Family intervention for schizophrenia". The Cochrane Database of Systematic Reviews. 12 (12): CD000088. doi:10.1002/14651858.CD000088.pub2. PMC 4204509. PMID 21154340.
  195. ^ Bellani M, Ricciardi C, Rossetti MG, Zovetti N, Perlini C, Brambilla P (September 2019). "Cognitive remediation in schizophrenia: the earlier the better?". Epidemiol Psychiatr Sci. 29: e57. doi:10.1017/S2045796019000532. PMC 8061237. PMID 31556864.
  196. ^ Philipp R, Kriston L, Lanio J, et al. (2019). "Effectiveness of metacognitive interventions for mental disorders in adults-A systematic review and meta-analysis (METACOG)". Clinical Psychology & Psychotherapy. 26 (2): 227–240. doi:10.1002/cpp.2345. PMID 30456821. S2CID 53872643.
  197. ^ Rouy, Martin; Saliou, Pauline; Nalborczyk, Ladislas; Pereira, Michael; Roux, Paul; Faivre, Nathan (2021). "Systematic review and meta-analysis of metacognitive abilities in individuals with schizophrenia spectrum disorders" (PDF). Neuroscience & Biobehavioral Reviews. 126: 329–337. doi:10.1016/j.neubiorev.2021.03.017. PMID 33757817. S2CID 232288918.
  198. ^ Dixon LB, Dickerson F, Bellack AS, et al. (January 2010). "The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements". Schizophrenia Bulletin. 36 (1): 48–70. doi:10.1093/schbul/sbp115. PMC 2800143. PMID 19955389.
  199. ^ Bond GR, Drake RE (June 2015). "The critical ingredients of assertive community treatment". World Psychiatry. 14 (2): 240–242. doi:10.1002/wps.20234. PMC 4471983. PMID 26043344.
  200. ^ Smeerdijk M (2017). "[Using resource groups in assertive community treatment; literature review and recommendation]". Tijdschrift voor Psychiatrie. 59 (8): 466–473. PMID 28880347.
  201. ^ Dieterich M (6 January 2017). "Intensive case management for severe mental illness". The Cochrane Database of Systematic Reviews. 1 (1): CD007906. doi:10.1002/14651858.CD007906.pub3. PMC 6472672. PMID 28067944.
  202. ^ Jauhar S, McKenna PJ, Radua J, et al. (January 2014). "Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias". The British Journal of Psychiatry (Review). 204 (1): 20–29. doi:10.1192/bjp.bp.112.116285. PMID 24385461.
  203. ^ a b Jones C, Hacker D, Meaden A, et al. (November 2018). "Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia". The Cochrane Database of Systematic Reviews. 11 (6): CD008712. doi:10.1002/14651858.CD008712.pub3. PMC 6516879. PMID 30480760.
  204. ^ Health Quality, Ontario (2018). "Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment". Ontario Health Technology Assessment Series. 18 (5): 1–141. PMC 6235075. PMID 30443277.
  205. ^ Ruddy R, Milnes D (October 2005). "Art therapy for schizophrenia or schizophrenia-like illnesses". The Cochrane Database of Systematic Reviews (4): CD003728. doi:10.1002/14651858.CD003728.pub2. PMID 16235338. from the original on 27 October 2011.
  206. ^ Ruddy RA, Dent-Brown K (January 2007). "Drama therapy for schizophrenia or schizophrenia-like illnesses". The Cochrane Database of Systematic Reviews (1): CD005378. doi:10.1002/14651858.CD005378.pub2. PMID 17253555. from the original on 25 August 2011.
  207. ^ Galletly C, Castle D, Dark F, et al. (May 2016). "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders". Aust N Z J Psychiatry. 50 (5): 410–472. doi:10.1177/0004867416641195. PMID 27106681. S2CID 6536743.
  208. ^ Chien WT, Clifton AV, Zhao S, Lui S (4 April 2019). "Peer support for people with schizophrenia or other serious mental illness". The Cochrane Database of Systematic Reviews. 4 (6): CD010880. doi:10.1002/14651858.CD010880.pub2. PMC 6448529. PMID 30946482.
  209. ^ a b Girdler SJ, Confino JE, Woesner ME (15 February 2019). "Exercise as a Treatment for Schizophrenia: A Review". Psychopharmacology Bulletin. 49 (1): 56–69. PMC 6386427. PMID 30858639.
  210. ^ a b Firth J (1 May 2017). "Aerobic Exercise Improves Cognitive Functioning in People With Schizophrenia: A Systematic Review and Meta-Analysis". Schizophrenia Bulletin. 43 (3): 546–556. doi:10.1093/schbul/sbw115. PMC 5464163. PMID 27521348.
  211. ^ Tréhout M, Dollfus S (December 2018). "[Physical activity in patients with schizophrenia: From neurobiology to clinical benefits]". L'Encéphale. 44 (6): 538–547. doi:10.1016/j.encep.2018.05.005. PMID 29983176. S2CID 150334210.
  212. ^ "Quality statement 7: Promoting healthy eating, physical activity and smoking cessation | Psychosis and schizophrenia in adults". UK National Institute for Health and Care Excellence.
  213. ^ a b c Firth J, Carney R, Stubbs B, et al. (October 2018). "Nutritional Deficiencies and Clinical Correlates in First-Episode Psychosis: A Systematic Review and Meta-analysis". Schizophrenia Bulletin. 44 (6): 1275–1292. doi:10.1093/schbul/sbx162. PMC 6192507. PMID 29206972.
  214. ^ a b c d Rastogi A, Viani-Walsh D, Akbari S, Gall N, Gaughran F, Lally J (October 2020). "Pathogenesis and management of Brugada syndrome in schizophrenia: A scoping review". General Hospital Psychiatry. 67: 83–91. doi:10.1016/j.genhosppsych.2020.09.003. PMC 7537626. PMID 33065406.
  215. ^ Martone G (April 2018). "Enhancement of recovery from mental illness with l-methylfolate supplementation". Perspectives in Psychiatric Care. 54 (2): 331–334. doi:10.1111/ppc.12227. PMID 28597528.
  216. ^ a b Firth J, Teasdale SB, Allott K, et al. (October 2019). "The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials". World Psychiatry. 18 (3): 308–324. doi:10.1002/wps.20672. PMC 6732706. PMID 31496103.
  217. ^ Kritharides L, Chow V, Lambert TJ (6 February 2017). "Cardiovascular disease in patients with schizophrenia". The Medical Journal of Australia. 206 (2): 91–95. doi:10.5694/mja16.00650. PMID 28152356. S2CID 5388097.
  218. ^ Erlangsen A, Eaton WW, Mortensen PB, Conwell Y (February 2012). "Schizophrenia—a predictor of suicide during the second half of life?". Schizophrenia Research. 134 (2–3): 111–117. doi:10.1016/j.schres.2011.09.032. PMC 3266451. PMID 22018943.
March 20, 2023
schizophrenia, other, uses, disambiguation, mental, disorder, characterized, continuous, relapsing, episodes, psychosis, major, symptoms, include, hallucinations, typically, hearing, voices, delusions, disorganized, thinking, other, symptoms, include, social, . For other uses see Schizophrenia disambiguation Schizophrenia is a mental disorder 13 characterized by continuous or relapsing episodes of psychosis 5 Major symptoms include hallucinations typically hearing voices delusions and disorganized thinking 7 Other symptoms include social withdrawal decreased emotional expression and apathy 5 Symptoms typically develop gradually begin during young adulthood and in many cases never become resolved 3 7 There is no objective diagnostic test diagnosis is based on observed behavior a psychiatric history that includes the person s reported experiences and reports of others familiar with the person 7 To be diagnosed with schizophrenia symptoms and functional impairment need to be present for six months DSM 5 or one month ICD 11 7 14 Many people with schizophrenia have other mental disorders especially substance use disorders depressive disorders anxiety disorders and obsessive compulsive disorder 7 SchizophreniaCloth embroidered by a person diagnosed with schizophreniaPronunciation ˌ s k ɪ t s e ˈ f r iː n i e UK also ˌ s k ɪ d z e US also ˈ f r ɛ n i e 1 SpecialtyPsychiatrySymptomsHallucinations usually hearing voices delusions confused thinking 2 3 ComplicationsSuicide heart disease lifestyle diseases 4 Usual onsetAges 16 to 30 3 DurationChronic 3 CausesEnvironmental and genetic factors 5 Risk factorsFamily history cannabis use in adolescence problems during pregnancy childhood adversity birth in late winter or early spring older father being born or raised in a city 5 6 Diagnostic methodBased on observed behavior reported experiences and reports of others familiar with the person 7 Differential diagnosisSubstance use disorder Huntington s disease mood disorders bipolar disorder autism 8 borderline personality disorder 9 ManagementCounseling life skills training 2 5 MedicationAntipsychotics 5 Prognosis20 28 years shorter life expectancy 10 11 Deaths 17 000 2015 12 About 0 3 to 0 7 of people are diagnosed with schizophrenia during their lifetime 15 In 2017 there were an estimated 1 1 million new cases and in 2022 a total of 24 million cases globally 2 16 Males are more often affected and on average have an earlier onset 2 The causes of schizophrenia include genetic and environmental factors 5 Genetic factors include a variety of common and rare genetic variants 17 Possible environmental factors include being raised in a city childhood adversity cannabis use during adolescence infections the ages of a person s mother or father and poor nutrition during pregnancy 5 18 About half of those diagnosed with schizophrenia will have a significant improvement over the long term with no further relapses and a small proportion of these will recover completely 7 19 The other half will have a lifelong impairment 20 In severe cases people may be admitted to hospitals 19 Social problems such as long term unemployment poverty homelessness exploitation and victimization are commonly correlated with schizophrenia 21 22 Compared to the general population people with schizophrenia have a higher suicide rate about 5 overall and more physical health problems 23 24 leading to an average decrease in life expectancy by 20 10 to 28 years 11 In 2015 an estimated 17 000 deaths were linked to schizophrenia 12 The mainstay of treatment is antipsychotic medication along with counseling job training and social rehabilitation 5 Up to a third of people do not respond to initial antipsychotics in which case clozapine may be used 25 In a network comparative meta analysis of 15 antipsychotic drugs clozapine was significantly more effective than all other drugs although clozapine s heavily multimodal action may cause more side effects 26 In situations where doctors judge that there is a risk of harm to self or others they may impose short involuntary hospitalization 27 Long term hospitalization is used on a small number of people with severe schizophrenia 28 In some countries where supportive services are limited or unavailable long term hospital stays are more common 29 Contents 1 Signs and symptoms 1 1 Positive symptoms 1 2 Negative symptoms 1 3 Cognitive symptoms 1 4 Onset 2 Risk factors 2 1 Genetic 2 2 Environmental 2 2 1 Substance use 3 Mechanism 4 Diagnosis 4 1 Criteria 4 2 Comorbidities 4 3 Differential diagnosis 5 Prevention 6 Management 6 1 Medication 6 1 1 Adverse effects 6 2 Psychosocial interventions 6 3 Other 7 Prognosis 7 1 Violence 8 Epidemiology 9 History 9 1 Conceptual development 9 2 Breadth of diagnosis 9 3 Historical treatment 9 4 Political abuse 10 Society and culture 10 1 Stigma 10 2 Cultural depictions 11 Research directions 12 Explanatory notes 13 References 14 External linksSigns and symptoms My Eyes at the Moment of the Apparitions by German artist August Natterer who had schizophrenia Schizophrenia is a mental disorder characterized by significant alterations in perception thoughts mood and behavior 30 Symptoms are described in terms of positive negative and cognitive symptoms 3 31 The positive symptoms of schizophrenia are the same for any psychosis and are sometimes referred to as psychotic symptoms These may be present in any of the different psychoses and are often transient making early diagnosis of schizophrenia problematic Psychosis noted for the first time in a person who is later diagnosed with schizophrenia is referred to as a first episode psychosis FEP 32 33 Positive symptoms Positive symptoms are those symptoms that are not normally experienced but are present in people during a psychotic episode in schizophrenia They include delusions hallucinations and disorganized thoughts and speech typically regarded as manifestations of psychosis 32 Hallucinations occur at some point in the lifetimes of 80 of those with schizophrenia 34 and most commonly involve the sense of hearing most often hearing voices but can sometimes involve any of the other senses of taste sight smell and touch 35 The frequency of hallucinations involving multiple senses is double the rate of those involving only one sense 34 They are also typically related to the content of the delusional theme 36 Delusions are bizarre or persecutory in nature Distortions of self experience such as feeling as if one s thoughts or feelings are not really one s own to believing that thoughts are being inserted into one s mind sometimes termed passivity phenomena are also common 37 Thought disorders can include thought blocking and disorganized speech 3 Positive symptoms generally respond well to medication 5 and become reduced over the course of the illness perhaps related to the age related decline in dopamine activity 7 Negative symptoms Negative symptoms are deficits of normal emotional responses or of other thought processes The five recognized domains of negative symptoms are blunted affect showing flat expressions or little emotion alogia a poverty of speech anhedonia an inability to feel pleasure asociality the lack of desire to form relationships and avolition a lack of motivation and apathy 38 39 Avolition and anhedonia are seen as motivational deficits resulting from impaired reward processing 40 41 Reward is the main driver of motivation and this is mostly mediated by dopamine 41 It has been suggested that negative symptoms are multidimensional and they have been categorised into two subdomains of apathy or lack of motivation and diminished expression 38 42 Apathy includes avolition anhedonia and social withdrawal diminished expression includes blunt affect and alogia 43 Sometimes diminished expression is treated as both verbal and non verbal 44 Apathy accounts for around 50 percent of the most often found negative symptoms and affects functional outcome and subsequent quality of life Apathy is related to disrupted cognitive processing affecting memory and planning including goal directed behaviour 45 The two subdomains have suggested a need for separate treatment approaches 46 A lack of distress relating to a reduced experience of depression and anxiety is another noted negative symptom 47 A distinction is often made between those negative symptoms that are inherent to schizophrenia termed primary and those that result from positive symptoms from the side effects of antipsychotics substance use disorder and social deprivation termed secondary negative symptoms 48 Negative symptoms are less responsive to medication and the most difficult to treat 46 However if properly assessed secondary negative symptoms are amenable to treatment 42 Scales for specifically assessing the presence of negative symptoms and for measuring their severity and their changes have been introduced since the earlier scales such as the PANNS that deals with all types of symptoms 46 These scales are the Clinical Assessment Interview for Negative Symptoms CAINS and the Brief Negative Symptom Scale BNSS also known as second generation scales 46 47 49 In 2020 ten years after its introduction a cross cultural study of the use of BNSS found valid and reliable psychometric evidence for the five domain structure cross culturally 47 The BNSS is designed to assess both the presence and severity and change of negative symptoms of the five recognized domains and the additional item of reduced normal distress 47 BNSS can register changes in negative symptoms concerning psychosocial and pharmacological intervention trials BNSS has also been used to study a proposed non D2 treatment called SEP 363856 Findings supported the favouring of five domains over the two dimensional proposition 47 Cognitive symptoms See also Visual processing abnormalities in schizophrenia Map of deficits in neural tissue throughout the human brain in a patient with schizophrenia Lighter colored areas have more deficiencies An estimated 70 of those with schizophrenia have cognitive deficits and these are most pronounced in early onset and late onset illness 50 51 These are often evident long before the onset of illness in the prodromal stage and may be present in early adolescence or childhood 52 53 They are a core feature but not considered to be core symptoms as are positive and negative symptoms 54 55 However their presence and degree of dysfunction is taken as a better indicator of functionality than the presentation of core symptoms 52 Cognitive deficits become worse at first episode psychosis but then return to baseline and remain fairly stable over the course of the illness 56 57 The deficits in cognition are seen to drive the negative psychosocial outcome in schizophrenia and are claimed to equate to a possible reduction in IQ from the norm of 100 to 70 85 58 59 Cognitive deficits may be of neurocognition nonsocial or of social cognition 50 Neurocognition is the ability to receive and remember information and includes verbal fluency memory reasoning problem solving speed of processing and auditory and visual perception 57 Verbal memory and attention are seen to be the most affected 59 60 Verbal memory impairment is associated with a decreased level of semantic processing relating meaning to words 61 Another memory impairment is that of episodic memory 62 An impairment in visual perception that is consistently found in schizophrenia is that of visual backward masking 57 Visual processing impairments include an inability to perceive complex visual illusions 63 Social cognition is concerned with the mental operations needed to interpret and understand the self and others in the social world 57 50 This is also an associated impairment and facial emotion perception is often found to be difficult 64 65 Facial perception is critical for ordinary social interaction 66 Cognitive impairments do not usually respond to antipsychotics and there are a number of interventions that are used to try to improve them cognitive remediation therapy is of particular help 55 Neurological soft signs of clumsiness and loss of fine motor movement are often found in schizophrenia which may resolve with effective treatment of FEP 14 67 Onset Further information Basic symptoms of schizophrenia See also Childhood schizophrenia and Adolescence Changes in the brain Onset typically occurs between the late teens and early 30s with the peak incidence occurring in males in the early to mid twenties and in females in the late twenties 3 7 14 Onset before the age of 17 is known as early onset 68 and before the age of 13 as can sometimes occur is known as childhood schizophrenia or very early onset 7 69 Onset can occur between the ages of 40 and 60 known as late onset schizophrenia 50 Onset over the age of 60 which may be difficult to differentiate as schizophrenia is known as very late onset schizophrenia like psychosis 50 Late onset has shown that a higher rate of females are affected they have less severe symptoms and need lower doses of antipsychotics 50 The tendency for earlier onset in males is later seen to be balanced by a post menopausal increase in the development in females Estrogen produced pre menopause has a dampening effect on dopamine receptors but its protection can be overridden by a genetic overload 70 There has been a dramatic increase in the numbers of older adults with schizophrenia 71 Onset may happen suddenly or may occur after the slow and gradual development of a number of signs and symptoms a period known as the prodromal stage 7 Up to 75 of those with schizophrenia go through a prodromal stage 72 The negative and cognitive symptoms in the prodrome stage can precede FEP first episode psychosis by many months and up to five years 56 73 The period from FEP and treatment is known as the duration of untreated psychosis DUP which is seen to be a factor in functional outcome The prodromal stage is the high risk stage for the development of psychosis 57 Since the progression to first episode psychosis is not inevitable an alternative term is often preferred of at risk mental state 57 Cognitive dysfunction at an early age impacts a young person s usual cognitive development 74 Recognition and early intervention at the prodromal stage would minimize the associated disruption to educational and social development and has been the focus of many studies 56 73 Risk factorsMain article Risk factors of schizophrenia Schizophrenia is described as a neurodevelopmental disorder with no precise boundary or single cause and is thought to develop from gene environment interactions with involved vulnerability factors 5 75 76 The interactions of these risk factors are complex as numerous and diverse insults from conception to adulthood can be involved 76 A genetic predisposition on its own without interacting environmental factors will not give rise to the development of schizophrenia 76 77 The genetic component means that prenatal brain development is disturbed and environmental influence affects the postnatal development of the brain 78 Evidence suggests that genetically susceptible children are more likely to be vulnerable to the effects of environmental risk factors 78 Genetic Estimates of the heritability of schizophrenia are between 70 and 80 which implies that 70 to 80 of the individual differences in risk of schizophrenia are associated with genetics 17 79 These estimates vary because of the difficulty in separating genetic and environmental influences and their accuracy has been queried 80 81 The greatest risk factor for developing schizophrenia is having a first degree relative with the disease risk is 6 5 more than 40 of identical twins of those with schizophrenia are also affected 82 If one parent is affected the risk is about 13 and if both are affected the risk is nearly 50 79 However the DSM 5 indicates that most people with schizophrenia have no family history of psychosis 7 Results of candidate gene studies of schizophrenia have generally failed to find consistent associations 83 and the genetic loci identified by genome wide association studies explain only a small fraction of the variation in the disease 84 Many genes are known to be involved in schizophrenia each with small effects and unknown transmission and expression 17 85 86 The summation of these effect sizes into a polygenic risk score can explain at least 7 of the variability in liability for schizophrenia 87 Around 5 of cases of schizophrenia are understood to be at least partially attributable to rare copy number variations CNVs these structural variations are associated with known genomic disorders involving deletions at 22q11 2 DiGeorge syndrome and 17q12 17q12 microdeletion syndrome duplications at 16p11 2 most frequently found and deletions at 15q11 2 Burnside Butler syndrome 88 Some of these CNVs increase the risk of developing schizophrenia by as much as 20 fold and are frequently comorbid with autism and intellectual disabilities 88 The genes CRHR1 and CRHBP are associated with the severity of suicidal behavior These genes code for stress response proteins needed in the control of the HPA axis and their interaction can affect this axis Response to stress can cause lasting changes in the function of the HPA axis possibly disrupting the negative feedback mechanism homeostasis and the regulation of emotion leading to altered behaviors 77 The question of how schizophrenia could be primarily genetically influenced given that people with schizophrenia have lower fertility rates is a paradox It is expected that genetic variants that increase the risk of schizophrenia would be selected against due to their negative effects on reproductive fitness A number of potential explanations have been proposed including that alleles associated with schizophrenia risk confers a fitness advantage in unaffected individuals 89 90 While some evidence has not supported this idea 81 others propose that a large number of alleles each contributing a small amount can persist 91 A meta analysis found that oxidative DNA damage was significantly increased in schizophrenia 92 Environmental Further information Prenatal nutrition Prenatal stress and Neuroplastic effects of pollution Environmental factors each associated with a slight risk of developing schizophrenia in later life include oxygen deprivation infection prenatal maternal stress and malnutrition in the mother during prenatal development 93 A risk is associated with maternal obesity in increasing oxidative stress and dysregulating the dopamine and serotonin pathways 94 Both maternal stress and infection have been demonstrated to alter fetal neurodevelopment through an increase of pro inflammatory cytokines 95 There is a slighter risk associated with being born in the winter or spring possibly due to vitamin D deficiency 96 or a prenatal viral infection 82 Other infections during pregnancy or around the time of birth that have been linked to an increased risk include infections by Toxoplasma gondii and Chlamydia 97 The increased risk is about five to eight percent 98 Viral infections of the brain during childhood are also linked to a risk of schizophrenia during adulthood 99 Adverse childhood experiences ACEs severe forms of which are classed as childhood trauma range from being bullied or abused to the death of a parent 100 Many adverse childhood experiences can cause toxic stress and increase the risk of psychosis 100 101 102 Chronic trauma including ACEs can promote lasting inflammatory dysregulation throughout the nervous system 103 104 It is suggested that early stress may contribute to the development of schizophrenia through these alterations in the immune system 103 Schizophrenia was the last diagnosis to benefit from the link made between ACEs and adult mental health outcomes 105 Living in an urban environment during childhood or as an adult has consistently been found to increase the risk of schizophrenia by a factor of two 23 106 even after taking into account drug use ethnic group and size of social group 107 A possible link between the urban environment and pollution has been suggested to be the cause of the elevated risk of schizophrenia 108 Other risk factors include social isolation immigration related to social adversity and racial discrimination family dysfunction unemployment and poor housing conditions 82 109 Having a father older than 40 years or parents younger than 20 years are also associated with schizophrenia 5 110 Substance use Further information Risk factors of schizophrenia Substance use and Substance induced psychosis About half of those with schizophrenia use recreational drugs including cannabis tobacco and alcohol excessively 111 112 Use of stimulants such as amphetamine and cocaine can lead to a temporary stimulant psychosis which presents very similarly to schizophrenia Rarely alcohol use can also result in a similar alcohol related psychosis 82 113 Drugs may also be used as coping mechanisms by people who have schizophrenia to deal with depression anxiety boredom and loneliness 111 114 The use of cannabis and tobacco are not associated with the development of cognitive deficits and sometimes a reverse relationship is found where their use improves these symptoms 55 However substance use disorders are associated with an increased risk of suicide and a poor response to treatment 115 116 Cannabis use may be a contributory factor in the development of schizophrenia potentially increasing the risk of the disease in those who are already at risk 117 118 119 The increased risk may require the presence of certain genes within an individual 18 Its use is associated with doubling the rate 120 MechanismMain article Mechanisms of schizophreniaSee also Aberrant salience The mechanisms of schizophrenia are unknown and a number of models have been put forward to explain the link between altered brain function and schizophrenia 23 The prevailing model of schizophrenia is that of a neurodevelopmental disorder and the underlying changes that occur before symptoms become evident are seen as arising from the interaction between genes and the environment 121 Extensive studies support this model 72 Maternal infections malnutrition and complications during pregnancy and childbirth are known risk factors for the development of schizophrenia which usually emerges between the ages of 18 25 a period that overlaps with certain stages of neurodevelopment 122 Gene environment interactions lead to deficits in the neural circuitry that affect sensory and cognitive functions 72 The common dopamine and glutamate models proposed are not mutually exclusive each is seen to have a role in the neurobiology of schizophrenia 123 The most common model put forward was the dopamine hypothesis of schizophrenia which attributes psychosis to the mind s faulty interpretation of the misfiring of dopaminergic neurons 124 This has been directly related to the symptoms of delusions and hallucinations 125 126 127 Abnormal dopamine signaling has been implicated in schizophrenia based on the usefulness of medications that affect the dopamine receptor and the observation that dopamine levels are increased during acute psychosis 128 129 A decrease in D1 receptors in the dorsolateral prefrontal cortex may also be responsible for deficits in working memory 130 131 The glutamate hypothesis of schizophrenia links alterations between glutamatergic neurotransmission and the neural oscillations that affect connections between the thalamus and the cortex 132 Studies have shown that a reduced expression of a glutamate receptor NMDA receptor and glutamate blocking drugs such as phencyclidine and ketamine can mimic the symptoms and cognitive problems associated with schizophrenia 132 133 134 Post mortem studies consistently find that a subset of these neurons fail to express GAD67 GAD1 135 in addition to abnormalities in brain morphometry The subsets of interneurons that are abnormal in schizophrenia are responsible for the synchronizing of neural ensembles needed during working memory tasks These give the neural oscillations produced as gamma waves that have a frequency of between 30 and 80 hertz Both working memory tasks and gamma waves are impaired in schizophrenia which may reflect abnormal interneuron functionality 135 136 137 138 An important process that may be disrupted in neurodevelopment is astrogenesis the formation of astrocytes Astrocytes are crucial in contributing to the formation and maintenance of neural circuits and it is believed that disruption in this role can result in a number of neurodevelopmental disorders including schizophrenia 139 Evidence suggests that reduced numbers of astrocytes in deeper cortical layers are assocociated with a diminished expression of EAAT2 a glutamate transporter in astrocytes supporting the glutamate hypothesis 139 Deficits in executive functions such as planning inhibition and working memory are pervasive in schizophrenia Although these functions are separable their dysfunction in schizophrenia may reflect an underlying deficit in the ability to represent goal related information in working memory and to utilize this to direct cognition and behavior 140 141 These impairments have been linked to a number of neuroimaging and neuropathological abnormalities For example functional neuroimaging studies report evidence of reduced neural processing efficiency whereby the dorsolateral prefrontal cortex is activated to a greater degree to achieve a certain level of performance relative to controls on working memory tasks These abnormalities may be linked to the consistent post mortem finding of reduced neuropil evidenced by increased pyramidal cell density and reduced dendritic spine density These cellular and functional abnormalities may also be reflected in structural neuroimaging studies that find reduced grey matter volume in association with deficits in working memory tasks 142 Positive symptoms have been linked to cortical thinning in the superior temporal gyrus 143 The severity of negative symptoms has been linked to reduced thickness in the left medial orbitofrontal cortex 144 Anhedonia traditionally defined as a reduced capacity to experience pleasure is frequently reported in schizophrenia However a large body of evidence suggests that hedonic responses are intact in schizophrenia 145 and that what is reported to be anhedonia is a reflection of dysfunction in other processes related to reward 146 Overall a failure of reward prediction is thought to lead to impairment in the generation of cognition and behavior required to obtain rewards despite normal hedonic responses 147 Another theory links abnormal brain lateralization to the development of being left handed which is significantly more common in those with schizophrenia 148 This abnormal development of hemispheric asymmetry is noted in schizophrenia 149 Studies have concluded that the link is a true and verifiable effect that may reflect a genetic link between lateralization and schizophrenia 148 150 Bayesian models of brain functioning have been utilized to link abnormalities in cellular functioning to symptoms 151 152 Both hallucinations and delusions have been suggested to reflect improper encoding of prior expectations thereby causing expectation to excessively influence sensory perception and the formation of beliefs In approved models of circuits that mediate predictive coding reduced NMDA receptor activation could in theory result in the positive symptoms of delusions and hallucinations 153 154 155 DiagnosisMain article Diagnosis of schizophrenia Criteria Schizophrenia is diagnosed based on criteria in either the Diagnostic and Statistical Manual of Mental Disorders DSM published by the American Psychiatric Association or the International Statistical Classification of Diseases and Related Health Problems ICD published by the World Health Organization WHO These criteria use the self reported experiences of the person and reported abnormalities in behavior followed by a psychiatric assessment The mental status examination is an important part of the assessment 156 An established tool for assessing the severity of positive and negative symptoms is the Positive and Negative Syndrome Scale PANSS 157 This has been seen to have shortcomings relating to negative symptoms and other scales the Clinical Assessment Interview for Negative Symptoms CAINS and the Brief Negative Symptoms Scale BNSS have been introduced 46 The DSM 5 published in 2013 gives a Scale to Assess the Severity of Symptom Dimensions outlining eight dimensions of symptoms 54 DSM 5 states that to be diagnosed with schizophrenia two diagnostic criteria have to be met over the period of one month with a significant impact on social or occupational functioning for at least six months One of the symptoms needs to be either delusions hallucinations or disorganized speech A second symptom could be one of the negative symptoms or severely disorganized or catatonic behaviour 7 A different diagnosis of schizophreniform disorder can be made before the six months needed for the diagnosis of schizophrenia 7 In Australia the guideline for diagnosis is for six months or more with symptoms severe enough to affect ordinary functioning 158 In the UK diagnosis is based on having the symptoms for most of the time for one month with symptoms that significantly affect the ability to work study or carry on ordinary daily living and with other similar conditions ruled out 159 The ICD criteria are typically used in European countries the DSM criteria are used predominantly in the United States and Canada and are prevailing in research studies In practice agreement between the two systems is high 160 The current proposal for the ICD 11 criteria for schizophrenia recommends adding self disorder as a symptom 37 A major unresolved difference between the two diagnostic systems is that of the requirement in DSM of an impaired functional outcome WHO for ICD argues that not all people with schizophrenia have functional deficits and so these are not specific for the diagnosis 54 Comorbidities Many people with schizophrenia may have one or more other mental disorders such as panic disorder obsessive compulsive disorder or substance use disorder These are separate disorders that require treatment 7 When comorbid with schizophrenia substance use disorder and antisocial personality disorder both increase the risk for violence 161 Comorbid substance use disorder also increases the risk of suicide 115 Sleep disorders often co occur with schizophrenia and may be an early sign of relapse 162 Sleep disorders are linked with positive symptoms such as disorganized thinking and can adversely affect cortical plasticity and cognition 162 The consolidation of memories is disrupted in sleep disorders 163 They are associated with severity of illness a poor prognosis and poor quality of life 164 165 Sleep onset and maintenance insomnia is a common symptom regardless of whether treatment has been received or not 164 Genetic variations have been found associated with these conditions involving the circadian rhythm dopamine and histamine metabolism and signal transduction 166 Differential diagnosis See also Dual diagnosis and Comparison of bipolar disorder and schizophrenia To make a diagnosis of schizophrenia other possible causes of psychosis need to be excluded 167 858 Psychotic symptoms lasting less than a month may be diagnosed as brief psychotic disorder or as schizophreniform disorder Psychosis is noted in Other specified schizophrenia spectrum and other psychotic disorders as a DSM 5 category Schizoaffective disorder is diagnosed if symptoms of mood disorder are substantially present alongside psychotic symptoms Psychosis that results from a general medical condition or substance is termed secondary psychosis 7 Psychotic symptoms may be present in several other conditions including bipolar disorder 8 borderline personality disorder 9 substance intoxication substance induced psychosis and a number of drug withdrawal syndromes Non bizarre delusions are also present in delusional disorder and social withdrawal in social anxiety disorder avoidant personality disorder and schizotypal personality disorder Schizotypal personality disorder has symptoms that are similar but less severe than those of schizophrenia 7 Schizophrenia occurs along with obsessive compulsive disorder OCD considerably more often than could be explained by chance although it can be difficult to distinguish obsessions that occur in OCD from the delusions of schizophrenia 168 There can be considerable overlap with the symptoms of post traumatic stress disorder 169 A more general medical and neurological examination may be needed to rule out medical illnesses which may rarely produce psychotic schizophrenia like symptoms such as metabolic disturbance systemic infection syphilis HIV associated neurocognitive disorder epilepsy limbic encephalitis and brain lesions Stroke multiple sclerosis hyperthyroidism hypothyroidism and dementias such as Alzheimer s disease Huntington s disease frontotemporal dementia and the Lewy body dementias may also be associated with schizophrenia like psychotic symptoms 170 It may be necessary to rule out a delirium which can be distinguished by visual hallucinations acute onset and fluctuating level of consciousness and indicates an underlying medical illness Investigations are not generally repeated for relapse unless there is a specific medical indication or possible adverse effects from antipsychotic medication 171 In children hallucinations must be separated from typical childhood fantasies 7 It is difficult to distinguish childhood schizophrenia from autism 69 PreventionPrevention of schizophrenia is difficult as there are no reliable markers for the later development of the disorder 172 It is unclear as of 2011 whether treating patients in the prodrome phase of schizophrenia provides benefits needs update 173 43 There is a discrepancy between the growth in the implementation of early intervention programmes for psychosis and the underlying empirical evidence 173 44 There is some evidence as of 2009 that early intervention in those with first episode psychosis may improve short term outcomes but there is little benefit from these measures after five years needs update 23 Cognitive behavioral therapy may reduce the risk of psychosis in those at high risk after a year 174 and is recommended in this group by the National Institute for Health and Care Excellence NICE 30 Another preventive measure is to avoid drugs that have been associated with development of the disorder including cannabis cocaine and amphetamines 82 Antipsychotics are prescribed following a first episode psychosis and following remission a preventive maintenance use is continued to avoid relapse However it is recognized that some people do recover following a single episode and that long term use of antipsychotics will not be needed but there is no way of identifying this group 175 ManagementMain article Management of schizophrenia The primary treatment of schizophrenia is the use of antipsychotic medications often in combination with psychosocial interventions and social supports 23 176 Community support services including drop in centers visits by members of a community mental health team supported employment 177 and support groups are common The time between the onset of psychotic symptoms to being given treatment the duration of untreated psychosis DUP is associated with a poorer outcome in both the short term and the long term 178 Voluntary or involuntary admission to hospital may be imposed by doctors and courts who deem a person to be having a severe episode In the UK large mental hospitals termed asylums began to be closed down in the 1950s with the advent of antipsychotics and with an awareness of the negative impact of long term hospital stays on recovery 21 This process was known as deinstitutionalization and community and supportive services were developed in order to support this change Many other countries followed suit with the US starting in the 60s 179 There still remain a smaller group of people who do not improve enough to be discharged 21 28 In some countries that lack the necessary supportive and social services long term hospital stays are more usual 29 Medication Risperidone trade name Risperdal is a common atypical antipsychotic medication The first line treatment for schizophrenia is an antipsychotic The first generation antipsychotics now called typical antipsychotics are dopamine antagonists that block D2 receptors and affect the neurotransmission of dopamine Those brought out later the second generation antipsychotics known as atypical antipsychotics can also have an effect on another neurotransmitter serotonin Antipsychotics can reduce the symptoms of anxiety within hours of their use but for other symptoms they may take several days or weeks to reach their full effect 32 180 They have little effect on negative and cognitive symptoms which may be helped by additional psychotherapies and medications 181 There is no single antipsychotic suitable for first line treatment for everyone as responses and tolerances vary between people 182 Stopping medication may be considered after a single psychotic episode where there has been a full recovery with no symptoms for twelve months Repeated relapses worsen the long term outlook and the risk of relapse following a second episode is high and long term treatment is usually recommended 183 184 About half of those with schizophrenia will respond favourably to antipsychotics and have a good return of functioning 185 However positive symptoms persist in up to a third of people Following two trials of different antipsychotics over six weeks that also prove ineffective they will be classed as having treatment resistant schizophrenia TRS and clozapine will be offered 186 25 Clozapine is of benefit to around half of this group although it has the potentially serious side effect of agranulocytosis lowered white blood cell count in less than 4 of people 23 82 187 About 30 to 50 percent of people with schizophrenia do not accept that they have an illness or comply with their recommended treatment 188 For those who are unwilling or unable to take medication regularly long acting injections of antipsychotics may be used 189 which reduce the risk of relapse to a greater degree than oral medications 190 When used in combination with psychosocial interventions they may improve long term adherence to treatment 191 Adverse effects Further information Antipsychotic Adverse effects Extrapyramidal symptoms including akathisia are associated with all commercially available antipsychotic to varying degrees 192 566 There is little evidence that second generation antipsychotics have reduced levels of extrapyramidical symptoms compared to typical antipsychotics 192 566 Tardive dyskinesia can occur due to long term use of antipsychotics developing after months or years of use 193 The antipsychotic clozapine is also associated with thromboembolism including pulmonary embolism myocarditis and cardiomyopathy Psychosocial interventions Further information Management of schizophrenia Psychosocial A number of psychosocial interventions that include several types of psychotherapy may be useful in the treatment of schizophrenia such as family therapy 194 group therapy cognitive remediation therapy CRT 195 cognitive behavioral therapy CBT and metacognitive training 196 197 Skills training help with substance use and weight management often needed as a side effect of an antipsychotic are also offered 198 In the US interventions for first episode psychosis have been brought together in an overall approach known as coordinated speciality care CSC and also includes support for education 32 In the UK care across all phases is a similar approach that covers many of the treatment guidelines recommended 30 The aim is to reduce the number of relapses and stays in the hospital 194 Other support services for education employment and housing are usually offered For people with severe schizophrenia who are discharged from a stay in the hospital these services are often brought together in an integrated approach to offer support in the community away from the hospital setting In addition to medicine management housing and finances assistance is given for more routine matters such as help with shopping and using public transport This approach is known as assertive community treatment ACT and has been shown to achieve positive results in symptoms social functioning and quality of life 199 200 Another more intense approach is known as intensive care management ICM ICM is a stage further than ACT and emphasises support of high intensity in smaller caseloads less than twenty This approach is to provide long term care in the community Studies show that ICM improves many of the relevant outcomes including social functioning 201 Some studies have shown little evidence for the effectiveness of CBT in either reducing symptoms or preventing relapse 202 203 However other studies have found that CBT does improve overall psychotic symptoms when in use with medication and it has been recommended in Canada but has been seen to have no effect on social function relapse or quality of life 204 In the UK it is recommended as an add on therapy in the treatment of schizophrenia 180 203 Arts therapies are seen to improve negative symptoms in some people and are recommended by NICE in the UK 180 This approach is criticised as having not been well researched 205 206 and arts therapies are not recommended in Australian guidelines for example 207 Peer support in which people with personal experience of schizophrenia provide help to each other is of unclear benefit 208 Other Exercise including aerobic exercise has been shown to improve positive and negative symptoms cognition working memory and improve quality of life 209 210 Exercise has also been shown to increase the volume of the hippocampus in those with schizophrenia A decrease in hippocampal volume is one of the factors linked to the development of the disease 209 However there still remains the problem of increasing motivation for and maintaining participation in physical activity 211 Supervised sessions are recommended 210 In the UK healthy eating advice is offered alongside exercise programs 212 An inadequate diet is often found in schizophrenia and associated vitamin deficiencies including those of folate and vitamin D are linked to the risk factors for the development of schizophrenia and for early death including heart disease 213 214 Those with schizophrenia possibly have the worst diet of all the mental disorders Lower levels of folate and vitamin D have been noted as significantly lower in first episode psychosis 213 The use of supplemental folate is recommended 215 A zinc deficiency has also been noted 216 Vitamin B12 is also often deficient and this is linked to worse symptoms Supplementation with B vitamins has been shown to significantly improve symptoms and to put in reverse some of the cognitive deficits 213 It is also suggested that the noted dysfunction in gut microbiota might benefit from the use of probiotics 216 PrognosisMain article Prognosis of schizophreniaSee also Physical health in schizophrenia Disability adjusted life years lost due to schizophrenia per 100 000 inhabitants in 2004 no data 185 185 197 197 207 207 218 218 229 229 240 240 251 251 262 262 273 273 284 284 295 295 Schizophrenia has great human and economic costs 5 It decreases life expectancy by between 20 10 and 28 years 11 This is primarily because of its association with heart disease 217 diabetes 11 obesity poor diet a sedentary lifestyle and smoking with an increased rate of suicide playing a lesser role 10 218 Side effects of antipsychotics may also increase the risk 10 Almost 40 of those with schizophrenia die from complications of cardiovascular disease which is seen to be increasingly associated 214 An underlying factor of sudden cardiac death may be Brugada syndrome BrS BrS mutations that overlap with those linked with schizophrenia are the calcium channel mutations 214 BrS may also be drug induced from certain antipsychotics and antidepressants 214 Primary polydipsia or excessive fluid intake is relatively common in people with chronic schizophrenia 219 220 This may lead to hyponatremia which can be life threatening Antipsychotics can lead to a dry mouth but there are several other factors that may contribute to the disorder it may reduce life expectancy by 13 per cent 220 Barriers to improving the mortality rate in schizophrenia are poverty overlooking the symptoms of other illnesses stress stigma and medication side effects 221 Schizophrenia is a major cause of disability In 2016 it was classed as the 12th most disabling condition 222 Approximately 75 of people with schizophrenia have ongoing disability with relapses 223 Some people do recover completely and others function well in society 224 Most people with schizophrenia live independently with community support 23 About 85 are unemployed 5 In people with a first episode of psychosis in schizophrenia a good long term outcome occurs in 31 an intermediate outcome in 42 and a poor outcome in 31 225 Males are affected more often than females and have a worse outcome 226 Studies showing that outcomes for schizophrenia appear better in the developing than the developed world 227 have been questioned 228 Social problems such as long term unemployment poverty homelessness exploitation stigmatization and victimization are common consequences and lead to social exclusion 21 22 There is a higher than average suicide rate associated with schizophrenia estimated at 5 to 6 most often occurring in the period following onset or first hospital admission 14 24 Several times more 20 to 40 attempt suicide at least once 7 96 There are a variety of risk factors including male sex depression a high IQ 229 heavy smoking 230 and substance use 115 Repeated relapse is linked to an increased risk of suicidal behavior 175 The use of clozapine can reduce the risk of suicide and of aggression 231 A strong association between schizophrenia and tobacco smoking has been shown in worldwide studies 232 233 Smoking is especially high in those diagnosed with schizophrenia with estimates ranging from 80 to 90 being regular smokers as compared to 20 of the general population 233 Those who smoke tend to smoke heavily and additionally smoke cigarettes with high nicotine content 36 Some propose that this is in an effort to improve symptoms 234 Among people with schizophrenia use of cannabis is also common 115 Schizophrenia leads to an increased risk of dementia 235 Violence Most people with schizophrenia are not aggressive and are more likely to be victims of violence rather than perpetrators 7 People with schizophrenia are commonly exploited and victimized by violent crime as part of a broader dynamic of social exclusion 21 22 People diagnosed with schizophrenia are also subject to forced drug injections seclusion and restraint at high rates 27 28 The risk of violence by people with schizophrenia is small There are minor subgroups where the risk is high 161 This risk is usually associated with a comorbid disorder such as a substance use disorder in particular alcohol or with antisocial personality disorder 161 Substance use disorder is strongly linked and other risk factors are linked to deficits in cognition and social cognition including facial perception and insight that are in part included in theory of mind impairments 236 237 Poor cognitive functioning decision making and facial perception may contribute to making a wrong judgement of a situation that could result in an inappropriate response such as violence 238 These associated risk factors are also present in antisocial personality disorder which when present as a comorbid disorder greatly increases the risk of violence 239 240 EpidemiologyMain article Epidemiology of schizophrenia Deaths per million persons due to schizophrenia in 2012 0 0 1 1 2 2 3 3 4 6 7 20 In 2017 needs update the Global Burden of Disease Study estimated there were 1 1 million new cases 16 in 2022 the World Health Organization WHO reported a total of 24 million cases globally 2 Schizophrenia affects around 0 3 0 7 of people at some point in their life 15 11 In areas of conflict this figure can rise to between 4 0 and 6 5 241 It occurs 1 4 times more frequently in males than females and typically appears earlier in men 82 Worldwide schizophrenia is the most common psychotic disorder 51 The frequency of schizophrenia varies across the world 7 within countries 242 and at the local and neighborhood level 243 this variation in prevalence between studies over time across geographical locations and by gender is as high as fivefold 5 Schizophrenia causes approximately one percent of worldwide disability adjusted life years needs update 82 and resulted in 17 000 deaths in 2015 12 In 2000 needs update WHO found the percentage of people affected and the number of new cases that develop each year is roughly similar around the world with age standardized prevalence per 100 000 ranging from 343 in Africa to 544 in Japan and Oceania for men and from 378 in Africa to 527 in Southeastern Europe for women 244 HistoryMain article History of schizophrenia Conceptual development Main article History of schizophrenia Conceptual development Further information Dementia praecox The term schizophrenia was coined by Eugen Bleuler Accounts of a schizophrenia like syndrome are rare in records before the 19th century the earliest case reports were in 1797 and 1809 245 Dementia praecox meaning premature dementia was used by German psychiatrist Heinrich Schule in 1886 and then in 1891 by Arnold Pick in a case report of hebephrenia In 1893 Emil Kraepelin used the term in making a distinction known as the Kraepelinian dichotomy between the two psychoses dementia praecox and manic depression now called bipolar disorder 10 When it became evident that the disorder was not a degenerative dementia it was renamed schizophrenia by Eugen Bleuler in 1908 246 The word schizophrenia translates as splitting of the mind and is Modern Latin from the Greek words schizein sxizein to split and phren frhn mind 247 Its use was intended to describe the separation of function between personality thinking memory and perception 246 In the early 20th century the psychiatrist Kurt Schneider categorized the psychotic symptoms of schizophrenia into two groups hallucinations and delusions The hallucinations were listed as specific to auditory and the delusions included thought disorders These were seen as important symptoms termed first rank The most common first rank symptom was found to belong to thought disorders page needed 248 page needed 249 In 2013 the first rank symptoms were excluded from the DSM 5 criteria 250 while they may not be useful in diagnosing schizophrenia they can assist in differential diagnosis 251 Subtypes of schizophrenia classified as paranoid disorganized catatonic undifferentiated and residual were difficult to distinguish and are no longer recognized as separate conditions by DSM 5 2013 or ICD 11 252 253 254 Breadth of diagnosis Before the 1960s nonviolent petty criminals and women were sometimes diagnosed with schizophrenia categorizing the latter as ill for not performing their duties within patriarchy as wives and mothers 255 In the mid to late 1960s black men were categorized as hostile and aggressive and diagnosed as schizophrenic at much higher rates their civil rights and Black Power activism labeled as delusions 255 256 In the early 1970s in the US the diagnostic model for schizophrenia was broad and clinically based using DSM II Schizophrenia was diagnosed far more in the US than in Europe which used the ICD 9 criteria The US model was criticised for failing to demarcate clearly those people with a mental illness In 1980 DSM III was published and showed a shift in focus from the clinically based biopsychosocial model to a reason based medical model 257 DSM IV brought an increased focus on an evidence based medical model 258 Historical treatment Main article History of schizophrenia Development of treatments in the 20th century A molecule of chlorpromazine the first antipsychotic developed in the 1950s In the 1930s a number of shock procedures which induced seizures convulsions or comas were used to treat schizophrenia 259 Insulin shock involved injecting large doses of insulin to induce comas which in turn produced hypoglycemia and convulsions 259 260 The use of electricity to induce seizures was in use as electroconvulsive therapy ECT by 1938 261 Psychosurgery including the lobotomy and frontal lobotomy carried out from the 1930s until the 1970s in the United States and until the 1980s in France are recognized as a human rights abuse 262 263 In the mid 1950s the first typical antipsychotic chlorpromazine was introduced 264 followed in the 1970s by the first atypical antipsychotic clozapine 265 Political abuse Further information Political abuse of psychiatry From the 1960s until 1989 psychiatrists in the USSR and Eastern Bloc diagnosed thousands of people with sluggish schizophrenia 266 267 without signs of psychosis based on the assumption that symptoms would later appear 268 Now discredited the diagnosis provided a convenient way to confine political dissidents 269 Society and cultureSee also Social construction of schizophrenia List of people with schizophrenia and Religion and schizophreniaIn the United States the annual cost of schizophrenia including direct costs outpatient inpatient drugs and long term care and non healthcare costs law enforcement reduced workplace productivity and unemployment was estimated at 62 7 billion for the year 2002 270 a In the UK the cost in 2016 was put at 11 8 billion per year with a third of that figure directly attributable to the cost of hospital social care and treatment 5 Stigma John Nash an American mathematician and joint recipient of the 1994 Nobel Memorial Prize in Economic Sciences had schizophrenia His life was the subject of the 1998 book A Beautiful Mind by Sylvia Nasar In 2002 the term for schizophrenia in Japan was changed from seishin bunretsu byō 精神分裂病 lit mind split disease to tōgō shitchō shō 統合失調症 lit integration dysregulation syndrome to reduce stigma 273 The new name also interpreted as integration disorder was inspired by the biopsychosocial model 274 A similar change was made in South Korea in 2012 to attunement disorder 275 Cultural depictions The book A Beautiful Mind chronicled the life of John Forbes Nash who had been diagnosed with schizophrenia and won the Nobel Memorial Prize in Economic Sciences The book was made into a film with the same name an earlier documentary film was A Brilliant Madness In 1964 a case study of three males diagnosed with schizophrenia who each had the delusional belief that they were Jesus Christ was published as The Three Christs of Ypsilanti a film with the title Three Christs was released in 2020 276 277 Media coverage reinforces public perception of an association between schizophrenia and violence 278 in film people with schizophrenia are highly likely to be portrayed as a danger to others 279 In the UK guidelines for reporting conditions and award campaigns have shown a reduction in negative reporting since 2013 280 Research directionsSee also Animal models of schizophrenia A 2015 Cochrane review found unclear evidence of benefit from brain stimulation techniques to treat the positive symptoms of schizophrenia in particular auditory verbal hallucinations AVHs 281 Most studies focus on transcranial direct current stimulation tDCM and repetitive transcranial magnetic stimulation rTMS 282 Techniques based on focused ultrasound for deep brain stimulation could provide insight for the treatment of AVHs 282 The study of potential biomarkers that would help in diagnosis and treatment of schizophrenia is an active area of research as of 2020 Possible biomarkers include markers of inflammation 95 neuroimaging 283 brain derived neurotrophic factor BDNF 284 and speech analysis Some markers such as C reactive protein are useful in detecting levels of inflammation implicated in some psychiatric disorders but they are not disorder specific Other inflammatory cytokines are found to be elevated in first episode psychosis and acute relapse that are normalized after treatment with antipsychotics and these may be considered as state markers 285 Deficits in sleep spindles in schizophrenia may serve as a marker of an impaired thalamocortical circuit and a mechanism for memory impairment 163 MicroRNAs are highly influential in early neuronal development and their disruption is implicated in several CNS disorders circulating microRNAs cimiRNAs are found in body fluids such as blood and cerebrospinal fluid and changes in their levels are seen to relate to changes in microRNA levels in specific regions of brain tissue These studies suggest that cimiRNAs have the potential to be early and accurate biomarkers in a number of disorders including schizophrenia 286 287 Explanatory notes A 2007 review stated that the 2002 estimate was still the best available 271 and a 2018 review cited the same 62 7 billion 272 References Jones D 2003 1917 Roach P Hartmann J Setter J eds English Pronouncing Dictionary Cambridge University Press ISBN 978 3 12 539683 8 a b c d e Schizophrenia Fact sheet World Health Organization 10 January 2022 Retrieved 23 August 2022 a b c d e f g Schizophrenia Health topics US National Institute of Mental Health April 2022 Retrieved 22 August 2022 Medicinal treatment of psychosis schizophrenia Swedish Agency for Health Technology Assessment and Assessment of Social Services SBU 21 November 2012 Archived from the original on 29 June 2017 Retrieved 26 June 2017 a b c d e f g h i j k l m n o p Owen MJ Sawa A Mortensen PB July 2016 Schizophrenia The Lancet 388 10039 86 97 doi 10 1016 S0140 6736 15 01121 6 PMC 4940219 PMID 26777917 Gruebner O Rapp MA Adli M et al February 2017 Cities and mental health Deutsches Arzteblatt International 114 8 121 127 doi 10 3238 arztebl 2017 0121 PMC 5374256 PMID 28302261 a b c d e f g h i j k l m n o p q r s t u Diagnostic and Statistical Manual of Mental Disorders DSM 5 5th ed Arlington VA American Psychiatric Association 2013 pp 99 105 ISBN 978 0 89042 555 8 a b Ferri FF 2010 Chapter S Ferri s differential diagnosis a practical guide to the differential diagnosis of symptoms signs and clinical disorders 2nd ed Philadelphia Elsevier Mosby ISBN 978 0 323 07699 9 a b Paris J December 2018 Differential Diagnosis of Borderline Personality Disorder The Psychiatric Clinics of North America 41 4 575 582 doi 10 1016 j psc 2018 07 001 PMID 30447725 S2CID 53951650 a b c d e f Laursen TM Nordentoft M Mortensen PB 2014 Excess early mortality in schizophrenia Annual Review of Clinical Psychology 10 425 448 doi 10 1146 annurev clinpsy 032813 153657 PMID 24313570 a b c d e Schizophrenia Statistics US National Institute of Mental Health NIMH 22 April 2022 Retrieved 23 August 2022 a b c Wang H Naghavi M Allen C et al October 2016 Global regional and national life expectancy all cause mortality and cause specific mortality for 249 causes of death 1980 2015 a systematic analysis for the Global Burden of Disease Study 2015 The Lancet 388 10053 1459 1544 doi 10 1016 S0140 6736 16 31012 1 PMC 5388903 PMID 27733281 ICD 11 6A20 Schizophrenia World Health Organization Retrieved 23 August 2022 a b c d Ferri FF 2019 Ferri s clinical advisor 2019 5 books in 1 pp 1225 1226 ISBN 9780323530422 a b Javitt DC June 2014 Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia a clinical overview The American Journal of Managed Care 20 8 Suppl S160 165 PMID 25180705 a b James SL Abate D November 2018 Global regional and national incidence prevalence and years lived with disability for 354 diseases and injuries for 195 countries and territories 1990 2017 a systematic analysis for the Global Burden of Disease Study 2017 The Lancet 392 10159 1789 1858 doi 10 1016 S0140 6736 18 32279 7 PMC 6227754 PMID 30496104 a b c van de Leemput J Hess JL Glatt SJ Tsuang MT 2016 Genetics of Schizophrenia Historical Insights and Prevailing Evidence Advances in Genetics 96 99 141 doi 10 1016 bs adgen 2016 08 001 PMID 27968732 a b Parakh P Basu D August 2013 Cannabis and psychosis have we found the missing links Asian Journal of Psychiatry Review 6 4 281 287 doi 10 1016 j ajp 2013 03 012 PMID 23810133 Cannabis acts as a component cause of psychosis that is it increases the risk of psychosis in people with certain genetic or environmental vulnerabilities though by itself it is neither a sufficient nor a necessary cause of psychosis a b Vita A Barlati S May 2018 Recovery from schizophrenia is it possible Current Opinion in Psychiatry 31 3 246 255 doi 10 1097 YCO 0000000000000407 PMID 29474266 S2CID 35299996 Lawrence RE First MB Lieberman JA 2015 Chapter 48 Schizophrenia and Other Psychoses In Tasman A Kay J Lieberman JA First MB Riba MB eds Psychiatry fourth ed John Wiley amp Sons Ltd pp 798 816 819 doi 10 1002 9781118753378 ch48 ISBN 978 1 118 84547 9 a b c d e Killaspy H September 2014 Contemporary mental health rehabilitation East Asian Archives of Psychiatry 24 3 89 94 PMID 25316799 a b c Charlson FJ Ferrari AJ Santomauro DF et al 17 October 2018 Global Epidemiology and Burden of Schizophrenia Findings From the Global Burden of Disease Study 2016 Schizophrenia Bulletin 44 6 1195 1203 doi 10 1093 schbul sby058 PMC 6192504 PMID 29762765 a b c d e f g van Os J Kapur S August 2009 Schizophrenia PDF Lancet 374 9690 635 645 doi 10 1016 S0140 6736 09 60995 8 PMID 19700006 S2CID 208792724 Archived from the original PDF on 23 June 2013 Retrieved 23 December 2011 a b Hor K Taylor M November 2010 Suicide and schizophrenia a systematic review of rates and risk factors Journal of Psychopharmacology 24 4 Suppl 81 90 doi 10 1177 1359786810385490 PMC 2951591 PMID 20923923 a b Siskind D Siskind V Kisely S November 2017 Clozapine Response Rates among People with Treatment Resistant Schizophrenia Data from a Systematic Review and Meta Analysis Canadian Journal of Psychiatry 62 11 772 777 doi 10 1177 0706743717718167 PMC 5697625 PMID 28655284 Leucht S Cipriani A Spineli L et al September 2013 Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia a multiple treatments meta analysis The Lancet 382 9896 951 962 doi 10 1016 S0140 6736 13 60733 3 PMID 23810019 S2CID 32085212 a b Becker T Kilian R 2006 Psychiatric services for people with severe mental illness across western Europe what can be generalized from current knowledge about differences in provision costs and outcomes of mental health care Acta Psychiatrica Scandinavica Supplementum 113 429 9 16 doi 10 1111 j 1600 0447 2005 00711 x PMID 16445476 S2CID 34615961 a b c Capdevielle D Boulenger JP Villebrun D Ritchie K September 2009 Durees d hospitalisation des patients souffrant de schizophrenie implication des systemes de soin et consequences medicoeconomiques Schizophrenic patients length of stay mental health care implication and medicoeconomic consequences L Encephale in French 35 4 394 399 doi 10 1016 j encep 2008 11 005 PMID 19748377 a b Narayan KK Kumar DS January 2012 Disability in a Group of Long stay Patients with Schizophrenia Experience from a Mental Hospital Indian Journal of Psychological Medicine 34 1 70 75 doi 10 4103 0253 7176 96164 PMC 3361848 PMID 22661812 a b c Psychosis and schizophrenia in adults treatment and management PDF National Institute for Health and Care Excellence NICE March 2014 pp 4 34 Archived from the original PDF on 20 April 2014 Retrieved 19 April 2014 Stepnicki P Kondej M Kaczor AA 20 August 2018 Current Concepts and Treatments of Schizophrenia Molecules 23 8 2087 doi 10 3390 molecules23082087 PMC 6222385 PMID 30127324 a b c d RAISE Questions and Answers US National Institute of Mental Health Retrieved 29 December 2019 Marshall M September 2005 Association between duration of untreated psychosis and outcome in cohorts of first episode patients a systematic review Archives of General Psychiatry 62 9 975 983 doi 10 1001 archpsyc 62 9 975 PMID 16143729 a b Montagnese M Leptourgos P Fernyhough C et al January 2021 A Review of Multimodal Hallucinations Categorization Assessment Theoretical Perspectives and Clinical Recommendations Schizophr Bull 47 1 237 248 doi 10 1093 schbul sbaa101 PMC 7825001 PMID 32772114 Csaszar N Kapocs G Bokkon I 27 May 2019 A possible key role of vision in the development of schizophrenia Reviews in the Neurosciences 30 4 359 379 doi 10 1515 revneuro 2018 0022 PMID 30244235 S2CID 52813070 a b American Psychiatric Association Task Force on DSM IV 2000 Diagnostic and statistical manual of mental disorders DSM IV TR American Psychiatric Pub pp 299 304 ISBN 978 0 89042 025 6 a b Heinz A Voss M Lawrie SM et al September 2016 Shall we really say goodbye to first rank symptoms European Psychiatry 37 8 13 doi 10 1016 j eurpsy 2016 04 010 PMID 27429167 S2CID 13761854 a b Adida M Azorin JM Belzeaux R Fakra E December 2015 Negative Symptoms Clinical and Psychometric Aspects L Encephale 41 6 Suppl 1 6S15 17 doi 10 1016 S0013 7006 16 30004 5 PMID 26776385 Mach C Dollfus S April 2016 Scale for Assessing Negative Symptoms in Schizophrenia A Systematic Review L Encephale 42 2 165 171 doi 10 1016 j encep 2015 12 020 PMID 26923997 Waltz JA Gold JM 2016 Motivational Deficits in Schizophrenia and the Representation of Expected Value Current Topics in Behavioral Neurosciences 27 375 410 doi 10 1007 7854 2015 385 ISBN 978 3 319 26933 7 PMC 4792780 PMID 26370946 a b Husain M Roiser JP August 2018 Neuroscience of apathy and anhedonia a transdiagnostic approach Nature Reviews Neuroscience 19 8 470 484 doi 10 1038 s41583 018 0029 9 PMID 29946157 S2CID 49428707 a b Galderisi S Mucci A Buchanan RW Arango C August 2018 Negative symptoms of schizophrenia new developments and unanswered research questions The Lancet Psychiatry 5 8 664 677 doi 10 1016 S2215 0366 18 30050 6 PMID 29602739 S2CID 4483198 Klaus F Dorsaz O Kaiser S 19 September 2018 Negative symptoms in schizophrenia overview and practical implications Revue medicale suisse 14 619 1660 1664 doi 10 53738 REVMED 2018 14 619 1660 PMID 30230774 S2CID 246764656 Batinic B June 2019 Cognitive Models of Positive and Negative Symptoms of Schizophrenia and Implications for Treatment Psychiatria Danubina 31 Suppl 2 181 184 PMID 31158119 Bortolon C Macgregor A Capdevielle D Raffard S September 2018 Apathy in schizophrenia A review of neuropsychological and neuroanatomical studies Neuropsychologia 118 Pt B 22 33 doi 10 1016 j neuropsychologia 2017 09 033 PMID 28966139 S2CID 13411386 a b c d e Marder SR Kirkpatrick B May 2014 Defining and measuring negative symptoms of schizophrenia in clinical trials European Neuropsychopharmacology 24 5 737 743 doi 10 1016 j euroneuro 2013 10 016 PMID 24275698 S2CID 5172022 a b c d e Tatsumi K Kirkpatrick B Strauss GP Opler M April 2020 The brief negative symptom scale in translation A review of psychometric properties and beyond European Neuropsychopharmacology 33 36 44 doi 10 1016 j euroneuro 2020 01 018 PMID 32081498 S2CID 211141678 Klaus F Kaiser S Kirschner M June 2018 Negative Symptoms in Schizophrenia an Overview Therapeutische Umschau 75 1 51 56 doi 10 1024 0040 5930 a000966 PMID 29909762 S2CID 196502392 Wojciak P Rybakowski J 30 April 2018 Clinical picture pathogenesis and psychometric assessment of negative symptoms of schizophrenia Psychiatria Polska 52 2 185 197 doi 10 12740 PP 70610 PMID 29975360 a b c d e f Murante T Cohen CI January 2017 Cognitive Functioning in Older Adults With Schizophrenia Focus American Psychiatric Publishing 15 1 26 34 doi 10 1176 appi focus 20160032 PMC 6519630 PMID 31975837 a b Kar SK Jain M July 2016 Current understandings about cognition and the neurobiological correlates in schizophrenia Journal of Neurosciences in Rural Practice 7 3 412 418 doi 10 4103 0976 3147 176185 PMC 4898111 PMID 27365960 a b Bozikas VP Andreou C February 2011 Longitudinal studies of cognition in first episode psychosis a systematic review of the literature The Australian and New Zealand Journal of Psychiatry 45 2 93 108 doi 10 3109 00048674 2010 541418 PMID 21320033 S2CID 26135485 Shah JN Qureshi SU Jawaid A Schulz PE June 2012 Is there evidence for late cognitive decline in chronic schizophrenia The Psychiatric Quarterly 83 2 127 144 doi 10 1007 s11126 011 9189 8 PMID 21863346 S2CID 10970088 a b c Biedermann F Fleischhacker WW August 2016 Psychotic disorders in DSM 5 and ICD 11 CNS Spectrums 21 4 349 354 doi 10 1017 S1092852916000316 PMID 27418328 S2CID 24728447 a b c Vidailhet P September 2013 First episode psychosis cognitive difficulties and remediation L Encephale in French 39 Suppl 2 S83 92 doi 10 1016 S0013 7006 13 70101 5 PMID 24084427 a b c Hashimoto K 5 July 2019 Recent Advances in the Early Intervention in Schizophrenia Future Direction from Preclinical Findings Current Psychiatry Reports 21 8 75 doi 10 1007 s11920 019 1063 7 PMID 31278495 S2CID 195814019 a b c d e f Green MF Horan WP Lee J June 2019 Nonsocial and social cognition in schizophrenia current evidence and future directions World Psychiatry 18 2 146 161 doi 10 1002 wps 20624 PMC 6502429 PMID 31059632 Javitt DC Sweet RA September 2015 Auditory dysfunction in schizophrenia integrating clinical and basic features Nature Reviews Neuroscience 16 9 535 550 doi 10 1038 nrn4002 PMC 4692466 PMID 26289573 a b Megreya AM 2016 Face perception in schizophrenia a specific deficit Cognitive Neuropsychiatry 21 1 60 72 doi 10 1080 13546805 2015 1133407 PMID 26816133 S2CID 26125559 Eack SM July 2012 Cognitive remediation a new generation of psychosocial interventions for people with schizophrenia Social Work 57 3 235 246 doi 10 1093 sw sws008 PMC 3683242 PMID 23252315 Pomarol Clotet E Oh M Laws KR McKenna PJ February 2008 Semantic priming in schizophrenia systematic review and meta analysis The British Journal of Psychiatry 192 2 92 97 doi 10 1192 bjp bp 106 032102 hdl 2299 2735 PMID 18245021 Goldberg TE Keefe RS Goldman RS Robinson DG Harvey PD April 2010 Circumstances under which practice does not make perfect a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies Neuropsychopharmacology 35 5 1053 1062 doi 10 1038 npp 2009 211 PMC 3055399 PMID 20090669 King DJ Hodgekins J Chouinard PA Chouinard VA Sperandio I June 2017 A review of abnormalities in the perception of visual illusions in schizophrenia Psychonomic Bulletin and Review 24 3 734 751 doi 10 3758 s13423 016 1168 5 PMC 5486866 PMID 27730532 Kohler CG Walker JB Martin EA Healey KM Moberg PJ September 2010 Facial emotion perception in schizophrenia a meta analytic review Schizophrenia Bulletin 36 5 1009 1019 doi 10 1093 schbul sbn192 PMC 2930336 PMID 19329561 Le Gall E Iakimova G December 2018 Social cognition in schizophrenia and autism spectrum disorder Points of convergence and functional differences L Encephale 44 6 523 537 doi 10 1016 j encep 2018 03 004 PMID 30122298 S2CID 150099236 Grill Spector K Weiner KS Kay K Gomez J September 2017 The Functional Neuroanatomy of Human Face Perception Annual Review of Vision Science 3 167 196 doi 10 1146 annurev vision 102016 061214 PMC 6345578 PMID 28715955 Fountoulakis KN Panagiotidis P Kimiskidis V Nimatoudis I Gonda X February 2019 Neurological soft signs in familial and sporadic schizophrenia Psychiatry Research 272 222 229 doi 10 1016 j psychres 2018 12 105 PMID 30590276 S2CID 56476015 Bourgou Gaha S Halayem Dhouib S Amado I Bouden A June 2015 Neurological soft signs in early onset schizophrenia L Encephale 41 3 209 214 doi 10 1016 j encep 2014 01 005 PMID 24854724 a b Da Fonseca D Fourneret P December 2018 Very early onset schizophrenia L Encephale 44 6S S8 S11 doi 10 1016 S0013 7006 19 30071 5 PMID 30935493 S2CID 150798223 Hafner H 2019 From Onset and Prodromal Stage to a Life Long Course of Schizophrenia and Its Symptom Dimensions How Sex Age and Other Risk Factors Influence Incidence and Course of Illness Psychiatry Journal 2019 9804836 doi 10 1155 2019 9804836 PMC 6500669 PMID 31139639 Cohen CI Freeman K Ghoneim D et al March 2018 Advances in the Conceptualization and Study of Schizophrenia in Later Life The Psychiatric Clinics of North America 41 1 39 53 doi 10 1016 j psc 2017 10 004 PMID 29412847 a b c George M Maheshwari S Chandran S Manohar JS Sathyanarayana Rao TS October 2017 Understanding the schizophrenia prodrome Indian Journal of Psychiatry 59 4 505 509 doi 10 4103 psychiatry IndianJPsychiatry 464 17 inactive 31 December 2022 PMC 5806335 PMID 29497198 a href Template Cite journal html title Template Cite journal cite journal a CS1 maint DOI inactive as of December 2022 link a b Conroy S Francis M Hulvershorn LA March 2018 Identifying and treating the prodromal phases of bipolar disorder and schizophrenia Current Treatment Options in Psychiatry 5 1 113 128 doi 10 1007 s40501 018 0138 0 PMC 6196741 PMID 30364516 Lecardeur L Meunier Cussac S Dollfus S May 2013 Cognitive deficits in first episode psychosis patients and people at risk for psychosis from diagnosis to treatment L Encephale 39 Suppl 1 S64 71 doi 10 1016 j encep 2012 10 011 PMID 23528322 Mullin AP Gokhale A Moreno De Luca A Sanyal S Waddington JL Faundez V December 2013 Neurodevelopmental disorders mechanisms and boundary definitions from genomes interactomes and proteomes Transl Psychiatry 3 12 e329 doi 10 1038 tp 2013 108 PMC 4030327 PMID 24301647 a b c Davis J Eyre H Jacka FN et al June 2016 A review of vulnerability and risks for schizophrenia Beyond the two hit hypothesis Neurosci Biobehav Rev 65 185 194 doi 10 1016 j neubiorev 2016 03 017 PMC 4876729 PMID 27073049 a b Perkovic MN Erjavec GN Strac DS et al March 2017 Theranostic biomarkers for schizophrenia International Journal of Molecular Sciences 18 4 733 doi 10 3390 ijms18040733 PMC 5412319 PMID 28358316 a b Suvisaari J 2010 Risk factors of schizophrenia Duodecim in Finnish 126 8 869 876 PMID 20597333 a b Combs DR Mueser KT Gutierrez MM 2011 Chapter 8 Schizophrenia Etiological considerations In Hersen M Beidel DC eds Adult psychopathology and diagnosis 6th ed John Wiley amp Sons ISBN 978 1 118 13884 7 O Donovan MC Williams NM Owen MJ October 2003 Recent advances in the genetics of schizophrenia Human Molecular Genetics 12 Spec No 2 R125 133 doi 10 1093 hmg ddg302 PMID 12952866 a b Torrey EF Yolken RH August 2019 Schizophrenia as a pseudogenetic disease A call for more gene environmental studies Psychiatry Research 278 146 150 doi 10 1016 j psychres 2019 06 006 PMID 31200193 S2CID 173991937 a b c d e f g h Picchioni MM Murray RM July 2007 Schizophrenia BMJ 335 7610 91 95 doi 10 1136 bmj 39227 616447 BE PMC 1914490 PMID 17626963 Farrell MS Werge T Sklar P et al May 2015 Evaluating historical candidate genes for schizophrenia Molecular Psychiatry 20 5 555 562 doi 10 1038 mp 2015 16 PMC 4414705 PMID 25754081 Schulz SC Green MF Nelson KJ 2016 Schizophrenia and Psychotic Spectrum Disorders Oxford University Press pp 124 125 ISBN 9780199378067 Schork AJ Wang Y Thompson WK Dale AM Andreassen OA February 2016 New statistical approaches exploit the polygenic architecture of schizophrenia implications for the underlying neurobiology Current Opinion in Neurobiology 36 89 98 doi 10 1016 j conb 2015 10 008 PMC 5380793 PMID 26555806 Coelewij L Curtis D 2018 Mini review Update on the genetics of schizophrenia Annals of Human Genetics 82 5 239 243 doi 10 1111 ahg 12259 ISSN 0003 4800 PMID 29923609 S2CID 49311660 Kendler KS March 2016 The Schizophrenia Polygenic Risk Score To What Does It Predispose in Adolescence JAMA Psychiatry 73 3 193 194 doi 10 1001 jamapsychiatry 2015 2964 PMID 26817666 a b Lowther C Costain G Baribeau DA Bassett AS September 2017 Genomic Disorders in Psychiatry What Does the Clinician Need to Know Current Psychiatry Reports 19 11 82 doi 10 1007 s11920 017 0831 5 PMID 28929285 S2CID 4776174 Bundy H Stahl D MacCabe JH February 2011 A systematic review and meta analysis of the fertility of patients with schizophrenia and their unaffected relatives Fertility in schizophrenia Acta Psychiatrica Scandinavica 123 2 98 106 doi 10 1111 j 1600 0447 2010 01623 x PMID 20958271 S2CID 45179016 van Dongen J Boomsma DI March 2013 The evolutionary paradox and the missing heritability of schizophrenia American Journal of Medical Genetics Part B Neuropsychiatric Genetics 162 2 122 136 doi 10 1002 ajmg b 32135 PMID 23355297 S2CID 9648115 Owen MJ Sawa A Mortensen PB 2 July 2016 Schizophrenia Lancet 388 10039 86 97 doi 10 1016 S0140 6736 15 01121 6 PMC 4940219 PMID 26777917 Goh XX Tang PY Tee SF July 2021 8 Hydroxy 2 Deoxyguanosine and Reactive Oxygen Species as Biomarkers of Oxidative Stress in Mental Illnesses A Meta Analysis Psychiatry Investig Meta analysis 18 7 603 618 doi 10 30773 pi 2020 0417 PMC 8328836 PMID 34340273 Stilo SA Murray RM 14 September 2019 Non Genetic Factors in Schizophrenia Current Psychiatry Reports 21 10 100 doi 10 1007 s11920 019 1091 3 PMC 6745031 PMID 31522306 Cirulli F Musillo C Berry A 5 February 2020 Maternal Obesity as a Risk Factor for Brain Development and Mental Health in the Offspring Neuroscience 447 122 135 doi 10 1016 j neuroscience 2020 01 023 hdl 11573 1387747 PMID 32032668 S2CID 211029692 a b Upthegrove R Khandaker GM 2020 Cytokines Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia PDF Current Topics in Behavioral Neurosciences 44 49 66 doi 10 1007 7854 2018 88 ISBN 978 3 030 39140 9 PMID 31115797 S2CID 162169817 a b Chiang M Natarajan R Fan X February 2016 Vitamin D in schizophrenia a clinical review Evidence Based Mental Health 19 1 6 9 doi 10 1136 eb 2015 102117 PMID 26767392 S2CID 206926835 Arias I Sorlozano A Villegas E et al April 2012 Infectious agents associated with schizophrenia a meta analysis Schizophrenia Research 136 1 3 128 136 doi 10 1016 j schres 2011 10 026 PMID 22104141 S2CID 2687441 Yolken R June 2004 Viruses and schizophrenia a focus on herpes simplex virus Herpes 11 Suppl 2 Suppl 2 83A 88A PMID 15319094 Khandaker GM August 2012 Childhood infection and adult schizophrenia a meta analysis of population based studies Schizophr Res 139 1 3 161 168 doi 10 1016 j schres 2012 05 023 PMC 3485564 PMID 22704639 a b Pearce J Murray C Larkin W July 2019 Childhood adversity and trauma experiences of professionals trained to routinely enquire about childhood adversity Heliyon 5 7 e01900 doi 10 1016 j heliyon 2019 e01900 PMC 6658729 PMID 31372522 Dvir Y Denietolis B Frazier JA October 2013 Childhood trauma and psychosis Child and Adolescent Psychiatric Clinics of North America 22 4 629 641 doi 10 1016 j chc 2013 04 006 PMID 24012077 S2CID 40053289 Misiak B Krefft M Bielawski T Moustafa AA Sasiadek MM Frydecka D April 2017 Toward a unified theory of childhood trauma and psychosis A comprehensive review of epidemiological clinical neuropsychological and biological findings Neuroscience and Biobehavioral Reviews 75 393 406 doi 10 1016 j neubiorev 2017 02 015 PMID 28216171 S2CID 21614845 a b Nettis MA Pariante CM Mondelli V 2020 Early Life Adversity Systemic Inflammation and Comorbid Physical and Psychiatric Illnesses of Adult Life Current Topics in Behavioral Neurosciences 44 207 225 doi 10 1007 7854 2019 89 ISBN 978 3 030 39140 9 PMID 30895531 S2CID 84842249 Kasznia Justyna Pytel Aleksandra Stanczykiewicz Bartlomiej Samochowiec Jerzy Waszczuk Katarzyna Kulik Malgorzata Cyran Agnieszka Misiak Blazej 2021 The Impact of Adverse Childhood Experiences on Coping Strategies in Schizophrenia Spectrum Disorders A Case Control Study Psychology Research and Behavior Management 14 1315 1323 doi 10 2147 PRBM S324152 ISSN 1179 1578 PMC 8403075 PMID 34466040 Guloksuz S van Os J January 2018 The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum Psychological Medicine 48 2 229 244 doi 10 1017 S0033291717001775 PMID 28689498 Costa E Silva JA Steffen RE November 2019 Urban environment and psychiatric disorders a review of the neuroscience and biology Metabolism Clinical and Experimental 100S 153940 doi 10 1016 j metabol 2019 07 004 PMID 31610855 S2CID 204704312 van Os J April 2004 Does the urban environment cause psychosis The British Journal of Psychiatry 184 4 287 8 doi 10 1192 bjp 184 4 287 PMID 15056569 Attademo L Bernardini F Garinella R Compton MT March 2017 Environmental pollution and risk of psychotic disorders A review of the science to date Schizophrenia Research 181 55 59 doi 10 1016 j schres 2016 10 003 PMID 27720315 S2CID 25505446 Selten JP Cantor Graae E Kahn RS March 2007 Migration and schizophrenia Current Opinion in Psychiatry 20 2 111 115 doi 10 1097 YCO 0b013e328017f68e PMID 17278906 S2CID 21391349 Sharma R Agarwal A Rohra VK et al April 2015 Effects of increased paternal age on sperm quality reproductive outcome and associated epigenetic risks to offspring Reprod Biol Endocrinol 13 35 doi 10 1186 s12958 015 0028 x PMC 4455614 PMID 25928123 a b Gregg L Barrowclough C Haddock G May 2007 Reasons for increased substance use in psychosis Clinical Psychology Review 27 4 494 510 doi 10 1016 j cpr 2006 09 004 PMID 17240501 Sagud M Mihaljevic Peles A Muck Seler D et al September 2009 Smoking and schizophrenia Psychiatria Danubina 21 3 371 375 PMID 19794359 Larson M 30 March 2006 Alcohol Related Psychosis EMedicine Archived from the original on 9 November 2008 Retrieved 27 September 2006 Leweke FM Koethe D June 2008 Cannabis and psychiatric disorders it is not only addiction Addiction Biology 13 2 264 75 doi 10 1111 j 1369 1600 2008 00106 x PMID 18482435 S2CID 205400285 a b c d Khokhar JY Henricks AM Sullivan ED Green AI 2018 Unique Effects of Clozapine A Pharmacological Perspective Apprentices to Genius A tribute to Solomon H Snyder Advances in Pharmacology Vol 82 pp 137 162 doi 10 1016 bs apha 2017 09 009 ISBN 978 0128140871 PMC 7197512 PMID 29413518 Bighelli Irene Rodolico Alessandro Garcia Mieres Helena Pitschel Walz Gabi Hansen Wulf Peter Schneider Thoma Johannes Siafis Spyridon Wu Hui Wang Dongfang Salanti Georgia Furukawa Toshi A Barbui Corrado Leucht Stefan 2021 Psychosocial and psychological interventions for relapse prevention in schizophrenia a systematic review and network meta analysis The Lancet Psychiatry 8 11 969 980 doi 10 1016 S2215 0366 21 00243 1 PMID 34653393 S2CID 239003358 Patel S Khan S M S Hamid P July 2020 The Association Between Cannabis Use and Schizophrenia Causative or Curative A Systematic Review Cureus 12 7 e9309 doi 10 7759 cureus 9309 PMC 7442038 PMID 32839678 Hasan A von Keller R Friemel CM Hall W Schneider M Koethe D Leweke FM Strube W Hoch E June 2020 Cannabis use and psychosis a review of reviews Eur Arch Psychiatry Clin Neurosci 270 4 403 412 doi 10 1007 s00406 019 01068 z PMID 31563981 S2CID 203567900 Causes Schizophrenia UK National Health Service 11 November 2019 Retrieved 8 December 2021 Ortiz Medina MB Perea M Torales J et al November 2018 Cannabis consumption and psychosis or schizophrenia development The International Journal of Social Psychiatry 64 7 690 704 doi 10 1177 0020764018801690 PMID 30442059 S2CID 53563635 Hayes D Kyriakopoulos M August 2018 Dilemmas in the treatment of early onset first episode psychosis Therapeutic Advances in Psychopharmacology 8 8 231 239 doi 10 1177 2045125318765725 PMC 6058451 PMID 30065814 Cannon TD December 2015 How Schizophrenia Develops Cognitive and Brain Mechanisms Underlying Onset of Psychosis Trends Cogn Sci 19 12 744 756 doi 10 1016 j tics 2015 09 009 PMC 4673025 PMID 26493362 Correll CU Schooler NR 2020 Negative Symptoms in Schizophrenia A Review and Clinical Guide for Recognition Assessment and Treatment Neuropsychiatric Disease and Treatment 16 519 534 doi 10 2147 NDT S225643 PMC 7041437 PMID 32110026 Howes OD 1 January 2017 The Role of Genes Stress and Dopamine in the Development of Schizophrenia Biological Psychiatry 81 1 9 20 doi 10 1016 j biopsych 2016 07 014 PMC 5675052 PMID 27720198 Broyd A Balzan RP Woodward TS Allen P June 2017 Dopamine cognitive biases and assessment of certainty A neurocognitive model of delusions Clinical Psychology Review 54 96 106 doi 10 1016 j cpr 2017 04 006 PMID 28448827 Howes OD Murray RM May 2014 Schizophrenia an integrated sociodevelopmental cognitive model Lancet 383 9929 1677 1687 doi 10 1016 S0140 6736 13 62036 X PMC 4127444 PMID 24315522 Grace AA August 2016 Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression Nature Reviews Neuroscience 17 8 524 532 doi 10 1038 nrn 2016 57 PMC 5166560 PMID 27256556 Fusar Poli P Meyer Lindenberg A January 2013 Striatal presynaptic dopamine in schizophrenia part II meta analysis of 18 F 11 C DOPA PET studies Schizophrenia Bulletin 39 1 33 42 doi 10 1093 schbul sbr180 PMC 3523905 PMID 22282454 Howes OD Kambeitz J Kim E et al August 2012 The nature of dopamine dysfunction in schizophrenia and what this means for treatment Archives of General Psychiatry 69 8 776 786 doi 10 1001 archgenpsychiatry 2012 169 PMC 3730746 PMID 22474070 Arnsten AF Girgis RR Gray DL Mailman RB January 2017 Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia Biological Psychiatry 81 1 67 77 doi 10 1016 j biopsych 2015 12 028 PMC 4949134 PMID 26946382 Maia TV Frank MJ January 2017 An Integrative Perspective on the Role of Dopamine in Schizophrenia Biological Psychiatry 81 1 52 66 doi 10 1016 j biopsych 2016 05 021 PMC 5486232 PMID 27452791 a b Pratt J Dawson N Morris BJ et al February 2017 Thalamo cortical communication glutamatergic neurotransmission and neural oscillations A unique window into the origins of ScZ PDF Schizophrenia Research 180 4 12 doi 10 1016 j schres 2016 05 013 PMID 27317361 S2CID 205075178 Catts VS Lai YL Weickert CS Weickert TW Catts SV April 2016 A quantitative review of the post mortem evidence for decreased cortical N methyl D aspartate receptor expression levels in schizophrenia How can we link molecular abnormalities to mismatch negativity deficits Biological Psychology 116 57 67 doi 10 1016 j biopsycho 2015 10 013 PMID 26549579 Michie PT Malmierca MS Harms L Todd J April 2016 The neurobiology of MMN and implications for schizophrenia Biological Psychology 116 90 97 doi 10 1016 j biopsycho 2016 01 011 PMID 26826620 S2CID 41179430 a b Marin O January 2012 Interneuron dysfunction in psychiatric disorders Nature Reviews Neuroscience 13 2 107 120 doi 10 1038 nrn3155 PMID 22251963 S2CID 205507186 Lewis DA Hashimoto T Volk DW April 2005 Cortical inhibitory neurons and schizophrenia Nature Reviews Neuroscience 6 4 312 324 doi 10 1038 nrn1648 PMID 15803162 S2CID 3335493 Senkowski D Gallinat J June 2015 Dysfunctional prefrontal gamma band oscillations reflect working memory and other cognitive deficits in schizophrenia Biological Psychiatry 77 12 1010 1019 doi 10 1016 j biopsych 2015 02 034 PMID 25847179 S2CID 206104940 Several studies that investigated perceptual processes found impaired GBR in ScZ patients over sensory areas such as the auditory and visual cortex Moreover studies examining steady state auditory evoked potentials showed deficits in the gen eration of oscillations in the gamma band Reilly TJ Nottage JF Studerus E et al July 2018 Gamma band oscillations in the early phase of psychosis A systematic review Neuroscience and Biobehavioral Reviews 90 381 399 doi 10 1016 j neubiorev 2018 04 006 PMID 29656029 S2CID 4891072 Decreased gamma power in response to a task was a relatively consistent finding with 5 out of 6 studies reported reduced evoked or induced power a b Sloan SA Barres BA August 2014 Mechanisms of astrocyte development and their contributions to neurodevelopmental disorders Curr Opin Neurobiol 27 75 81 doi 10 1016 j conb 2014 03 005 PMC 4433289 PMID 24694749 Lesh TA Niendam TA Minzenberg MJ Carter CS January 2011 Cognitive control deficits in schizophrenia mechanisms and meaning Neuropsychopharmacology 36 1 316 338 doi 10 1038 npp 2010 156 PMC 3052853 PMID 20844478 Barch DM Ceaser A January 2012 Cognition in schizophrenia core psychological and neural mechanisms Trends in Cognitive Sciences 16 1 27 34 doi 10 1016 j tics 2011 11 015 PMC 3860986 PMID 22169777 Eisenberg DP Berman KF January 2010 Executive function neural circuitry and genetic mechanisms in schizophrenia Neuropsychopharmacology 35 1 258 277 doi 10 1038 npp 2009 111 PMC 2794926 PMID 19693005 Walton E Hibar DP van Erp TG et al May 2017 Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium Acta Psychiatrica Scandinavica 135 5 439 447 doi 10 1111 acps 12718 PMC 5399182 PMID 28369804 Walton E Hibar DP van Erp TG et al Karolinska Schizophrenia Project Consortium KaSP January 2018 Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium Psychological Medicine 48 1 82 94 doi 10 1017 S0033291717001283 PMC 5826665 PMID 28545597 Cohen AS Minor KS January 2010 Emotional experience in patients with schizophrenia revisited meta analysis of laboratory studies Schizophrenia Bulletin 36 1 143 150 doi 10 1093 schbul sbn061 PMC 2800132 PMID 18562345 Strauss GP Gold JM April 2012 A new perspective on anhedonia in schizophrenia The American Journal of Psychiatry 169 4 364 373 doi 10 1176 appi ajp 2011 11030447 PMC 3732829 PMID 22407079 Young J Anticevic A Barch D 2018 Cognitive and Motivational Neuroscience of Psychotic Disorders In Charney D Buxbaum J Sklar P Nestler E eds Charney amp Nestler s Neurobiology of Mental Illness 5th ed New York Oxford University Press pp 215 217 ISBN 9780190681425 Several recent reviews e g Cohen and Minor 2010 have found that individuals with schizophrenia show relatively intact self reported emotional responses to affect eliciting stimuli as well as other indicators of intact response 215 Taken together the literature increasingly suggests that there may be a deficit in putatively DA mediated reward learning and or reward prediction functions in schizophrenia Such findings suggest that impairment in striatal reward prediction mechanisms may influence wanting in schizophrenia in a way that reduces the ability of individuals with schizophrenia to use anticipated rewards to drive motivated behavior 217 a b Wiberg A Ng M Al Omran Y et al 1 October 2019 Handedness language areas and neuropsychiatric diseases insights from brain imaging and genetics Brain A Journal of Neurology 142 10 2938 2947 doi 10 1093 brain awz257 PMC 6763735 PMID 31504236 Tzourio Mazoyer N Kennedy H Van Essen DC Christen Y 2016 Intra and Inter hemispheric Connectivity Supporting Hemispheric Specialization Micro Meso and Macro Connectomics of the Brain Research and Perspectives in Neurosciences pp 129 146 doi 10 1007 978 3 319 27777 6 9 ISBN 978 3 319 27776 9 PMID 28590670 S2CID 147813648 Ocklenburg S Gunturkun O Hugdahl K Hirnstein M December 2015 Laterality and mental disorders in the postgenomic age A closer look at schizophrenia and language lateralization Neuroscience and Biobehavioral Reviews 59 100 110 doi 10 1016 j neubiorev 2015 08 019 PMID 26598216 S2CID 15983622 Friston KJ Stephan KE Montague R Dolan RJ July 2014 Computational psychiatry the brain as a phantastic organ The Lancet Psychiatry 1 2 148 158 doi 10 1016 S2215 0366 14 70275 5 PMID 26360579 Griffin JD Fletcher PC May 2017 Predictive Processing Source Monitoring and Psychosis Annual Review of Clinical Psychology 13 265 289 doi 10 1146 annurev clinpsy 032816 045145 PMC 5424073 PMID 28375719 Fletcher PC Frith CD January 2009 Perceiving is believing a Bayesian approach to explaining the positive symptoms of schizophrenia PDF Nature Reviews Neuroscience 10 1 48 58 doi 10 1038 nrn2536 PMID 19050712 S2CID 6219485 Corlett PR Taylor JR Wang XJ Fletcher PC Krystal JH November 2010 Toward a neurobiology of delusions Progress in Neurobiology 92 3 345 369 doi 10 1016 j pneurobio 2010 06 007 PMC 3676875 PMID 20558235 Bastos AM Usrey WM Adams RA et al 21 November 2012 Canonical microcircuits for predictive coding Neuron 76 4 695 711 doi 10 1016 j neuron 2012 10 038 PMC 3777738 PMID 23177956 Soltan M Girguis J 8 May 2017 How to approach the mental state examination BMJ 357 j1821 doi 10 1136 sbmj j1821 PMID 31055448 S2CID 145820368 Retrieved 9 January 2020 Lindenmayer JP 1 December 2017 Are Shorter Versions of the Positive and Negative Syndrome Scale PANSS Doable A Critical Review Innovations in Clinical Neuroscience 14 11 12 73 76 PMC 5788254 PMID 29410940 Diagnosis of schizophrenia Australian Department of Health 10 January 2019 Retrieved 28 January 2020 Schizophrenia Diagnosis UK National Health Service 23 October 2017 Retrieved 28 January 2020 Jakobsen KD Frederiksen JN Hansen T et al 2005 Reliability of clinical ICD 10 schizophrenia diagnoses Nordic Journal of Psychiatry 59 3 209 212 doi 10 1080 08039480510027698 PMID 16195122 S2CID 24590483 a b c Richard Devantoy S Olie JP Gourevitch R December 2009 Risk of homicide and major mental disorders a critical review L Encephale 35 6 521 530 doi 10 1016 j encep 2008 10 009 PMID 20004282 a b Staedt J Hauser M Gudlowski Y Stoppe G February 2010 Sleep disorders in schizophrenia Fortschritte der Neurologie Psychiatrie 78 2 70 80 doi 10 1055 s 0028 1109967 PMID 20066610 a b Pocivavsek A Rowland LM 13 January 2018 Basic Neuroscience Illuminates Causal Relationship Between Sleep and Memory Translating to Schizophrenia Schizophrenia Bulletin 44 1 7 14 doi 10 1093 schbul sbx151 PMC 5768044 PMID 29136236 a b Monti JM BaHammam AS Pandi Perumal SR et al 3 June 2013 Sleep and circadian rhythm dysregulation in schizophrenia Progress in Neuro psychopharmacology amp Biological Psychiatry 43 209 216 doi 10 1016 j pnpbp 2012 12 021 PMID 23318689 S2CID 19626589 Faulkner SM Bee PE Meyer N Dijk DJ Drake RJ August 2019 Light therapies to improve sleep in intrinsic circadian rhythm sleep disorders and neuro psychiatric illness A systematic review and meta analysis Sleep Medicine Reviews 46 108 123 doi 10 1016 j smrv 2019 04 012 PMID 31108433 Assimakopoulos K Karaivazoglou K Skokou M et al 24 March 2018 Genetic Variations Associated with Sleep Disorders in Patients with Schizophrenia A Systematic Review Medicines 5 2 27 doi 10 3390 medicines5020027 PMC 6023503 PMID 29587340 Schrimpf LA Aggarwal A Lauriello J June 2018 Psychosis Continuum Minneap Minn 24 3 845 860 doi 10 1212 CON 0000000000000602 PMID 29851881 S2CID 243933980 Bottas A 15 April 2009 Comorbidity Schizophrenia With Obsessive Compulsive Disorder Psychiatric Times 26 4 Archived from the original on 3 April 2013 OConghaile A DeLisi LE May 2015 Distinguishing schizophrenia from posttraumatic stress disorder with psychosis Curr Opin Psychiatry 28 3 249 255 doi 10 1097 YCO 0000000000000158 PMID 25785709 S2CID 12523516 Murray ED Buttner N Price BH 2012 Depression and Psychosis in Neurological Practice In Bradley WG Daroff RB Fenichel GM Jankovic J eds Bradley s neurology in clinical practice Vol 1 6th ed Philadelphia PA Elsevier Saunders pp 92 111 ISBN 978 1 4377 0434 1 Leucht Stefan Bauer Sofia Siafis Spyridon Hamza Tasnim Wu Hui Schneider Thoma Johannes Salanti Georgia Davis John M 1 November 2021 Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia A Meta analysis JAMA Psychiatry 78 11 1238 1248 doi 10 1001 jamapsychiatry 2021 2130 ISSN 2168 622X PMC 8374744 PMID 34406325 Cannon TD Cornblatt B McGorry P May 2007 The empirical status of the ultra high risk prodromal research paradigm Schizophrenia Bulletin 33 3 661 664 doi 10 1093 schbul sbm031 PMC 2526144 PMID 17470445 a b Marshall M Rathbone J June 2011 Early intervention for psychosis The Cochrane Database of Systematic Reviews 6 CD004718 doi 10 1002 14651858 CD004718 pub3 PMC 4163966 PMID 21678345 Stafford MR Jackson H Mayo Wilson E Morrison AP Kendall T January 2013 Early interventions to prevent psychosis systematic review and meta analysis BMJ 346 f185 doi 10 1136 bmj f185 PMC 3548617 PMID 23335473 a b Taylor M Jauhar S September 2019 Are we getting any better at staying better The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia Therapeutic Advances in Psychopharmacology 9 204512531987003 doi 10 1177 2045125319870033 PMC 6732843 PMID 31523418 Weiden PJ July 2016 Beyond Psychopharmacology Emerging Psychosocial Interventions for Core Symptoms of Schizophrenia Focus American Psychiatric Publishing 14 3 315 327 doi 10 1176 appi focus 20160014 PMC 6526802 PMID 31975812 McGurk SR Mueser KT Feldman K Wolfe R Pascaris A March 2007 Cognitive training for supported employment 2 3 year outcomes of a randomized controlled trial The American Journal of Psychiatry 164 3 437 441 doi 10 1176 appi ajp 164 3 437 PMID 17329468 Souaiby L Gaillard R Krebs MO August 2016 Duration of untreated psychosis A state of the art review and critical analysis Encephale 42 4 361 366 doi 10 1016 j encep 2015 09 007 PMID 27161262 Fuller Torrey E June 2015 Deinstitutionalization and the rise of violence CNS Spectrums 20 3 207 214 doi 10 1017 S1092852914000753 PMID 25683467 a b c Schizophrenia Treatment UK National Health Service 23 October 2017 Retrieved 8 January 2020 Ortiz Orendain J Covarrubias Castillo SA Vazquez Alvarez AO Castiello de Obeso S Arias Quinones GE Seegers M Colunga Lozano LE December 2019 Modafinil for people with schizophrenia or related disorders The Cochrane Database of Systematic Reviews 12 12 CD008661 doi 10 1002 14651858 CD008661 pub2 PMC 6906203 PMID 31828767 Lally J MacCabe JH June 2015 Antipsychotic medication in schizophrenia a review British Medical Bulletin 114 1 169 179 doi 10 1093 bmb ldv017 PMID 25957394 Keks N Schwartz D Hope J October 2019 Stopping and switching antipsychotic drugs Australian Prescriber 42 5 152 157 doi 10 18773 austprescr 2019 052 PMC 6787301 PMID 31631928 Harrow M Jobe TH September 2013 Does long term treatment of schizophrenia with antipsychotic medications facilitate recovery Schizophrenia Bulletin 39 5 962 5 doi 10 1093 schbul sbt034 PMC 3756791 PMID 23512950 Elkis H Buckley PF June 2016 Treatment Resistant Schizophrenia The Psychiatric Clinics of North America 39 2 239 65 doi 10 1016 j psc 2016 01 006 PMID 27216902 Gillespie AL Samanaite R Mill J Egerton A MacCabe JH 13 January 2017 Is treatment resistant schizophrenia categorically distinct from treatment responsive schizophrenia a systematic review BMC Psychiatry 17 1 12 doi 10 1186 s12888 016 1177 y PMC 5237235 PMID 28086761 Essali A Al Haj Haasan N Li C Rathbone J January 2009 Clozapine versus typical neuroleptic medication for schizophrenia The Cochrane Database of Systematic Reviews 2009 1 CD000059 doi 10 1002 14651858 CD000059 pub2 PMC 7065592 PMID 19160174 Baier M August 2010 Insight in schizophrenia a review Current Psychiatry Reports 12 4 356 361 doi 10 1007 s11920 010 0125 7 PMID 20526897 S2CID 29323212 Peters L Krogmann A von Hardenberg L et al 19 November 2019 Long Acting Injections in Schizophrenia a 3 Year Update on Randomized Controlled Trials Published January 2016 March 2019 Current Psychiatry Reports 21 12 124 doi 10 1007 s11920 019 1114 0 PMID 31745659 S2CID 208144438 Leucht S Tardy M Komossa K et al June 2012 Antipsychotic drugs versus placebo for relapse prevention in schizophrenia a systematic review and meta analysis Lancet 379 9831 2063 2071 doi 10 1016 S0140 6736 12 60239 6 PMID 22560607 S2CID 2018124 McEvoy JP 2006 Risks versus benefits of different types of long acting injectable antipsychotics The Journal of Clinical Psychiatry 67 Suppl 5 15 18 PMID 16822092 a b Chow CL Kadouh NK Bostwick JR VandenBerg AM June 2020 Akathisia and Newer Second Generation Antipsychotic Drugs A Review of Current Evidence Pharmacotherapy 40 6 565 574 doi 10 1002 phar 2404 hdl 2027 42 155998 PMID 32342999 S2CID 216596357 Carbon M Kane JM Leucht S Correll CU October 2018 Tardive dyskinesia risk with first and second generation antipsychotics in comparative randomized controlled trials a meta analysis World Psychiatry 17 3 330 340 doi 10 1002 wps 20579 PMC 6127753 PMID 30192088 a b Pharoah F Mari J Rathbone J Wong W December 2010 Pharoah F ed Family intervention for schizophrenia The Cochrane Database of Systematic Reviews 12 12 CD000088 doi 10 1002 14651858 CD000088 pub2 PMC 4204509 PMID 21154340 Bellani M Ricciardi C Rossetti MG Zovetti N Perlini C Brambilla P September 2019 Cognitive remediation in schizophrenia the earlier the better Epidemiol Psychiatr Sci 29 e57 doi 10 1017 S2045796019000532 PMC 8061237 PMID 31556864 Philipp R Kriston L Lanio J et al 2019 Effectiveness of metacognitive interventions for mental disorders in adults A systematic review and meta analysis METACOG Clinical Psychology amp Psychotherapy 26 2 227 240 doi 10 1002 cpp 2345 PMID 30456821 S2CID 53872643 Rouy Martin Saliou Pauline Nalborczyk Ladislas Pereira Michael Roux Paul Faivre Nathan 2021 Systematic review and meta analysis of metacognitive abilities in individuals with schizophrenia spectrum disorders PDF Neuroscience amp Biobehavioral Reviews 126 329 337 doi 10 1016 j neubiorev 2021 03 017 PMID 33757817 S2CID 232288918 Dixon LB Dickerson F Bellack AS et al January 2010 The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements Schizophrenia Bulletin 36 1 48 70 doi 10 1093 schbul sbp115 PMC 2800143 PMID 19955389 Bond GR Drake RE June 2015 The critical ingredients of assertive community treatment World Psychiatry 14 2 240 242 doi 10 1002 wps 20234 PMC 4471983 PMID 26043344 Smeerdijk M 2017 Using resource groups in assertive community treatment literature review and recommendation Tijdschrift voor Psychiatrie 59 8 466 473 PMID 28880347 Dieterich M 6 January 2017 Intensive case management for severe mental illness The Cochrane Database of Systematic Reviews 1 1 CD007906 doi 10 1002 14651858 CD007906 pub3 PMC 6472672 PMID 28067944 Jauhar S McKenna PJ Radua J et al January 2014 Cognitive behavioural therapy for the symptoms of schizophrenia systematic review and meta analysis with examination of potential bias The British Journal of Psychiatry Review 204 1 20 29 doi 10 1192 bjp bp 112 116285 PMID 24385461 a b Jones C Hacker D Meaden A et al November 2018 Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia The Cochrane Database of Systematic Reviews 11 6 CD008712 doi 10 1002 14651858 CD008712 pub3 PMC 6516879 PMID 30480760 Health Quality Ontario 2018 Cognitive Behavioural Therapy for Psychosis A Health Technology Assessment Ontario Health Technology Assessment Series 18 5 1 141 PMC 6235075 PMID 30443277 Ruddy R Milnes D October 2005 Art therapy for schizophrenia or schizophrenia like illnesses The Cochrane Database of Systematic Reviews 4 CD003728 doi 10 1002 14651858 CD003728 pub2 PMID 16235338 Archived from the original on 27 October 2011 Ruddy RA Dent Brown K January 2007 Drama therapy for schizophrenia or schizophrenia like illnesses The Cochrane Database of Systematic Reviews 1 CD005378 doi 10 1002 14651858 CD005378 pub2 PMID 17253555 Archived from the original on 25 August 2011 Galletly C Castle D Dark F et al May 2016 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders Aust N Z J Psychiatry 50 5 410 472 doi 10 1177 0004867416641195 PMID 27106681 S2CID 6536743 Chien WT Clifton AV Zhao S Lui S 4 April 2019 Peer support for people with schizophrenia or other serious mental illness The Cochrane Database of Systematic Reviews 4 6 CD010880 doi 10 1002 14651858 CD010880 pub2 PMC 6448529 PMID 30946482 a b Girdler SJ Confino JE Woesner ME 15 February 2019 Exercise as a Treatment for Schizophrenia A Review Psychopharmacology Bulletin 49 1 56 69 PMC 6386427 PMID 30858639 a b Firth J 1 May 2017 Aerobic Exercise Improves Cognitive Functioning in People With Schizophrenia A Systematic Review and Meta Analysis Schizophrenia Bulletin 43 3 546 556 doi 10 1093 schbul sbw115 PMC 5464163 PMID 27521348 Trehout M Dollfus S December 2018 Physical activity in patients with schizophrenia From neurobiology to clinical benefits L Encephale 44 6 538 547 doi 10 1016 j encep 2018 05 005 PMID 29983176 S2CID 150334210 Quality statement 7 Promoting healthy eating physical activity and smoking cessation Psychosis and schizophrenia in adults UK National Institute for Health and Care Excellence a b c Firth J Carney R Stubbs B et al October 2018 Nutritional Deficiencies and Clinical Correlates in First Episode Psychosis A Systematic Review and Meta analysis Schizophrenia Bulletin 44 6 1275 1292 doi 10 1093 schbul sbx162 PMC 6192507 PMID 29206972 a b c d Rastogi A Viani Walsh D Akbari S Gall N Gaughran F Lally J October 2020 Pathogenesis and management of Brugada syndrome in schizophrenia A scoping review General Hospital Psychiatry 67 83 91 doi 10 1016 j genhosppsych 2020 09 003 PMC 7537626 PMID 33065406 Martone G April 2018 Enhancement of recovery from mental illness with l methylfolate supplementation Perspectives in Psychiatric Care 54 2 331 334 doi 10 1111 ppc 12227 PMID 28597528 a b Firth J Teasdale SB Allott K et al October 2019 The efficacy and safety of nutrient supplements in the treatment of mental disorders a meta review of meta analyses of randomized controlled trials World Psychiatry 18 3 308 324 doi 10 1002 wps 20672 PMC 6732706 PMID 31496103 Kritharides L Chow V Lambert TJ 6 February 2017 Cardiovascular disease in patients with schizophrenia The Medical Journal of Australia 206 2 91 95 doi 10 5694 mja16 00650 PMID 28152356 S2CID 5388097 Erlangsen A Eaton WW Mortensen PB Conwell Y February 2012 Schizophrenia a predictor of suicide during the second half of life Schizophrenia Research 134 2 3 111 117 doi 10 1016 j schres 2011 09 032 PMC 3266451 PMID 22018943 span, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.